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suitAblE DruG trEAtMEnt for chilDrEn
A major part (40-70%) of drugs prescribed to children are used either unlicensed or 
off-label, leading to increased risk of drug toxicity or therapeutic failure [1, 2]. Despite 
increasing efforts by US and EU regulatory authorities who require that the pharma-
ceutic industry perform pediatric studies while developing drugs, most drug treatment 
is based on adult studies [3, 4]. Appropriate pediatric dose-selection solely based on 
adult data is not acceptable due to development causing changes in drug absorption, 
distribution, metabolism and excretion [5]. Simple size- or weight-based extrapolations 
from adult to pediatric doses is not enough, particularly not in neonates and young 
infants. Simulation models like physiologically-based pharmacokinetic models (PBPK) 
and population pharmacokinetic (popPK) are used to optimize pediatric dose predic-
tions [6-8]. The limitation of these models is the limited ontogeny data that is available 
for input or to validate these models. Subsequently new data on the impact of age on 
the processes affecting drug disposition during childhood are needed.
orAl DruG trEAtMEnt for chilDrEn
Nowadays, most drugs prescribed to children in the community are taken orally [1]. 
Even critically ill neonates and children receive many oral drug formulations, due to 
the unavailability of intravenous formulations, intravenous access issues or cost and 
safety concerns or patients soon being discharged from the intensive care unit (ICU). 
Extrinsic factors, like food and drug formulation, and intrinsic factors of physiological 
nature affect the extent of absorption of orally administered drugs [9]. Intrinsic factors 
include many gastrointestinal processes such as gastric pH, gastric and intestinal motil-
ity, gastrointestinal fluids, the pH and buffer capacity of these fluids, digestive enzymes, 
intestinal membrane transporters and intestinal drug metabolism.
Important progress has been made to elucidate age-related changes in phase I 
hepatic drug metabolism and renal excretion [10, 11]. Meanwhile, our knowledge on 
developmental changes governing variation in oral bioavailability including intestinal 
and hepatic drug transport and phase II drug metabolism is far less developed. A major 
reason for a lack of studies in children is the ethical and practical limitations. Hence, 
the development of innovative methods and a thorough understanding of the ethical 
challenges and potential solutions are highly needed.
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MEMbrAnE trAnsPortErs
Plasma membrane transporters are proteins that facilitate uptake and excretion of 
compounds in and out of the cell. More than 400 transporters are identified nowadays 
[12]. Located on, amongst others, the enterocyte, hepatocyte and renal cells, they play 
an essential role in mediating the uptake, distribution and excretion of many drugs [13, 
14]. The classification of transporters is according to their properties and grouped in 
superfamilies. The disposition of drugs is most often associated with two superfamilies 
of transporters: the solute carrier (SLC) and ATP-binding cassette transporters (ABC) 
families. Their physiological function is to facilitate translocation of endogenous com-
pounds, such as bile salts and steroids. Exogenous compounds, such as nutrients, drugs 
and metabolites, are also substrates for specific transporters [15]. The clinical relevance 
of transporters in drug disposition has been shown in drug-drug interaction and phar-
macogenomics studies in adults [13, 16]. Little is known on the ontogeny of membrane 
transporters in pediatric organ tissues and their roles in pediatric pharmacotherapy. 
Growth and maturation are likely to impact on activity of transporters as has been shown 
in drug metabolizing enzymes, especially as transporters function in endogenous pro-
cesses. Animal studies have indeed shown maturational changes in transporter expres-
sion. Human data in fetuses and children are very limited and definitive conclusions on 
their impact on drug disposition across the pediatric age range can hardly be drawn.
innoVAtiVE MEthoD: Ex ViVo trAnsPortEr stuDiEs
To date, no solid substrate can be identified to study in vivo transporter activity in 
children and in vitro expression studies might serve as alternatives. For in vitro studies 
on transporters, human organ tissue is necessary and to study the ontogeny specifi-
cally, pediatric tissue is essential. Nevertheless, pediatric tissue is scarce and difficult to 
harvest. Tissues can be harvested from diagnostic biopsies, surgical waste material, 
postmortem or be collected within the framework of a biobank. Within the context of 
the postmortem biobank and surgical tissue waste collection for specific projects was 
available. This tissue availability has been shown to be unique, even worldwide.
This relative scarcity demands study techniques that rely on efficient use of minimal 
amounts of pediatric tissue. Protein expression methods, especially, require large 
amounts of samples, can only quantify single transporters and are very labor-intensive. 
Recently, liquid chromatography tandem mass spectrometry (LC-MS/MS) has been 
increasingly used to study protein expression, including membrane transporters in 
humans. It may also be an attractive method for pediatric studies, as it only requires very 
limited sample volume and enables the quantification of multiple transporters at once.
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PhAsE ii DruG MEtAbolisM
Drug metabolizing enzymes are abundant in the liver and gut and contribute to the 
first-pass metabolism of many orally administered drugs. Drugs are often metabolized 
in two phases. Phase I reactions involve formation of a new or modified group (oxida-
tion, reduction, hydrolysis), whereas phase II reactions involve conjugation with an 
endogenous substance (e.g. glucuronic acid, sulfate, glycine) which serves the purpose 
of enhancing the water-solubility of the substrate and consequently its excretion by 
liver or kidneys. Uridine 5’-diphospho-glucuronosyltransferase (UGT) iso-enzymes and 
sulfotransferases (SULT) are families of drug metabolizing enzymes, important in the 
phase II drug metabolism. UGTs add glucuronic acid to a substrate, i.e., drugs, bilirubin, 
bile salts, and SULTs add a sulfo-group to a substrate.
In vitro, human hepatic UGTs show an enzyme-specific developmental pattern in 
early years of age of UGT1A9, UGT1A1, and UGT1A6 [17, 18]. A limitation is that liver 
samples of children younger than 2 years were not included. In vivo studies showed 
that postnatal age and postmenstrual age co-determine the interindividual variability 
in for instance tramadol glucuronidation in neonates after 10 days of age [19]. Morphine 
glucuronidation changes with age due to UGT2B7 maturation [20]. The ontogeny of 
other UGTs or SULTs are less well studied and especially not during the continuum of 
childhood age but in small populations of limited ages.
Paracetamol (acetaminophen, AAP) is a suitable probe drug to study UGT activity in 
vivo in children. Its main metabolism pathways are glucuronidation and sulfation; mainly 
via UGT1A1, 1A6, 1A9 and 2B15 and SULT1A1, 1A3, 1A4, and 2A1 [21]. Furthermore, AAP 
can be given orally and intravenously, is frequently prescribed to children, has dose-
linear pharmacokinetics, and UGT metabolism can be detected by the ratio of glucuro-
nide (AAP-glu) and sulfate (AAP-sul) metabolites in plasma and urine. Its metabolism has 
been characterized in children, but information gaps remain, especially in the first two 
years of age. Moreover, its metabolism after exclusive oral administration has not been 
very well characterized.
innoVAtiVE MEthoD: MicroDosinG to PhEnotyPE DruG MEtAbolisM
Pediatric drug studies are hampered by practical and ethical limitations. To protect 
children as a vulnerable population often incapable of expressing themselves, stringent 
medical ethical criteria are justified for research trials. Nevertheless, to ensure safe and 
effective drug treatment, adequate and reliable research tools are necessary. Pharma-
cokinetic studies, according to a classic design, are done by giving a ‘non-therapeutic’ 
drug after which multiple blood samples are taken to determine the drug concentra-
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tions. Ethical and practical arguments limit these studies in children, because it means 
‘non-therapeutic’ drug doses with exposure to unnecessary effects and toxicity followed 
by extensive blood sampling, which is often a painful procedure. Blood sampling, for 
example, is especially limited in premature neonates in whom circulating blood volume 
is very small (e.g., blood sampling volume would be 0.4 mL per 24 h in a 500-gram-
neonate with a circulating blood volume of around 40 mL).
To overcome the limitations of a drug dose only for non-therapeutic reasons, a mi-
crodose can be given. Microdosing promises to study the pharmacokinetics of drugs in 
children, without the risk of adverse events and with minimal burden [22, 23]. Microdos-
ing is defined by the EMA and FDA as the lowest of i) one-hundredth of the No Observed 
Adverse Effect Level (NOAEL) or ii) one-hundredth of the predicted pharmacologic dose 
based on animal data or iii) as 100 micrograms of the new drug [4, 24]. Additionally, label-
ing of the drug enables oral bioavailability studies when the microdose is administered 
per one route and the (therapeutic) unlabeled dose is administered via another route. 
Even after simultaneously administering the doses, separation of drug concentration 
levels is possible and so limits blood sampling time points.
Dose linearity between the microdose and therapeutic dose is a prerequisite in obtain-
ing pharmacokinetic data for clinically relevant dosing guidelines. For several drugs such 
dose-linearity has been shown in adults [22, 25]. Sensitive measurements are needed to 
detect the extremely low dose levels in plasma or urine. Accelerator mass spectrometry 
(AMS) measures low attomolar to zeptomolar isotope ratios ranges, and quantifies [14C] 
labeled drug/metabolite levels [26]. The extremely low dose implies that a [14C] labeled 
microdose can be administered simultaneously with a non-labeled therapeutic dose. 
And thus, the bioavailability can be studied. Radiation associated with [14C] labeling 
in adults is less than 10 µSv which is negligible in the light of the yearly background 
exposure of 2.5 mSv in the Netherlands. In premature neonates, microdosing has been 
used once in a small pharmacokinetic study of ursodiol in the US [27].
We chose to use [14C] labeled microdosing to delineate developmental changes in the 
intestinal and hepatic UGT metabolism pathway involved in paracetamol. The contribu-
tion of intestinal and hepatic drug metabolism of paracetamol during childhood needs 
to be elucidated. Dose linearity of paracetamol has been shown in adults under normal 
conditions and after probenecid glucuronidation inhibition [25].
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AiMs AnD outlinE of this thEsis
The aims of this thesis are:
•	 To	study	the	extent	of	oral	drugs	used	in	neonatal	and	pediatric	intensive	care.
•	 To	review	the	current	knowledge	of	age-related	variation	in	processes	that	govern	
oral drug absorption.
•	 To	review	the	current	literature	on	human	membrane	transporters	during	childhood.
•	 To	assess	the	ontogeny	of	relevant	human	membrane	transporters	gene	and	protein	
expression in pediatric intestinal and hepatic tissues.
•	 To	study	the	feasibility	of	[14C]-labeled microdosing studies in children.
•	 To	investigate	the	effect	of	age	on	the	combined	intestinal	and	hepatic	glucuronida-
tion and sulfation in young children, using a paracetamol microdosing study.
Part i describes a study on the extent of the oral drugs used in neonatal and pediatric 
intensive care [chapter 2].The available data on age-related changes in gastro-intestinal 
processes that govern oral drug absorption is highlighted in chapter 3. In chapter 4 and 
5 extensive up-to-date overviews are given on the ontogeny of membrane transport-
ers in children. Chapter 4 is a complete history of available transporter ontogeny data. 
Chapter 5 reviews the literature on the role of transporter ontogeny on pediatric drug 
disposition and effect.
Part ii focusses on the hepatic and intestinal membrane transporters. In chapter 6, 
the age-related changes in gene expression of MDR1, MRP2, OATP1B1, OATP1B3 and 
OATP2B1 are studied in intestinal and hepatic fetal and pediatric tissues. Intestinal 
PEPT1 mRNA expression and PEPT1, MDR1, MRP2 and OATP2B1 protein localizations 
are discussed in chapter 7. Chapter 8 evaluates the protein expression in hepatic tissues 
during fetal and childhood age.
Part iii presents the results of a [14C] labeled paracetamol microdosing study in children. 
Chapter 9 presents pilot data to describe the proof-of-concept of microdosing studies in 
children. Chapter 10 evaluates our study and a second study using [14C]paracetamol in 
children of 0-2 years. The effect of age on intestinal and hepatic paracetamol glucuroni-
dation and sulfation is described in chapter 11.
Part iV summarizes and discusses the results of these studies in the respect of available 
relevant literature, and speculates on areas of future research [chapter 12 and 13].
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AbstrAct
introduction
The disposition of orally prescribed drugs in critically ill children may be affected by age 
and critical illness, resulting in erratic effects and safety. We aimed to study oral drug 
prescribing in the neonatal and pediatric intensive care unit (NICU and PICU).
Methods
A one-year retrospective cohort study of all drug prescriptions, including route of ad-
ministration for all children admitted to the NICU and PICU of the Erasmus MC - Sophia’s 
children’s hospital.
results
1723 children with 2091 unique admissions received per admission (median [IQR]) 5 
(3-10) drugs; 1 (0-2) orally and 3 (1-7) intravenously (IV). During mechanical ventilation 
15% and 75% of drugs were given orally and IV, respectively. In non-ventilated patients, 
27% of drugs were given orally and 60% IV. The 5 most frequently orally prescribed 
drugs were: vitamin K, spironolactone, oral probiotics, amphotericin B (prophylaxis) and 
trimethoprim.
conclusion
Critically ill infants receive a considerable proportion of drugs orally, which might expose 
them to an increased risk of ineffective or unsafe drug therapy. This may similarly apply 
to other patient populations with clinical conditions potentially affecting intestinal drug 
absorption.
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introDuction
In the intensive care unit (ICU) it is assumed that patients typically receive considerably 
smaller proportions of oral drugs compared to patients in the community or at general 
hospital wards. Surprisingly, the extent to which ICU patients receive drugs orally has 
not been studied.
Most ICU patients have more than one intravenous (IV) line centrally or peripherally. 
Due to critical illness, oral drug absorption may be erratic, e.g., by changes in intestinal 
motility, gastric pH, intestinal wall permeability and venous portal flow. Moreover, in 
children the absorption of oral drugs may be affected by age-related changes in the pro-
cesses involved in drug absorption leading to even more variation in oral drug absorption 
[1, 2]. Hence, in critically ill children, intravenous administration is generally preferred for 
life-saving drugs. Nevertheless, several reasons can be identified for oral drug adminis-
tration: i.e., appropriate IV formulations may not be available, IV administration may be 
associated with more severe adverse events (e.g., infections associated with central lines 
and hypotension with sildenafil), or the site of action is the gastrointestinal tract (e.g., 
antifungal prophylaxis). Moreover, polypharmacy with incompatible drugs through the 
available intravenous access ports, inability to gain any venous access and higher costs 
of intravenous administration may all be reasons for oral drug administration.
Consequently despite the notion that oral drug administration may lead to erratic ab-
sorption, many drugs are prescribed orally to critically ill patients for legitimate reasons. 
As a first step towards improving the efficacy and safety of drug therapy in critically ill 
children, we aim to identify the prevalence of oral drug administration in this population, 
and to identify which types of drugs are most frequently administered orally. This study 
also serves as a proof of concept to further study oral drug use in other, non-critically 
ill patient populations with underlying disease also affecting drug absorption, such as 
oncology, heart failure and intestinal disease patients.
MAtEriAls / MEthoDs
Data on drug administration were collected from all patients admitted to the neonatal 
or pediatric ICU of the Erasmus MC – Sophia children’s hospital over a one-year period. 
The medical ethical review board of the Erasmus MC waived the need for ethics board 
approval for this study, according to the Dutch law on medical research with humans, as 
only patient chart data were collected.
In the electronic patient data management system (PDMS), the ICU nurse checks off 
the drug order as soon as the drug has been administered to a patient, and these verified 
orders were used for analysis. Other collected data from electronic medical records were: 
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gender, date of birth, primary diagnosis, intensive care (IC) admission and IC discharge 
date, invasive mechanical ventilation (yes/no), and all drugs administered to the patient 
with the associated route of administration. Oral route includes: oral, buccal, enteral, per 
feeding tube (gastric/duodenal), gastrostomy. Intravenous also includes per central line. 
Other routes included: rectal, nasal, eye, ear, tracheal, (sub)cutaneous, intramuscular 
local, topical, peritoneal, loco-regional, or epidural.
All data were collected per day of admission. Receiving a drug on a day was defined as 
a minimum of one dose (independent of actual dose). Parenteral nutrition was excluded. 
A patient was considered to have received invasive mechanical ventilation if the dura-
tion for a specific day was at least 6 hours. The primary outcome was the proportion of 
orally administered drugs in relation to drugs administered intravenously and by other 
routes. Secondary outcomes were the proportion of orally administered drugs, in ven-
tilated and non-ventilated patients. Furthermore, we described the 10 most frequently 
prescribed oral drugs by age group.
The data were expressed as median values with ranges or numbers with percentages. 
The data have a multilevel structure, where the administration (including mode of ad-
ministration) of each drug is measured for each admission each day. Each admission 
consists of one or more admission days, and multiple admissions are included for some 
patients. Descriptive data (age, admission days per patient, days with mechanical ven-
tilation or enteral/tube feeding) are described on the patient level, whereas diagnosis, 
proportion drugs per route and most frequently prescribed drugs are described on the 
level of an admission. For the proportion of drugs per admission, the admission days are 
pooled, so that a patient was considered to have received a drug during an admission 
if the drug was administered on any day of the admission. For the secondary analysis, 
ventilated and non-ventilated days were pooled separately and per patient one or two 
proportions resulted (not ventilated at all and ventilated all days was one proportion, 
partially ventilated was two proportion: with and without ventilation). Data manage-
ment and statistical analyses were performed using R and IBM SPSS Statistics software 
(SPSS Statistics for Windows, version 21.0; IBM, Armonk, NY).
rEsults
From July 1, 2014 to June 30, 2015, 2091 admissions of 1723 unique patients were 
recorded, with 17256 days of admission with medication use. Patient demographics are 
summarized by age group in table 1. In total 499 unique drug/route combinations were 
given. The median (IQR) number of drugs patients received per admission was 5 (3-10), 
this was 1 (0-2) per oral route, and 3 (1-7) per IV route. In mechanically ventilated pa-
tients (578 admissions) 15% of drugs were given orally and 75% IV. When patients were 
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not ventilated either before or after ventilation episodes or not at all in an admission, 
27% of drugs were given orally and 60% IV (Figure 1). The ten most prescribed oral drugs 
per age group are also shown in Table 1.
table 1. Patient demographics and results
Legend: (Median [range]) MV: mechanical ventilation. Prednison/prednisolone, HCT: hydrocholothiazide
characteristics newborns up to 
1 month
1 month to 1 year 1 year to 12 years 12 years to 19 years
Patients
Number of patients 752 288 450 233
Postnatal age at day 
of admission
0 (0-4) weeks 5 (1-12) months 4.6 (1-12) years 15 (12-19.5) years
Gestational age at 
birth (days)
223 (167-296)
(n=544, 
missing=208)
N/A N/A N/A
Total number of 
admission days
10217 3107 2811 1121
Median admission 
days per patient
6 (1-274) days 2 (1-188) days 2 (1-261) days 2 (1-135) days
Patients receiving 
MV during 
admission
58% (n=334) 21% (n=122) 17% (n=96) 5% (n=26)
Days MV per 
admission
4 (1-81) 4 (1-69) 3 (1-53) 3 (1-53)
Days with enteral 
feeding
0 (0-50) 0 (0-33) 1 (1-259) 1 (0-64)
Days with tube 
feeding
5 (0-255) 2 (0-163) 0 (1-224) 0 (0-129)
Admissions
Number of 
admissions
799 441 594 257
Median number of 
days per admission
6 (1-274) days 3 (1-169) days 2 (1-261) days 2 (1-135) days
Diagnosis: n % n % n % n %
1. Respiratory 108 14 40 9 86 15 21 8
2. Circulatory 36 5 44 10 43 7 23 9
3. Surgery 82 10 168 38 143 24 100 39
4. Other 240 30 189 43 322 54 113 44
5. Pre-/dysmaturity 333 42 N/A – N/A – N/A –
Proportion drugs per: % % % %
Oral route 18 23 27 29
Intravenous route 70 62 62 62
Other route 12 15 11 9
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Discussion
In critically ill children, intravenous drug administration is preferable but for many 
reasons drugs are administered orally. The extent and nature of oral drug prescribing 
in this population is not known. Data in our level III NICU and PICU shows that 15 and 
27% of drugs are given orally to ventilated and non-ventilated patients, respectively. 
As ventilated children are not able to take drugs by mouth and may not tolerate any 
oral food or drug, we also analyzed these groups separately. From a pharmacological 
point-of-view, this outcome is rather surprising as it shows a considerable extent of oral 
drug use and possible erratic drug absorption. The most often prescribed oral drugs 
table 1. Patient demographics and results (continued)
characteristics newborns up to 
1 month
1 month to 1 year 1 year to 12 years 12 years to 19 years
Oral drug n n n n
1 Vitamin K 299 Spironolacton 98 Trimethoprim 97 Paracetamol 54
2 Oral Probiotics 275 AmphotericinB 64 Macrogol 80 Macrogol 41
3 Spironolacton 112 Vitamin K 48 Spironolacton 64 Celecoxib 29
4 HCT 72 Lorazepam 44 Amphotericin B 56 Melatonine 22
5 AmphotericinB 51 HCT 39 Omeprazol 53 Omeprazol 19
6 Nystatin 49 Trimethoprim 34 Paracetamol 52 Diclofenac 19
7 Trimethoprim 29 Omeprazol 26 Prednison 41 Prednison 17
8 Omeprazol 23 Propranolol 24 Levetiracetam 36 Trimethoprim 15
9 Doxapram 22 Macrogol 22 Melatonine 35 AmphotericinB 15
10 Oxybutynin 16 Domperidon 20 Azithromycin 33 Azithromycin 12
INTRAVENOUS ROUTE
60%
ORAL ROUTE
27%
OTHER 
ROUTE
13%
Non-ventilated admissions
INTRAVENOUS ROUTE
61%
ORAL ROUTE
27%
OTHER
ROUTE
11%
Before/after ventilation
INTRAVENOUS ROUTE
75%
ORAL ROUTE
15%
OTHER 
ROUTE
9%
During ventilation
Ventilated admissions 
figure 1. Proportion of drugs per route
Total number of drugs in the days per admission or per ventilated/non-ventilated days of admission. At 
least one day receiving a drug. Different routes of the same drugs are noted as different drugs.
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consisted of oral probiotics, amphotericin B, and macrogol, for which erratic oral absorp-
tion is less relevant as its target is the gut or the gut flora. In contrast, other frequently 
prescribed drugs for which erratic oral absorption may affect their efficacy and safety 
are: analgesics, diuretics, vitamin K, omeprazole, and lorazepam. To date, data on the 
efficacy and safety of for example omeprazole, hydrochlorothiazide, spironolactone and 
lorazepam in this population are very scarce or completely lacking [3]. Moreover, no 
licensed liquid formulations are available. Extratemporaneous formulations are used, 
including IV formulations and crushed tablets. This further illustrates the risks associated 
with oral drug use in this setting.
Information is available about drug utilization in pediatric pharmacotherapy; most 
studies, however, are aimed on the statistics of the use of off-label and unlicensed drugs, 
but did not specify differences in label status by administration route [4-6]. Interest-
ingly very little data are available on the extent of drug prescription per route. One drug 
utilization study in a NICU in India found 92% of prescribed drugs in 6 months were 
intravenously used [7]. This is far more than the 70% of IV drugs in neonates of our study, 
although the non-western setting may be quite different.
Maat et al. looked at the rate of pharmacy interventions after electronic prescribing in 
a four-year study in a tertiary children’s hospital (excluding the ICUs) [8]. Interestingly, 
of all medication-related characteristics, the oral dosage form and oral route of admin-
istration had relatively highest risk for interventions on prescriptions done by clinical 
pharmacists (OR=1.63 [95%CI 1.41-1.88] and OR=1.80 [95%CI 0.38-0.67]).
The strengths of this study include the large sample size, recent data and a reflection 
of current daily practice. Moreover, our data display actual administered drugs to the 
patient instead of prescriptions that might be changed before it arrives to the patient. 
To our knowledge, this is the first study specifically identifying oral drug use in the 
neonatal and pediatric ICU. There are some limitations. First, input mistakes on route 
of administration are rare but cannot be excluded. Second, in our institution, PDMS 
recordings continue while a patient is away from the ICU during surgery and drugs used 
during surgery are also recorded. This may have contributed to an underestimation 
of the proportion of oral drug use, as in this setting oral drug use is virtually absent. 
Third, drug dose and frequency of administration per day were not analyzed. Finally, this 
single-center study was performed in a tertiary Dutch referral hospital and data may not 
be completely translatable to other centers.
Oral prescriptions may not be all bad, as oral administration may reduce drug admin-
istration costs and IV line related infections. Physicians’ choosing the oral route should 
nevertheless be aware of the uncertainties related to the oral disposition of drugs in 
critically ill children and should weigh these uncertainties against the apparent advan-
tages. Our paper presents data on oral prescription in a specific patient population; i.e., 
critically ill children. The uncertainties in oral drug exposure may similarly apply to other 
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patient populations, including adults, where oral drug absorption may also be affected 
by underlying clinical conditions disease, e.g., intestinal disease, heart and liver failure, 
cancer and in palliative care.
In conclusion, orally administered drugs comprise up to 27% of the pharmacotherapy 
of patients in the ICU, possibly leaving children at risk of ineffective or unsafe drug 
therapy.
Significant oral drug use in critically ill children 29
2
rEfErEncEs
 [1] Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental 
pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 2003 
Sep 18; 349(12): 1157-67.
 [2] Mooij MG, de Koning BA, Huijsman ML, de Wildt SN. Ontogeny of oral drug absorption processes 
in children. Expert Opin Drug Metab Toxicol 2012 Oct; 8(10): 1293-303.
 [3] Segar JL. Neonatal diuretic therapy: furosemide, thiazides, and spironolactone. Clin Perinatol 
2012 Mar; 39(1): 209-20.
 [4] Kumar P, Walker JK, Hurt KM, Bennett KM, Grosshans N, Fotis MA. Medication use in the neonatal 
intensive care unit: current patterns and off-label use of parenteral medications. J Pediatr 2008 
Mar; 152(3): 412-5.
 [5] Kieran EA, O’Callaghan N, O’Donnell CP. Unlicensed and off-label drug use in an Irish neonatal 
intensive care unit: a prospective cohort study. Acta Paediatr 2014 Apr; 103(4): e139-42.
 [6] Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK, Jr., Smith PB, et al. Medication use in 
the neonatal intensive care unit. Am J Perinatol 2014 Oct; 31(9): 811-21.
 [7] Chatterjee S, Mandal A, Lyle N, Mukherjee S, Singh AK. Drug utilization study in a neonatology 
unit of a tertiary care hospital in eastern India. Pharmacoepidemiol Drug Saf 2007 Oct; 16(10): 
1141-5.
 [8] Maat B, Au YS, Bollen CW, van Vught AJ, Egberts TC, Rademaker CM. Clinical pharmacy interven-
tions in paediatric electronic prescriptions. Arch Dis Child 2013 Mar; 98(3): 222-7.

3 Ontogeny of oral drug absorption processes in children
Miriam G. Mooij, Barbara A.E. de Koning, 
Mark L. Huijsman, Saskia N. de Wildt
Expert Opinion on Drug Metabolism & Toxicology 2012, 
Oct;8(10):1293-303
32 Chapter 3
AbstrAct
introduction
A large proportion of prescribed drugs to children is administered orally. Age-related 
change in factors affecting oral absorption can have consequences for drug dosing.
Areas covered
For each process affecting oral drug absorption, a systematic search has been performed 
using Medline to identify relevant articles (from inception till February 2012) in humans. 
This review presents the findings on age-related changes of the following processes 
affecting oral drug absorption: gastric pH, gastrointestinal motility, bile salts, pancreatic 
function, intestinal pH, intestinal drug-metabolizing enzymes and transporter proteins.
Expert opinion
Clinicians should bear in mind the ontogeny of oral drug absorption processes when 
prescribing oral drugs to children. The authors’ review shows large information gaps on 
almost all drug absorption processes. It is important that more knowledge is acquired on 
intestinal transit time, intestinal pH, and the ontogeny of intestinal drug-metabolizing 
enzymes and drug transporter proteins. Furthermore, the ultimate goal in this field 
should be to predict more precisely the oral disposition of drugs in children across the 
entire pediatric age range.
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introDuction
orally administered drugs in children
A large proportion of drugs prescribed to children is administered orally [1]. Absorption 
of orally administered drugs may be affected by extrinsic factors (food and formulation) 
and intrinsic factors of a physiological nature. The latter includes volume of gastroin-
testinal fluids, the pH and buffer capacity of these fluids, contraction patterns, gastro-
intestinal transit, digestive enzymes, intestinal cellular transporters, drug metabolism 
enzymes, and intestinal bacterial flora [2]. Solubility and intestinal permeability of 
the individual drug will influence the impact of gastrointestinal (GI) processes on its 
absorption. A theory-based oral drug classification based on solubility and permeability 
characteristics of drugs, such as the biopharmaceutics classification system (BCS), may 
serve to predict which extrinsic or intrinsic variables will alter oral drug absorption [2, 3].
As many of the GI processes change with age, oral drug absorption expectedly will 
change with age as well [4]. The current EU and US regulations aimed at stimulating 
the study of drugs across the pediatric age range, have given an impetus to promoting 
clinical trials in children [5, 6]. Age-specific information on the processes governing drug 
disposition in children is needed for modelling and simulation approaches. Important 
progress has been made to elucidate age-related changes in: hepatic drug metabolism 
and renal excretion [7, 8]. By contrast, our knowledge on developmental changes in the 
GI processes involved in oral drug absorption is far less developed [4, 9-11].
The aim of this review is to present the available data on age-related variation in 
GI processes that govern oral drug absorption processes. We performed a systematic 
search in the literature using Medline. Reference lists of relevant retrieved papers were 
screened for additional relevant articles. We discuss current information gaps and pro-
vide suggestions for future research that may lead to develop evidence-based dosing 
guidelines for oral drugs in children.
Age-related changes in oral drug absorption processes
Gastric pH
Gastric pH is an important factor determining the stability of a drug passing through the 
stomach. Studies on gastric pH across the pediatric age range used pH measurement of 
gastric fluid aspirates and 24-h intragastric pH monitoring [12-29]. Figure 1 displays the 
mean and median gastric pH values in healthy children in the first three months of life.
The mean gastric pH in newborns min after delivery is 7.05, and within a few hours it 
declines to a pH of 2.7 [13, 28]. A less acidic stomach environment in these newborns af-
ter delivery is most likely explained by swallowing of amnion fluids, which is supported 
by the decrease in pH within a few hours after birth [28]. More than seventy years ago, 
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Miller observed a decrease in acidity over the first 10 days of life [30]. Many more recent 
studies report that the gastric pH declines already within a few hours after birth [13, 
28]. Miller titrated gastric juice with NaOH and then determined the amount of HCl as 
a measure of acidity. However, Miller did not provide information on the acidity of the 
primary gastric content; therefore, we are unable to translate this outcome to pH. Many 
other studies subsequently showed that the gastric pH remains low at a pH around 2 
and 3 in children of all ages [12, 14-27, 29].
More rarely, gastric pH can be described in terms of the proportion of time it peaks 
above 4 measured over 24 hours. In preterm infants, this proportion ranged from 46% 
to 70% over a 24-h period [31, 32]. In children up to 2 years of age it was around 51%; 
in older children it was 34% [33]. The higher proportion in younger children might be 
explained by the buffering effects of milk formula, older children are less frequently fed 
and receive more solid foods [23, 25, 33]. 24-h pH monitoring reflects the buffering ef-
fect as well; in preterm infants, the gastric pH first increased to 7 postprandially, but then 
immediately steadily declined to a pH of 2 [23]. Another study showed a similar pattern 
with a mean gastric pH returning to a value of 1.8 within 180 min postprandially [25]. 
Apparently, during the day, younger children tend to have more often a basic gastric 
environment than older children, although the mean gastric pH remains around 2 or 3 
in children of all ages.
figure 1. Gastric ph measured in neonates by 24-h monitoring or gastric aspirates.
References correspond with references in the text.
A: Gastric aspirates 3 minutes after delivery; vaginal delivery [12]
B: Gastric aspirates 3 minutes after delivery; caesarean section [12]
C: Less than 3 hours after delivery [13]
C, D, F, G: Continuous 24-h gastric pH monitoring [13, 18, 19, 25]
A, B, E, H: Gastric aspirates obtained by gentle suction [12, 12, 27, 26]
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Interestingly, this overview gives reason to contradict the widespread notion that 
absorption of gastric pH-dependent drugs in both neonates and young infants is af-
fected by high gastric pH [34, 35]. Gastric pH may be high due to continuous enteral 
feeds, but is comparable to adult values when oral feedings are given at longer than 3 
hour intervals. Children older than one week of age will typically receive such intermit-
tent feeding, especially during the night. We have not been able to identify studies that 
compared effect of different feeding regimes (continuous and intermittent) on drug 
absorption in neonates.
The consequences of changes in gastric pH are relevant for acid-labile drugs. These 
may be absorbed more efficiently in a higher gastric pH environment achieved by very 
frequent or continuous feeding regimens. Huang et al. found that serum penicillin levels 
in premature and term newborns were higher than those in infants and children. These 
age-related changes were hypothesized to be either due to higher gastric pH in the first 
10 days of life or to altered renal function [36].
Gastrointestinal motility
Gastric emptying
Next to intestinal motility, gastric emptying is a primary determinant of the rate at which 
drugs are presented to the small intestinal mucosa for absorption. Gastric emptying is 
usually measured by the following methods: gastric emptying breath test, scintigraphic 
procedure by Technetium-99M liquid gastric emptying scan or the paracetamol absorp-
tion test. Gastric emptying time is reported in various ways: gastric emptying time, 
gastric half-emptying time or residual gastric activity at 1 h.
We identified three studies using the gastric emptying breath tests. Hoekstra et al. 
tested the effect of glucose and fructose on gastric emptying using an L-glycine-1-13C 
breath test in four healthy children (mean age 14.3 years; age range 12.1-16.0 years). 
Gastric half-emptying time after fructose intake was 45.5 min (SD 4.9); after glucose 
intake 64.3 min (SD 2.4). Gastric half-emptying time was significantly longer when fruc-
tose and glucose were administered together, that is, 85.3 min (SD 7.0) [37]. The authors 
considered all values to be in the normal ranges established with other methods. Using 
the 13C-octanoic acid breath test, Perri et al. found a gastric half-emptying time of mean 
121 min (SD 42) in nine healthy control patients (mean age 9 years; age range 4-16 
years). These children had eaten a standard test meal (bread, ham, juice, egg), however, 
which hardly compares with a smaller fructose and/or glucose administration [38]. Hoff-
man et al. subjected 22 patients with gastroesophageal reflux symptoms (mean age 13.2 
years) to the 13C-octanoic acid breath test and compared half-emptying results between 
patients with or without pathologic acid exposure (84 (SD 24) vs 86 (SD 26) min) and 
with or without duodenogastroesophageal reflux (105 (SD 47) vs 76 (SD 24) min) were 
36 Chapter 3
compared. Results were not statistically significantly different [39]. In conclusion, breath 
test measurements for gastric emptying rate are highly variable and, probably for practi-
cal reasons, that tests have only been performed in relatively older children.
Scintigraphic imaging makes it possible to measure the gastric emptying time or 
gastric half-emptying time as well as the residual gastric activity at 1 h. We identified 
seven useful scintigraphy studies. In 10 preterm infants (median gestational age 28.9 
weeks; range 26-33), the median gastric half-emptying time at a postnatal median age 
of 9 days (range 6-37) was 60 min (30-180 min) [40]. Patients were all hourly fed although 
not receiving a standard meal size. The residual gastric activity at 1 h was 37.5% (range 
19-100%) [40]. Di Lorenzo and colleagues conducted a study in 477 patients across a 
wide age span; 291 patients with and 186 patients without gastroesophageal reflux dis-
ease (GERD) (based on pH and/or scintigraphy investigations) [41]. In children without 
bolus or acidic gastroesophageal reflux, gastric residual activity at 1 h was around 65% 
in those up to 3 years of age; it decreased to 51% in the age group 4-6 years; and to 
45% in children over 6 years of age [41]. Seibert et al. reported an opposite outcome in 
children being evaluated for gastroesophageal reflux (GER): the percentage emptied at 
1 h instead of the percentage residual activity [42]. The percentage emptied at 1 h was 
48% (SD 16) in 44 infants (mean age 5.7 months, range 1-23) and 51% (SD 7) in 8 children 
(mean age 9.1 years, range 2-14.5 years). When converted to residual gastric activity, 
values are still comparable (respectively 52% and 49%). Note that in the study reported 
by Di Lorenzo et al., a delay in gastric emptying was not related to GER symptoms until 
the age of 6 years [41]. Cucchiara et al. studied a poorly described control group suffer-
ing from diarrhoea and failure to thrive not related to gastrointestinal symptoms. The 
gastric emptying activity at 1 h was 38.1% (SD 6.5) [43]. Miele et al. reported a 43.3% (SD 
8.7) gastric emptying activity at 1 h in a control group of 11 children without gastroin-
testinal or neurologic disorders (mean age 5.6 years; SD 3.9 years; range 2-12 years) [44]. 
Describing gastric emptying alternatively as a mean emptying half time, Yahav et al., 
reported 87.8 min (SD 22.9) mean gastric emptying time in a control group with a mean 
age of 10.4 months for which no other details are reported [45]. Demirbilek et al. found 
an average gastric emptying time of 51.6 min (SD 8.04) in a selected group of children 
with GERD (mean age 3.2 years; SD 1.1); the selection might have resulted in bias [46].
To relate these results to adults, reported healthy adult gastric emptying times range 
between 56 (32-85) and 104 (49-126) min, for liquid and solid markers respectively [47, 
48].
Finally, the paracetamol absorption test was used in two small cohorts. In 15 critically 
ill patients (median age 5.3 years; interquartile range 1.2-6.5) who were food tolerant, 
it revealed a median 1.5 (interquartile range 0.7-2.2) ratio of time to reach paracetamol 
peak to the maximum paracetamol concentration (Tmax/Cmax) [49]. In seven adoles-
cents (mean age 16.4 years; SD 0.7 years; range 15.5-17.5), it revealed a paracetamol 
Ontogeny of oral drug absorption processes in children 37
3
absorption ratio of 1.4 for high-fat meals and 0.5 for low-fat meals [50]. The evidence of 
these two studies is too limited to conclude on age-related changes.
However, population pharmacokinetic analysis applied in another study yielded 
a significantly lower oral paracetamol absorption rate in the first days of life before 
stabilizing after 1 week [51]. The lag time reflects the time to reach and permeate the 
absorbing surface of the intestine [2]. Considering that a lag time was observed after 
oral paracetamol administration only and not after rectal administration, it suggests 
that gastric emptying may be the primary determinant of a lag time for oral absorption 
of paracetamol.
Antroduodenal contractions
Antroduodenal motor activity plays a role in the gastric emptying next to fundic con-
traction, pyloric sphincter relaxation and intestinal motor activity. It can be determined 
by antroduodenal manometry, which measures intraluminal pressures of the distal 
stomach and the proximal small bowel.
Fasting antral motor activity and antral motor activity in response to intraduodenal 
feeding did not significantly differ between term and preterm infants [52]. By contrast, 
the proportion of antral clusters temporally associated with duodenal activity in pre-
term infants was significantly lower than that in term infants. Moreover, the degree of 
association of antral and duodenal activity increased significantly with gestational age 
[53]. In preterm infants 29 to 32 weeks of gestational age, the frequency of contractions, 
the number of contractions per burst and the intraluminal peak pressure of duodenal 
motility during contractions all increased with postgestational age, resulting in a more 
efficient motility [54]. Similarly Bisset et al. reported that both the magnitude and or-
ganization of motor activity increased with increasing gestational age [55]. Berseth et 
al. reported shorter lasting individual duodenal cluster activity during fasting periods 
in preterm than in term infants, but duodenal motor activity in response to feeding in-
creased similarly in both groups [52]. The timing of introducing food seems to influence 
the preterm neonates’ (28-32 weeks of gestational age) duodenal motor activity; intro-
ducing formula early (day 3-5 postnatally) resulted in more mature motor complexes 
than introducing formula late (day 10-14 postnatally) [56]. Preterm infants showed more 
immature duodenal motor activity response to bolus feeding then did term infants [57].
In conclusion, proximal intestinal (duodenal) motor activity in contrast to antral motor 
activity matures throughout the first weeks of life, with increasing frequency, amplitude, 
and duration of propagating contractions. Regrettable, there are no such studies in 
healthy children beyond the newborn period.
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Intestinal transit time
Overall, gastrointestinal motility can be expressed as orocecal transit time (OCTT). This 
can be measured by different techniques: hydrogen breath test, 13C Ureide breath test, 
radiotransmitting capsule, red carmine marker test or scintigraphy. Most common is 
the hydrogen breath test with lactulose as nonabsorbable carbohydrate substrate. This 
breath test has limited use in the general population, which may include hydrogen-
non-responders. Also lactulose may accelerate transit time by its osmotic laxative effect. 
Accordingly, Vajro et al. reported in 11 control patients that the mean OCTT after a meal 
was significantly longer than that after lactulose [58]. Although this method can be used 
to compare groups in standardized studies, it is merely an approach to the physiological 
situation of intestinal motility.
We identified four studies using the hydrogen breath test to measure OCTT in differ-
ent pediatric age groups [58-62]. The populations were quite heterogeneous, but there 
does not appear to be an age-related difference in OCTT. In the whole age range from 1 
to 17 years, the mean OCTT was roughly between 60 and 110 min, as in adults [62]. The 
mean OCTT measured by the lactose-13C-ureide breath test was 255 min (range 165-
390) in children from 3 to 17 years of age [59]. This method cannot be used in infants 
below 6 months of age as they lack the intestinal bacterial enzymatic activity. In adults, 
the latter test was validated in respect to scintigraphy [63]. The lactulose-H2 breath test 
yielded a significant shorter OCTT than did the labeled ureide test, which may be due to 
the effect of lactulose [64]. Fallingborg et al. distinguished small intestinal and colonic 
transit times with the use of a radiotransmitting capsule in a small population of 12 
healthy children (8 to 14 years) [65]. Small intestinal transit time was 7.5 h and colonic 
transit time was 17.2 h. Interestingly, from the number of observations in each segment 
they estimated that the capsule resided in the duodenum for 8% of the small intestinal 
passage, in the proximal part of the small intestines for 5%, in the mid part for 12% and 
in the distal part for 75%. The small intestinal transit time of 7.1 h is considerably longer 
than that established by the breath tests. The fact that the capsule, which was larger 
than 2 mm, was located in the distal part of the terminal ileum for 75% of the small 
intestinal transit time suggests a longer ileo-cecal transit for large particles. By means 
of scintigraphy, Bodé et al. measured a mean OCTT of 3.1 h (range 1.3-6.1 h) in nine 
premature infants (mean gestational age 28.9 weeks) [40].
Bile acids
Bile is a complex secretory product produced by the liver. It eliminates waste products 
from the body and it promotes digestion and absorption of lipids by the intestines. In 
preterm neonates, the concentration of the bile acids was found to be 4.55 mmol/l in 
the first few weeks postnatally [66]. In 65 healthy preterm newborns, the total bile acid 
concentration was consistently higher in those fed with human milk in comparison with 
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those fed with formula. Concentrations did not significantly increase over a 3-week 
follow-up period [67]. Concentration did not differ between small- and appropriate-for-
gestational-age premature infants [66]. Challacombe et al. compared three age groups, 
that is, 2 days postnatal (n=12), 2 to 7 days (n=8), and 10 days to 7 months (n=14). 
Gestational ages were not documented. The total bile acid concentration in the oldest 
group was much higher than that in both other groups and at a value comparable to 
those in adults [68].
Changes in biliary function can influence solubilization and consequently absorption 
of lipophilic drugs [3].
Pancreatic function
The exocrine pancreas is a specialized secretory gland, which secretes juice rich in HCO3- 
and digestive enzymes that neutralizes the acidic gastric contents and helps digest food. 
Functioning of the exocrine pancreas is typically measured by the fecal elastase-1 (E-1) 
concentration. The E-1 enzyme is highly specific for the pancreas and is not degraded 
during the intestinal passage. Age-related differences in E-1 concentrations were absent 
in a large cohort of healthy subjects (mean age 11.2 years (SD 0.5); age range 2 months 
to 52 years) [69]. Even as many as 96.8% of preterm and term infants up to the age of 12 
months without known bowel or pancreatic disorders had adult E-1 values after 2 weeks 
of life, independent of gestational age [70]. However, up to 48 hours after birth, none 
of the preterm infants had a fecal E-1 concentration of greater than 30 µg/g meconium, 
whereas 43% of the term infants had normal adult values. This discrepancy may be due 
to either immaturity or insufficiency of the exocrine pancreatic function in premature 
neonates. However, the small sample size did not allow differentiating between these 
two possible causes. Deficient exocrine pancreas function as seen in cystic fibrosis 
patients was associated with lower oral bioavailability of mycophenolate mofetil [71]. 
This suggests an effect on oral drug absorption in neonates with immature pancreas 
function, but this has not been studied to date to our knowledge.
intestinal ph
In comparison with gastric pH, remarkably little is known about the intestinal pH in 
children. Fallingborg et al. measured gastrointestinal pH with a radiotransmitting pH-
sensitive capsule in 12 healthy children aged 8-14 years. The mean value of pH rose 
from 1.5 in the stomach to 6.4 in the duodenum; in the distal part of the small intestine, 
it reached an alkaline peak value of 7.4. The pH profile was almost identical to that in 
healthy adults. A broad conclusion on the development of the intestinal pH cannot be 
drawn as his small population consisted merely of older children. It would be worthwhile 
to repeat the experiment in other age groups [65].
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Intestinal drug metabolism
Many developmental changes in hepatic drug metabolism and renal clearance have 
been well documented. Data on the ontogeny of intestinal metabolism remain scarce. 
What is known is that enzymes of the cytochrome P450, especially the 3A (CYP3A) sub-
family, are abundant in liver and gut and contribute to the first-pass metabolism of many 
orally administered drugs in adults [72]. Hepatic CYP3A forms present a developmental 
expression in fetal and pediatric samples; CYP3A4 and CYP3A7 expression levels show 
to be age dependent with respectively increasing and decreasing levels of total CYP3A 
expression levels [73].
CYP3A ontogeny can be reported as changes in mRNA, protein or activity levels. We 
identified two in vitro studies on CYP3A ontogeny in the intestine. One studied 59 his-
tologically normal duodenal biopsies from children aged 1 month to 17 years for CYP3A 
mRNA by quantification and CYP3A proteins localization by immunohistochemistry [74]. 
The other studied duodenal biopsies and surgical sections from 104 children aged 2 
weeks to 17 years and 11 fetuses for CYP3A protein expression by immunohistochem-
istry and activity by the formation of 6beta-hydroxytestosterone from testosterone 
[75]. CYP3A4 and CYP3A5 mRNA expression levels were to decrease with age, showing 
expression levels were high in the first year of life and decreased thereafter [74]. This is 
in contrast with protein expression levels reported in the second study showing CYP3A 
protein expression significantly increased with age [75]. The discrepancy of decreasing 
mRNA expression and increasing protein levels with age might reflect a posttranscrip-
tional regulatory mechanism that is not elucidated to date according to the authors 
[74]. Dissociation between protein and mRNA levels during the maturation process was 
already reported for CYP2D6 liver enzymes [76]. The location of the CYP3A protein in 
enterocytes assumes a maturation profile occurs. In the duodenal biopsies of children 
less than 6 months of age, CYP3A protein was detected in only 50% of the enterocytes; in 
the older children, however, CYP3A protein was expressed in all cells [74]. Moreover, the 
increase in CYP3A protein levels with age is mirrored with increasing CYP3A4 activity. It 
changes from undetectable in fetal samples, low in neonates and adult levels in children 
older than 5 years of age, as reflected by 6beta-hydroxytestosterone formation [75].
Intestinal CYP3A4, CYP3A5 mRNA levels have been established in pediatric liver recipi-
ents (age 0.1-15 years) at the time of transplant surgery [77]. Unfortunately, the authors 
did not study the effect of age within their cohort. Adult data show similar CYP3A4 and 
CYP3A5 expression levels [78]. This suggests that intestinal CYP3A expression does not 
change beyond childhood. However, because the range of levels reported in children 
was very wide, age-related changes from 0.1 year of age onwards cannot be excluded 
[78]. Intestinal CYP3A5 mRNA levels were significantly higher in CYP3A5*1 gene carriers 
(expressors) than CYP3A5*3 homozygous patients (non-expressors) and observed in 
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both the children and adult study. In CYP3A5*1 carriers, CYP3A5 mRNA accounted for 
20-30% of all CYP3A mRNA detected [77, 78].
In vivo studies on oral bioavailability of CYP3A substrates in relation to age are scarce. 
Our own research showed that median midazolam oral bioavailability in preterm infants 
(28-32 weeks, <10 days of age) is significantly higher than in adults (50 vs. 30%) [79-81]. 
This probably reflects developmentally low intestinal and hepatic CYP3A activity, as 
midazolam is a validated probe drug for CYP3A4/5 activity.
Interestingly, the type of feeding (breast milk or formula) seems to impact the devel-
opmental pattern of combined intestinal and hepatic CYP3A in neonates. In children 
who received oral dextromethorphan six times between two weeks and 6 months of 
age, the urinary metabolite/dextromethorphan ratio as a measure of CYP3A4 activity 
clearly increased over this period. Moreover, this increase was faster for formula- than 
breastmilk-fed children [82]. This finding suggests a differential effect of components of 
these milk formulations on the induction of intestinal and hepatic CYP3A activity in the 
first months of life.
The ontogeny of other drug metabolizing enzymes in the intestine remains to be 
elucidated.
Intestinal drug transporter
Multidrug resistance protein 1 (MDR1/P-glycoprotein) is a plasma membrane glyco-
protein acting as an efflux system. Based on in vitro studies, it is currently considered 
the most prominent gut transporter [83]. It is located in many tissues and specifically 
within the brush border in the small intestine. Its expression is genetically controlled by 
the ABCB1 gene [84]. MDR1 action in the enterocyte reduces the bioavailability of orally 
administered drugs as these are expelled into the intestinal lumen. MDR1 protein can 
be localized by immunohistochemistry and mRNA quantification in intestinal tissue. In 
the earlier mentioned study evaluating 59 duodenal biopsies of children aged from 1 
month to 17 year, MDR1 mRNA expression was highly variable and not related to age 
[74]. MDR1 protein was detected in all the enterocytes and was located on the apical 
surface. In the biopsies in children younger than 3 years, additional staining was located 
on a limited upper part of the lateral surface.
A possible age effect in relation to of the ABCB1 genotype was found for oral bioavail-
ability of the MDR1 substrate cyclosporine. One hundred and four children with renal 
disease (age 0.36-16.3 years) were grouped by age and genotyped for ABCB1 gene. The 
pre-hepatic extraction ratio of cyclosporine was ABCB1 genotype dependent only in 
children older than 8 years, resulting in corresponding differences in oral bioavailability. 
No such association was found in younger patients, which suggests an interaction of 
age and genotype on MDR1 activity [85].
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In the context of the previously mentioned study in pediatric liver recipients, MDR1 
mRNA was determined as well and results were similar as for CYP3A; that is, the median 
MDR1 mRNA expression did not differ between children and adults, but widely ranged 
in the pediatric population [77, 78].
Interestingly, in noninflamed duodenal biopsies of children with Crohn’s disease, 
MDR1 mRNA expression was significantly higher than that in normal biopsies. Expression 
of MDR1 was highly variable in both groups [86]. The effect of age was not examined in 
this study. The higher levels of MDR1 expression could have been induced by systemic 
inflammation present in Crohn’s disease, which is likely to lead to an elevated first-pass 
metabolism of xenobiotics used in the treatment.
To our knowledge, the intestinal ontogeny of other members of the ATP-binding 
cassette transporters, such as multidrug resistance protein 2 (MRP2/ABCC2) or breast 
cancer resistance protein (BCRP/ABCG2), has not been studied to date [83, 87-89].
conclusion
This literature review makes clear that GI processes that govern drug absorption change 
from the neonatal period up to adulthood. Consequently, these changes could have an 
impact on drug absorption depending on the drug characteristics [3, 4]. The review also 
brought to light important knowledge gaps regarding these processes and especially 
their impact on drug absorption.
Key findings in the research done so far are the following. Apart from a brief peak 
postnatally, the gastric pH is about 2-3 in children of all ages. Postprandial, its rise is due 
to the buffering effect of milk-based feeding. Especially in frequently fed neonates, the 
pH may, therefore, be higher for a longer period during a 24-h period, than in older chil-
dren who eat less frequently. Gastric emptying time reported in the literature is highly 
variable. Standard gastric emptying tests do not reveal evident age-related changes. 
Population pharmacokinetic analysis shows a markedly paracetamol absorption de-
crease in the first few days of life, which suggests delayed gastric emptying. This delay 
could perhaps be explained by maturation of antroduodenal contractions.
There are no studies done examining antroduodenal contractions beyond the neona-
tal period. Intestinal transit time (in terms of mean OCTT) does not appear to be subject 
to age-related changes; it is roughly between 60 and 110 min in the age range of 1-17 
years, as measured by hydrogen breath test. The one study that used a capsule to mea-
sure OCTT showed a much longer transit time than any of the other studies using the 
lactulose breath test. This latter test probably rather measures intra-individual changes 
in OCTT or differences between cohorts. A developmental change in biliary function ap-
pears to be present, with bile acids concentration reaching adult values around the age 
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of 4 years. Pancreatic function appears to be sufficient in the large majority of healthy 
newborns, independent of gestational age. Intestinal pH has only been studied in a 
cohort of older children. Adult values were found in this cohort; therefore, possible age-
related changes remain to be elucidated. For a large proportion of drugs, there seems to 
be a developmental pattern in CYP3A, which is the most important drug-metabolizing 
enzyme in the intestines. CYP3A protein and activity levels were found to increase with 
age. These in vitro data are in line with higher oral bioavailability of midazolam in prema-
ture children compared with adults. Evidence on possible age-related effect on MDR1 
activity is contradictory and not elusive yet.
ExPErt oPinion
information gaps
In summary, the main information gaps on the ontogeny of GI processes governing oral 
drug absorption have not yet been bridged. We need more knowledge on intestinal 
transit time, intestinal pH and the ontogeny of intestinal drug-metabolizing enzymes 
and drug transporter proteins. The ultimate goal of research efforts in this field should 
be to predict more precisely the oral disposition of drugs in children across the pediatric 
age range. Below we describe some research approaches, both in vitro and in vivo, which 
are promising for future research to provide a better understanding of oral drug absorp-
tion in children.
in vitro drug dissolution/solubility model (tiM)
The Dutch Institute of Innovative Research has developed the TNO Gastro-Intestinal Tract 
model (TIM), a computer-controlled dynamic system that mimics the physiological hu-
man conditions in stomach and intestines [90, 91]. Parameters such as pH, temperature, 
peristaltic movements, transit time, secretion of digestion enzymes, bile and pancreatic 
juices can be adjusted. Intraluminal processing of drug dosage forms, including transit, 
release and dissolution, can be simulated [92]. Removal of dissolved drug molecules 
from the intestinal compartments allows assessing the fraction of drug potentially avail-
able for small intestinal absorption [91]. This model has been extensively validated to 
simulate these processes in adults. It appears an interesting approach to test oral drug 
absorption in conditions with typical age-related physiological characteristics. Espe-
cially, the additional impact of existing oral formulations frequently given to children 
can be studied. It may also help to study the effect of drug manipulations to enhance 
drug ingestion by children (e.g., dissolving tablets in apple juice, apple sauce, ‘hiding’ 
in regular food, crushing). Representative drugs of the different BCS classes can also be 
studied systematically for dissolution and solubility.
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in vitro drug metabolism and transporter studies
The extensive studies on in vitro hepatic drug metabolism, for example, by the group of 
Hines and colleagues could serve as an example [93]. Similarly, the ontogeny of drug-
metabolizing enzymes and transporters should be studied in intestinal samples from 
the different parts of the intestine and from children across the pediatric age span. New 
methods are quickly becoming available, to study not only drug transporter expression 
(mRNA) but also protein content, using sensitive LC-MS-MS methods.
Modeling and simulation: Pb-PK models and population PK
The available data on age-related changes in relevant GI processes as well as possibly 
those from the TIM simulations can be incorporated in population-based pharma-
cokinetics (PB-PK) software programs such as Simcyp®, PKsim® or GastroPlus®. These 
programs can then simulate fate of drugs given to children of different ages and provide 
guidance for age-appropriate dosing.
At this time, the usefulness of these programs is still hampered by the relative lack of 
physiological data across all age groups. Moreover, validation of the model is also still 
limited as we have little pharmacokinetic data to validate the model; especially in the 
neonatal and infant age groups, data are scarce [94]. It is to be expected that increasing 
use of these programs will generate sufficient data to further validate the models.
Mechanism-based approach for in vivo studies
Another approach to learn more about the ontogeny of specific (intestinal) drug-
metabolizing enzyme and/or transporter pathways is a mechanism-based one [95]. 
The pharmacokinetics of drugs that represent a single pathway, studied in children of 
all ages, may provide valuable information on the ontogeny of that specific pathway. 
For example, determination of the plasma clearance of midazolam is a validated and 
widely used method to study interindividual variation in CYP3A activity in both adults 
and children [96].
To elucidate age-related changes in intestinal enzymes/transporters, independent of 
hepatic activity, we will need both oral and intravenous pharmacokinetic data, prefer-
ably from the same patients. At this time, these data are scarce in children, even for 
CYP3A/midazolam. Full PK studies to determine bioavailability for a probe drug using 
a multi-day cross-over design are hardly feasible in children for ethical and practical 
reasons. As a major reason, children will not benefit from the drug but rather will experi-
ence the drug effect and risk adverse events and have significant burden. Alternatively, 
a stable-labeled isotope or a (very weak) radioactive-labeled microdose can be used [97, 
98]. In both, a labeled probe drug is added to an intravenous therapeutic dose. Parent 
compound and metabolites can, therefore, be traced in serum and urine. This enables 
simultaneous determination of the pharmacokinetics of therapeutic IV and the labeled 
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oral dose. It eliminates the risk of therapeutic effect/toxicity as the child already receives 
the drug for clinical reasons. A prerequisite for the use of microdosing in this context is 
that dose linearity exists across the dosing range. For a number of drugs, dose linearity 
for microdosing has been established, whereas others clearly do not qualify [99, 100].
Microdosing is a relatively novel technique used in adults. The microdose (one-
hundredth of the predicted pharmacologic dose or 100 µg) contains a natural occurring 
radioactive carbon label (carbon 14, 14C), which can be detected with highly sensitive 
methods as accelerator mass spectometry (AMS) [99]. Developmental changes in intesti-
nal drug-metabolizing enzymes can be delineated by investigating multiple age groups. 
Microdosing has been used once in preterm infants in a small pharmacokinetic study of 
ursodiol in the US [101].
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AbstrAct
The critical importance of membrane-bound transporters in pharmacotherapy is widely 
recognized, but little is known about drug transporter activity in children. In this white 
paper, the Pediatric Transporter Working Group presents a systematic review of the 
ontogeny of clinically relevant membrane transporters (e.g., SLC, ABC superfamilies) in 
intestine, liver, and kidney. Different developmental patterns for individual transporters 
emerge, but much remains unknown. Recommendations to increase our understanding 
of membrane transporters in pediatric pharmacotherapy are presented.
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oVErViEw of trAnsPortErs in PEDiAtrics
Transporters are membrane-bound proteins that are present in many tissues through-
out the body, notably in the apical and basolateral membranes of organs involved in 
absorption and excretion such as the gastrointestinal tract, liver, and kidney (Figure 1).[1] 
The biological role of transporters is to facilitate movement of important compounds 
across membranes; in addition to their physiological substrates, many transporters also 
have the capacity to transport drugs. It is now clear that drug transporters are critical 
determinants of tissue and cellular drug disposition, not only for the organs noted 
above, but also for sanctuary sites such as the brain.[2] Moreover, the sodium tauro-
cholate cotransporting polypeptide (NTCP), a hepatic bile acid transporter with affinity 
for some drug substrates, can act as a viral entry receptor for the hepatitis B virus.[3] A 
considerable body of in vitro and animal work, and a growing body of in vivo adult data, 
have demonstrated that variations in the activity of drug transporters—whether on the 
basis of genetic differences, drug–drug interactions, or environmental influences such 
as diet—impact the disposition of drugs and may influence drug efficacy and/or safety.
[2, 4] One important example is the statins, which are among the most commonly used 
medications in developed countries. It is clear that variations in transporter activity (e.g., 
OATP1B1) are key clinical determinants of statin-related myopathy. OATP1B1 activity can 
be modulated by polymorphisms in the SLCO1B1 gene. In fact, this has led to changes in 
the product label by drug regulatory agencies with respect to the maximum dosages of 
some statins in specific ethnic populations.[5, 6] This point is further highlighted by the 
Clinical Pharmacogenetics Implementation Consortium Guidelines, which recommend 
the use of haplotypes for dosing decisions of simvastatin.[7] While there are a growing 
number of examples of the importance of drug transporters in adult medicine, there has 
been relatively little work in this area with respect to children, or the potential impact of 
ontogeny of transport function on clinically relevant outcomes.
Recent data suggest that variability in drug transporter activity may be critically 
important for safe and effective antileukemia drug therapy in children. A high-dose 
methotrexate study performed in 1,883 acute lymphoblastic leukemia patients enrolled 
in a multicenter Children’s Oncology Group clinical trial revealed a relationship between 
multiple single nucleotide polymorphism (SNP) variants in the OATP1B1 gene SLCO1B1 
and high-dose methotrexate toxicity.[8] The study demonstrated that methotrexate 
clearance was lower in 1,279 patients carrying one of several loss-of-function SNP 
variants of SLCO1B1. Significant correlations also were established between lower clear-
ance rates after high-dose methotrexate administration in older children, girls, and in 
patients receiving delayed infusion of the drug.[8] Lower doses, increased hydration, 
and/or altered urine alkalinization were recommended, although the extent to which 
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figure 1. human transport Proteins for Drugs and Endogenous substances.
Schemes depict localization of transporters [protein (gene) nomenclature] on the apical (luminal) and ba-
solateral membrane of human intestinal epithelia, hepatocytes, and kidney proximal tubule cells. Develop-
mental changes have been reported for some human transporters (green circles), but no information, or 
only limited data, are available for other transporters (purple circles). Yellow circles depict other drug and/
or endogenous substrate transporters that were not included in the present literature search. Transporters 
recommended for evaluation in the 2012 FDA Draft Drug Interaction Guidance include: MDR1 P-glycopro-
tein (P-gp; ABCB1), breast cancer resistance protein (BCRP; ABCG2); two members of the organic anion trans-
porting polypeptide (OATP) family (OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3)); two members of the organic 
anion transporter (OAT) family (OAT1 (SLC22A6), OAT3 (SLC22A8)); and organic cation transporter 2 (OCT2 
(SLC22A2)). Transporters proposed for prospective investigation in drug development include: multidrug 
and toxin extrusion protein 1 and 2 (MATE1 (SLC47A1) and MATE2-K (SLC47A2)). Transporters recommend-
ed for retrospective inhibition studies based on preclinical and clinical observations include: multidrug 
resistance-associated protein 2 (MRP2 (ABCC2)) and bile salt export pump (BSEP (ABCB11)). Other transport-
ers that are of importance include: peptide transporter 1 and 2 (PEPT1 (SLC15A1) and PEPT2 (SLC15A2)); 
ileal apical sodium/bile acid cotransporter (ASBT (SLC10A2)); monocarboxylic acid transporter 1 (MCT1 
(SLC16A1)); OCT1 (SLC22A1); heteromeric organic solute transporter (OSTα–OSTβ); sodium/taurocholate 
cotransporting polypeptide (NTCP (SLC10A1)); OATP2B1 (SLCO2B1); OAT2 (SLC22A7); OAT7 (SLC22A9); MRP3 
(ABCC3); MRP4 (ABCC4); MRP6 (ABCC6); OAT4 (SLC22A11); urate transporter 1 (URAT1 (SCL22A12)); organic 
cation/ergothioneine transporter 1 and 2 (OCTN1 (SLC22A4)) and OCTN2 (SLC22A5)); OATP4C1 (SLCO4C1); 
and OAT3 (SLC22A8). Adapted from Giacomini et al.[1] and Zamek-Gliszczynski et al.[13]
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these adjustments would alleviate methotrexate toxicity was not clear. The impact of 
these SLCO1B1 variants on the clearance of other drug substrates in children remains to 
be determined. Polymorphisms in the MRP2 gene ABCC2 also have been associated with 
variability in methotrexate pharmacokinetics and an increased risk for methotrexate 
toxicity including leukopenia, thrombocytopenia, anemia, oral mucositis, and vomiting 
in children with acute lymphoblastic leukemia.[9, 10]
The clinical relevance of transporter genetic variability and pediatric drug therapy ex-
tends beyond childhood leukemia. As an example, combined polymorphisms in ABCC2 
and the UGT1A9 and UGT2B7 genes can be important predictors of interindividual 
variability in mycophenolic acid exposure, and have been associated with higher area 
under the curve (AUC) in pediatric kidney transplant recipients.[11] Lower morphine 
clearance was reported in children with defective OCT1 variants undergoing outpatient 
adenotonsillectomy. These findings are consistent with the role of OCT1 in the hepatic 
uptake of morphine.[12] Racial differences in the allelic frequency of these variants may 
explain, in part, the higher incidence of morphine-related adverse effects in Caucasian 
compared with African-American children. Examples continue to emerge demonstrat-
ing the importance of transport proteins in determining drug efficacy and toxicity in the 
pediatric population.
MEthoDs to stuDy DruG trAnsPortErs in PEDiAtrics
Researchers have used primarily two approaches to characterize the ontogeny of trans-
porters in the intestines, liver, and kidneys. The first approach is the quantification of 
transporter mRNA or protein expression in surgical or postmortem samples from humans 
at different ages. Typically, these studies are small in number and are not able to control 
for factors such as race/ethnicity, sex, environmental exposures, comorbidities, and other 
potentially important variables due to the limited sample size. The second approach is the 
assessment of transporter mRNA and/or protein levels, and to a lesser extent functional 
changes, in animal models such as rats and mice at various prenatal and postnatal ages.
Transport activity has been related to protein expression levels in adult tissue samples 
assuming that the transporter is localized predominantly in the plasma membrane, and 
that there is a correlation between the protein expression level and transporter function. 
Given that transporter expression at the mRNA and protein level do not always correlate 
well, it becomes important to understand transporter ontogeny at the protein level. 
Protein expression levels of membrane transporters have been estimated traditionally 
by western blot analysis using highly sensitive and specific, antibody-based methods. 
However, mass spectrometry-based targeted proteomics is being used increasingly to 
provide a quantitative assessment of protein expression levels.
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ontoGEny of trAnsPortErs
Key transport proteins relevant to drug disposition in the intestine, liver, and kidney 
were selected based on recent reviews by the International Transporter Consortium (see 
Figure 1 for protein and gene nomenclature and localization).[1, 13] A systematic search 
of the PubMed and EMBASE databases was performed to identify relevant published 
studies of drug transporters within these three organs. The search strategies were 
adapted to accommodate the unique searching features of each database, including 
database-specific MeSH and Emtree controlled vocabulary terms. Search queries for 
each transporter were combined with matching queries for the gastrointestinal tract 
(hereafter referred to as the intestine), the liver, or the kidney. Searches were limited to 
the pediatric population but were not limited by date, language, or publication status 
(see Appendix 1 for a detailed summary of the search strategies). The literature was 
reviewed, by organ, to evaluate changes in transporter expression with age, and the 
role that individual transporters may play from a developmental biology perspective. In 
addition, the age at which transporters reach adult levels and children “functionally” be-
come adults with respect to transporter activity was evaluated, where possible, for each 
transporter. The following sections and accompanying tables summarize the relevant 
pediatric transporter data recovered from the literature. Transport proteins depicted in 
Figure 1 were excluded from discussion for a particular organ if no pediatric data were 
available, or if the data were so limited that a broader discussion of the temporal or 
spatial expression, or activity as a function of development, was not possible. In all cases, 
human proteins are denoted by upper case text and rodent proteins by lower case text, 
with gene nomenclature in italics.
intestine
We searched for human and animal studies exploring the developmental changes of the 
following intestinal transporters: MDR1 P-glycoprotein (P-gp), BCRP, MRP1, MRP2, MRP3, 
OATP2B1, OATP1A2, OCT1, MCT1, and PEPT1. Only original, peer-reviewed research pub-
lications that explicitly presented fetal and/or pediatric data on transporter expression 
and/or localization were included. The focus was on human data, but in the absence 
of convincing human data relevant animal data are presented, as they may provide an 
indication of the expected developmental changes in humans (Table 1). When reported, 
the intestinal localization of the protein is denoted. For the fetal studies, no precise 
localization patterns are available due to intestinal immaturity.
P-gp
P-gp was the intestinal transport protein for which there is the most data relevant to pe-
diatrics. Numerous studies were evaluated to determine developmental differences in 
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expression or localization of P-gp in the intestine. Collectively samples from 55 fetuses, 
ranging from 5.5 to 28 weeks of gestation, and 302 additional samples across a pediatric 
age range, were investigated in this group of studies.[14-21] The majority of mRNA 
samples (upper jejunum) originated from one study in pediatric liver transplant patients, 
which may present confounding variation based on hepatic disorders.[14] In most stud-
ies, P-gp mRNA expression was determined; localization with immunohistochemistry 
was only conducted in a small number of samples. All of the studies demonstrated large 
interindividual variation. The overall developmental pattern of P-gp expression revealed 
a consistently emerging change from undetectable expression in the first trimester of 
fetal life to present and apparently stable P-gp expression from ~12 weeks of gestation 
onwards. Very limited data suggest that P-gp expression increased slowly to reach adult 
levels at or very shortly after birth. Interestingly, two studies reported higher intestinal 
P-gp expression in children with treated Crohn’s and celiac disease compared to healthy 
controls.[15]
BCRP
The localization of BCRP staining appeared stable from 5.5 to 28 weeks of gestation in 
humans.[21]
MRP1
In 35 human fetal samples from 5.5 to 28 weeks of gestation, MRP1 staining was visu-
alized in all samples using immunohistochemistry.[21] The intensity was weak during 
early gestation, but appeared to mature to an adult distribution pattern from 7 weeks 
of gestation onwards.
MRP2
Analogous to P-gp, the mRNA expression of MRP2 appeared stable from neonates to 
adults in ileal and jejunal surgical samples.[20]
OATP2B1
In contrast to MRP2, OATP2B1 mRNA expression was significantly higher in the samples 
from neonates compared to adults.[20]
Other intestinal transport proteins
Human data for MRP3 and PEPT1 appear to be missing, but animal data are available. In 
rabbits, Mrp3 mRNA expression was lowest in newborns and subsequently increased in 
weanlings until reaching the highest levels in adults.[22] The four available animal stud-
ies (three in rat; one in turkey) on PepT1 all support a similar developmental pattern of 
significant prenatal expression that reached maximal levels in the postnatal period, and 
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then decreased to adult levels from weaning onwards.[23-26] This finding seems consis-
tent with the role of PEPT1 in the absorption of di- and tripeptides, which constitutes an 
important part of infant nutrition. Intestinal temporal and spatial expression data during 
development for OATP1A2, OCT1, and MCT1 appear to be lacking.
It is clear from the data in Table 1 that no single developmental pattern can be identi-
fied for all of the intestinal transporters. Different patterns are apparent based on the 
available, albeit limited human data: 1) low in the embryo and then stable from neonate 
to adult (e.g., P-gp, MRP2); 2) high at birth and decreasing in the first months of life 
(OATP2B1).
liver
For the liver, all transport proteins designated by the International Transporter Consor-
tium as important for disposition of drugs and endogenous substances were reviewed.
[1, 13] These include the efflux transporters P-gp, BCRP, MRP2, MRP3, MRP4, MRP6, 
MATE1, BSEP, the uptake transporters NTCP, OATP1B1, OATP1B3, OATP2B1, OAT2, OCT1, 
and the bidirectional transporters OAT7 and OSTα/β. Similar to the other organs, this 
review on hepatic transporters exclusively focuses on human data, if available, but re-
sorts to animal data in the absence of any relevant human information (Table 2). Similar 
to intestinal transporters, most published data on the ontogeny of hepatic transport 
proteins is available for efflux transporters, particularly P-gp.
P-gp
Hepatic P-gp was already detectable in the wall of bile canaliculi in early fetal life at 14 
weeks by immunohistochemistry and at the mRNA level.[18] Although expression was 
low initially, it seemed to increase throughout fetal development and was considered 
moderate at the protein level by fetal week 19.[16, 27] mRNA expression for P-gp in-
creased throughout childhood development. In a study with 61 liver specimens, mRNA 
expression levels were 20–30-fold lower in the fetal and neonatal age group compared 
to adults. mRNA expression, however, rapidly increased in the early months of life: in 
infants (1–12 months), mRNA was only 5-fold lower compared to adults, and in children 
and adolescents it was indistinguishable from adult expression.[20] These observations 
are supported by less extensive studies from others,[28] and also revealed a similarly 
high interindividual variability in expression in children compared to adults.[20, 29] The 
limited results on P-gp protein expression, however, do not corroborate the reported 
age-dependent P-gp mRNA expression. P-gp protein was detectable in samples as early 
as 1 month,[29] and relative protein expression was not significantly different in 65 liver 
specimens from age groups 0.3–0.7, 0.7–2, 2–5, and 5–12 years.[30] This observation 
may not be surprising in light of the observed lack of correlation between mRNA and 
protein levels for P-gp in adult liver.[31] P-gp protein expression quantified by liquid 
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chromatography/tandem mass spectrometry (LC-MS/MS) was not associated with age 
in 64 liver specimens in the age range of 7–70 years.[32] Thus, further studies are needed 
to clarify whether the age-dependent differences in mRNA expression translate into dif-
ferences at the protein and ultimately the functional level for P-gp in the liver.
BCRP
BCRP was detectable by immunohistochemistry in fetal liver specimens from 5.5–28 
weeks[21] and mRNA expression increased from 18–22 week fetal samples to adults.[33] 
A comparison of relative protein expression between five neonates and five adult livers 
by western blot analysis indicated no detectable difference,[34] although mRNA expres-
sion seemed to increase between neonates and older children.[28] In 50 livers from age 
7–70 years, BCRP protein expression was correlated neither with age nor with mRNA 
expression.[35] These results together suggest that hepatic BCRP is expressed early dur-
ing human development and does not undergo relevant developmental changes after 
term birth.
MRP2
Similar to P-gp, MRP2 has been detected by immunohistochemistry in the bile cana-
licular membranes of 14-week-old fetuses, with a tendency for higher expression levels 
in older fetal liver[27] and adults.[33, 36] The differences in age-dependent expression 
seem to be similar to P-gp in fetal liver (30-fold lower mRNA expression), but were sub-
stantially more pronounced in neonates (200-fold lower mRNA expression) and infants 
(1–12 months) (100-fold lower mRNA expression) compared to adults.[20, 28] These 
substantial differences at the transcriptional level seem to translate into developmental 
differences in MRP2 protein expression: MRP2 protein levels determined by western blot 
were significantly lower in liver specimens from children younger than 8 months (n = 24) 
compared to older children up to 12 years (n = 59).[30] Later in childhood development, 
however, MRP2 protein expression assessed by mass spectrometry was independent of 
age in 51 liver specimens in the age range of 7–63 years.[37]
BSEP
At gestational weeks 14–20, BSEP was detectable by immunohistochemistry (36), and 
mRNA expression increased from neonates to older children[28] and adults.[33] Func-
tional studies in isolated sandwich-cultured fetal and adult hepatocytes suggest that 
the biliary excretion index for taurocholate is substantially higher in adults compared 
to fetal hepatocytes. This higher functional activity for the BSEP substrate taurocholate 
could be explained by a higher expression level of BSEP in adult cells, assuming that 
there is a correlation between BSEP mRNA and protein expression.[33]
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NTCP
NTCP was detectable by immunohistochemistry in fetal liver specimens at 14–20 weeks 
of gestation,[36] and mRNA expression was reduced substantially to 4% of adult values 
in fetal livers of 18–22 weeks of gestational age.[33] At the protein level postpartum, 
NTCP expression in neonates was comparable to that in adults.[34] Thus, there also 
seems to be no developmental maturation of NTCP expression after birth in humans. 
Rodent data suggest, however, that acquisition of functional transporter activity lags 
behind the developmental trajectories of mRNA and immunoreactive protein, and is not 
present until glycosylation is mature.[38]
OATPs
mRNA for the OATP isoforms OATP1B1, OATP1B3, and OATP2B1 was detectable in fetal 
hepatocytes by gestational weeks 18–23, and was significantly higher in adults com-
pared to fetal livers for OATP1B1 and OATP2B1.[33] In a limited number of neonatal and 
adult liver specimens (n = 5 each), no relevant difference was observed in OATP1B1 or 
OATP1B3 expression as determined by western blot analysis.[34] mRNA expression in 45 
liver specimens, however, was found to be highly age-dependent. For OATP1B1, mRNA 
expression was 20-fold lower in fetal liver, 500-fold lower in neonates, and 90-fold lower 
in infants compared to adults.[20] For OATP1B3, mRNA expression was 30-fold lower in 
fetuses, 600-fold lower in neonates, and 100-fold lower in infants (1–12 months) than in 
adults.[20] These data are supported by western blot analyses based on relative protein 
quantification in 78 liver samples that suggest a low expression from birth to age 6 years 
with increased expression thereafter for OATP1B1, and high expression for OATP1B3 at 
birth, which declines over the first month of life, and then rises again by age 6 years.[39] 
In 64 livers from age 7–70 years, relative protein expression of OATP1B1, OATP1B3, and 
OATP2B1 as assessed by mass spectrometry did not correlate with age.[32]
OCT1
There are only very limited human data on the ontogeny of hepatic OCT1. In human 
hepatocytes from pediatric and adult livers, there was no significant difference in the 
mRNA expression of OCT1, but OCT1-mediated transport seemed lower in pediatric 
compared to adult hepatocytes.[40]
Other liver transport proteins
For MRP3, MRP4, MRP6, MATE1, OAT2, OAT7, and OSTα/β, there are no or only very 
limited data available on the human ontogeny of these transporters. Thus, observations 
from rodent species also are provided in the following section, although there is so far 
no indication that rodent protein, and especially mRNA expression profiles, are in any 
way predictive of human transporter ontogeny.
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MRP3
In humans, MRP3 mRNA expression was significantly lower in fetal hepatocytes by ges-
tational weeks 18–23 compared to adults.[33] Similarly, Mrp3 in fetal rat liver progres-
sively increased from about 10% to over 30% of the maternal mRNA levels from day 15 of 
gestation to day 20, and increased to near 90% of the maternal level at day 21 and after 
birth.[41] This is consistent with increased mRNA expression observed from neonates to 
older children and adults in a small set of human specimens (perinatal n = 6, children n 
= 8, adult n = 6).[28]
MRP4
In humans, mRNA expression for MRP4 did not show any significant differences in fetal 
hepatocytes by gestational week 18–23 compared to adults[33] or when comparing 
neonates to older children and adults.[28] These observations are supported by mRNA 
expression in mice.[42, 43]
MRP6
Similar to MRP3, MRP6 mRNA expression increased in humans from neonates to older 
children and adults in a small set of subjects.[28] In rat liver, Mrp6 mRNA expression was 
detectable on embryonic day 16 at 5% of adult levels, and increased to 40% at birth, but 
did not reach adult levels until postnatal day 29.[44]
MATE1
mRNA expression for MATE1 increased in humans from neonates to older children and 
adults in a very small set of subjects.[28] Mate1 mRNA expression was absent on embry-
onic day 7.5 in mice.[45]
OAT2
Similar to MRP3 and MRP6, OAT2 mRNA expression increased from neonates to older 
children and adults in a small set of human subjects.[28]
OAT7
No information could be found on the ontogeny of OAT7 in humans or rodents.
OSTα/β
mRNA expression was detectable for OSTα and OSTβ in pediatric liver with an age 
around 1 year.[46] Although Ostα mRNA is expressed at low levels in liver throughout 
development from day –2 to day 45 in mice, Ostβ mRNA markedly increased to 4.5-fold 
of prenatal levels with a peak around 1 day after birth.[47]
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Overall, there are limited data available on the human ontogeny of hepatic transport 
proteins. The emerging picture, however, suggests that there may be substantial dif-
ferences between transporters in the time course of development and expression. 
Some transport proteins such as P-gp, BCRP, and NTCP are expressed early in childhood 
development, while others such as OATP1B1, BSEP, and MRP2 seem to exhibit delayed 
maturation and reduced expression levels compared to adults during at least the first 
months of life. In general, the differences seem to be absent between older children and 
adults. This conclusion is supported by the notion that localization of the canalicular 
transporters (BSEP, P-gp, MRP2) in pediatric liver (6–17 months) had reached a similar 
level and pattern as adult liver, indicating that the pediatric liver around 1 year of age 
has obtained a mature canalicular structure.[46]
Kidney
The drug transporters generally considered in the context of kidney development 
were: P-gp, BCRP, OAT1, OAT3, OCT2, and MATEs. Data on MRP2, MRP4, OATPs, OAT2, 
OCT1, OCTNs, and URAT1 (Rst) also were evaluated when presented in the literature 
regarding the aforementioned transporters. Currently, there is relatively little informa-
tion regarding drug transporter expression, at either the mRNA or protein level, or 
function in the human developing kidney. Given the paucity of human data, the studies 
described in Table 3 and Appendix 2 also include the considerable data on the ontogeny 
of drug transporters in the developing rodent (rat, mouse) kidney. In a limited number 
of instances, there are also data on postnatal developmental function of particular 
transporters, for instance, in a knockout mouse model or a study on the developmental 
clearance of a drug (digoxin) or probe substrate (p-aminohippurate, PAH) in rodents. 
Although there are differences in individual transporter expression patterns (e.g., P-gp, 
Bcrp, Mrp2, Mrp4, Mate1, Oat1, Oat3, Oct2, Octn1, Octn2, Urat1), these rodent studies 
generally indicate low expression of various transporters in the late stages of kidney 
development, followed by a rapid rise in expression after birth, and a further increase in 
expression (and function) during postnatal maturation.[48-50] (Please see Table 3 and 
Appendix 2 for additional rodent information.)
P-gp
In humans, P-gp transcript and protein levels have been analyzed in fetal and adult 
kidney.[17, 18] P-gp expression is detectable as early as 11 weeks of gestation.[18] In the 
fetal kidney, reverse-transcription polymerase chain reaction (RT-PCR) of tissue obtained 
by laser capture microdissection revealed transcripts in the renal tubule.[17]
It is important to note that developmental biology studies suggest that there may 
be some significant differences in postnatal nephron development and maturation 
between mice, rats, and humans, as well as between sexes. Of note, recent mRNA data 
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regarding the developmental expression of renal transporters in humans,[51] presented 
as an abstract, appears largely consistent with patterns reported in rats.[52]
In summary, information on the ontogeny of human drug transporters is scarce in the 
case of the kidney. A major knowledge gap exists regarding gene expression, protein 
abundance, and actual transporter activity in humans. This information is essential to 
understand how maturational changes impact the role that these transporters play in 
normal growth and development, and to accurately predict the impact of changes due 
to pathophysiological conditions on drug disposition, efficacy, and toxicity of medica-
tions. This knowledge is requisite to the development of personalized drug therapy in 
children.
coMPArAtiVE DEVEloPMEnt of orGAn functions
The majority of the data regarding transporter ontogeny has been obtained from devel-
opmental studies in rodents, although some literature does exist for larger species. The 
ability to extrapolate across species, namely rodents, to larger species (e.g., primates) and 
humans can be limited, however, by variation in the developmental timing of key ana-
tomical, physiological, biochemical, and physicochemical events, as well as significant 
functional variance in isoforms. These differences arise from comparative differences in 
the gestational length and the timing of parturition between the different species and 
humans. The conventional approach is to compare developmental milestones relative to 
birth (prenatal vs. postnatal); however, this may not always be appropriate. For example, 
in contrast to humans and porcine models, newborn rodents exhibit relatively immature 
intestines with few villi and little evidence of crypt formation.[53, 54] The timing of tis-
sue maturation between rodent species is also dependent on the organ. As an example, 
nephrogenesis is largely complete prior to birth in mice, which is similar to humans, but 
continues in rats during the postnatal period.[55] For this reason, the study of transporter 
ontogeny would be improved by reporting perinatal findings as days postconception, 
rather than days relative to parturition. By viewing development as a continuum instead 
of arbitrary categories (such as neonatal, infant, etc.), there will be greater potential to 
translate rodent and other mammalian studies to humans. One caveat to this approach 
is that some transporters increase in expression upon commencement of feeding, as has 
been observed for Ntcp, Bsep, and Mrp4 in the neonatal livers of mice.[42]
It should be noted that another considerable limitation occurs when contrasting 
mRNA expression data, because linearity in protein transcription and inferred function 
cannot be assumed. As mentioned in the Methods section, advances in quantitative pro-
teomics using LC-MS/MS have led to a significant increase in our ability to quantify drug 
transporter protein abundance in adult samples. While a number of technical challenges 
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still exist with this methodology, the application of quantitative proteomic approaches 
to ontogenic studies with pediatric tissues will yield more useful data for establishing 
predictive developmental physiologically based pharmacokinetic (PBPK) models. One 
major limitation is that the availability of human pediatric tissue specimens is limited, 
and shared pediatric biobanks need to be established. The application of quantitative 
proteomics in animal tissue developmental studies would provide greater insight into 
the utility of scaling across species to predict the function of drug transporter activity in 
pediatric patients.
There is also the potential for significant confounding variables to limit the ability of 
cross-species comparisons with humans, particularly with respect to pediatric popula-
tions. Of considerable concern is the health of the patients in which the specimens were 
obtained. A significant portion of the human pediatric tissue biopsied specimens origi-
nate from patients who suffer from comorbidity or are collected postmortem. Collection 
procedures and timing also can impact tissue quality and subsequent expression data. 
Most animal studies are conducted under controlled conditions, whereas human tissue 
specimens are collected from patients who will have varying xenobiotic and dietary 
exposures. These confounding factors cannot be readily normalized for in many cases. 
Another emerging issue is that mRNA expression of housekeeper genes can vary signifi-
cantly, thus calling into question quantitative data from qRT-PCR studies normalized to 
one control.[56, 57] These concerns may be alleviated by the use of RNA-sequencing to 
quantify human transporter ontogeny, as has been performed in rodents.[47]
There has been limited use of cell-based systems and mathematical models to describe 
the ontogeny of transporters. However, there may be the potential to complement in 
vivo rodent, other species, and human biopsy studies with human embryonic or induced 
pluripotent stem cells undergoing differentiation to hepatocytes, enterocytes, and renal 
tubule cells. While these cellular systems are artificial and lack the holistic development 
of an organism, they may be a mechanistic tool to probe the effects of exogenous fac-
tors such as hormones, drugs, and exposures on the sequence and timing of transporter 
expression. Initial studies have begun to profile the expression and activity of transport-
ers in hepatocyte-like cells derived from human embryonic and induced pluripotent 
stem cells,[58] although comparisons with juvenile human livers are needed. In addi-
tion, there is a need to develop mathematical and statistical modeling approaches that 
integrate transporter ontogeny with the maturation of physiological processes, such as 
tubule reabsorption or intestinal secretion. This effort would provide researchers with 
the ability to “translate time” between species by developing algorithms that compare 
and predict development.[59, 60] Moreover, this approach can integrate the ontogeny 
of multiple tissues in parallel and provide a more global view on whole organism de-
velopment. A computational and systems biology approach could be used to integrate 
genomic, epigenetic, proteomic, and pharmacokinetic endpoints (e.g., changes in pH, 
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plasma membrane composition, expression of drug metabolizing enzymes) to better 
assess the ontogeny of transport systems.[61] The utility of data-driven, PBPK models 
generated in this fashion would help to improve new pediatric drug translation from 
discovery to the clinical stages.[62]
EMErGinG ArEAs AnD MAjor chAllEnGEs in stuDyinG PEDiAtric DruG 
trAnsPort
Developmental programming and regulation of transporters
Little is known about the factors that govern the regulation of transporter expression 
and activity (e.g., induction and inhibition of transporters as a function of gestational 
age) during growth and development. The age-related variation in mRNA expression 
of the transcription factor PXR correlated with P-gp expression in a small number of 
fetal, neonatal, younger and older adult samples of human liver, kidney, and intestine.
[17] This finding suggests a role for transcription factor-mediated regulation of age-
related transporter expression. Moreover, the mechanism of age-related changes in 
transcription factors may be related to DNA methylation; in fetal liver, hypermethylation 
of important cytochrome P450 (CYP) 3A4 transcription factor binding sites has been 
observed, consistent with low CYP3A4 expression before birth.[63, 64] Endocrine 
changes in adolescents may impact drug transporter expression through hormonal and 
growth factor regulation of relevant transcription factors. To date, studies focused on 
the endocrine regulation of transporters have largely evaluated adult rodents[65, 66] 
and serve as a basis for future work that should be expanded to hormonal fluctuations 
during human development. Clearly, considerable work is needed to understand the 
factors that regulate drug transporters during human growth and development.
Pharmacogenomics
Genetic variation may add to the age-related variation in drug transporter expression 
and function. In contrast to adults, pharmacogenomic drug transporter studies in 
children are rare. The available studies have been performed primarily in age ranges 
at which full maturation of transporters can be expected, and the results in general are 
similar to adults.[12, 67] Further studies in children are needed to elucidate the interplay 
of age and genetic variation. Decreased transporter expression due to genetic variation 
may not become apparent until expression is at least at adult levels.[68]
Impact of disease, drug interactions, and/or environmental exposure
Other factors impacting drug transporter activity are disease, drug–gene interactions, 
drug–drug interactions (DDIs), food–drug interactions as well as exposures to environ-
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mental chemicals. In adults, the impact of liver disease has been investigated, but the 
findings may not be applicable to children, as the underlying disease may be very dif-
ferent: e.g., alcohol-induced liver steatosis is not a pediatric disease, while biliary atresia 
is the most prevalent disease in children who receive a liver transplant. As underlying 
liver disease may impact transporter expression,[69, 70] these pathophysiological dif-
ferences mandate studies in pediatric patients. In one study, MRP2, BSEP, and MDR3 
expression in livers from patients with pediatric biliary atresia taken at postnatal age 1–2 
months was much higher than both fetal and adult expression levels, but unfortunately 
no age-matched controls were studied.[36] Hence, it is unclear whether the observed 
differences can be attributed solely to the disease or whether age-related changes also 
played a role. DDIs also may be different in children due to developmental changes in 
drug disposition pathways; furthermore, the potential for a specific DDI may change 
during growth and development.[71] Finally, as nutrition changes during childhood, the 
impact of frequent milk or different types of formula feedings and fruit juice on drug 
transporter expression and function must be considered.
Development of human-relevant cell/in vitro and preclinical/in vivo transport models that are 
representative of the pediatric population in health and disease
Once transport protein expression and function have been characterized across the 
pediatric age spectrum in healthy and diseased tissue, an important next step will be 
to develop human-relevant in vitro models, such as cell lines, embryonic stem cells, or 
modified primary cells that mimic transporter expression and function at various ages. 
Such systems could be useful to predict drug disposition and DDIs in pediatrics. The 
utility of preclinical, in vivo transporter models as a predictive tool is less clear due to 
significant species differences in the expression and function of some transport proteins 
and regulatory machinery, and lack of established correlations between transporter 
data from animal models and humans.
Development of systems-based, mechanistic modeling approaches to integrate in vitro data 
and physiological processes to predict transporter-mediated changes in drug disposition as a 
function of age and disease
PBPK models link information about the anatomical and physiological structure of the 
body with the physicochemical and biopharmaceutical properties of the drug to predict 
drug disposition in the body. PBPK models are established tools for predicting human 
pharmacokinetics based on preclinical data from animals and in vitro studies.[72, 73] 
Successful applications include scaling the human pharmacokinetics from healthy 
volunteers to patient populations (e.g., liver cirrhosis) by accounting for changes in 
physiology.[74, 75] PBPK models are being applied increasingly in scaling adult pharma-
cokinetics to pediatric populations. This has been demonstrated for compounds elimi-
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nated primarily by metabolism, where the ontogeny has been better characterized than 
for some transporters.[76, 77] The use of modeling and simulation methods in pediatric 
drug development was endorsed at a recent US Food and Drug Administration (FDA) 
Clinical Pharmacology Advisory Committee meeting,[78] and also is recognized by the 
agency as a potentially useful tool in the design of pediatric clinical trials and helping to 
expedite pediatric drug development.[79] Between the years 2008 and 2012, the FDA’s 
Office of Clinical Pharmacology received 33 New Drug Application/Investigational New 
Drug submissions containing PBPK models; six of them were pediatric submissions.
[80] The main applications of pediatric PBPK models in these submissions included 
dose selection, study design, informing enzyme ontogeny using benchmark drugs, and 
facilitating covariate analysis. The applications in pediatric drug development generally 
start with development and validation of an adult model (frequently utilizing in vitro 
characterization of the drug’s interaction with enzymes and/or transporters) followed 
by scaling to pediatric populations by accounting for ontogeny of relevant physiologi-
cal processes across the age continuum from neonates (including premature neonates) 
to adults. However, currently there is limited availability of transporter information for 
modeling and simulation (e.g., PBPK modeling) of drug disposition, tissue exposure, and 
pharmacodynamic response in pediatrics. A possible approach to circumvent this issue 
is to utilize available pediatric clinical data for a variety of drugs to estimate the ontogeny 
of relevant enzymes and transporters. In one example, the ontogeny of renal transport 
was estimated from age-dependent renal clearance of a model compound known to 
be a substrate for the same renal transporter as the investigated drug.[81] In another 
example, a pediatric population model for zidovudine was constructed by utilizing a 
previously derived pediatric covariate model for morphine glucuronidation.[82] Finally, 
it is worth noting that systems biology approaches, as well as methods for integration of 
“omics” data from multiple levels of analysis (e.g., genomics, transcriptomics, proteomics, 
metabolomics) are advancing rapidly, and there is an ongoing effort to apply these ap-
proaches to the adult and developmental contexts.[83] While distinct from the usual 
methods used in PBPK, it is anticipated that these approaches may begin to converge in 
the near future, providing a deeper understanding of pediatric drug disposition.
Limited availability of quality pediatric tissue (all age groups) for protein quantification and 
assessment of transporter function
One of the major roadblocks to drug transporter research during human growth and 
development is the dearth of quality pediatric tissue. Current tissue sources include 
left-over tissue from surgery and biopsies, as well as postmortem tissue from organ 
transplants and autopsies. Collaboration between clinicians with access to these tissue 
sources and researchers in need of tissue appears to be a major obstacle. In order to over-
come these logistical challenges, a clear understanding and commitment on both sides 
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regarding the respective challenges and solutions may be the first step to increase the 
availability of quality pediatric tissue. For example, the logistics of collecting a sample, 
including asking for informed consent, retrieving a dry-ice container, transporting tissue 
to a storage facility, and collecting clinical data seem relatively straightforward, but are 
challenging when success depends on busy clinical staff to organize all these details. 
Also, a few inches of residual intestine may be very reasonable to obtain in adults, but 
cannot be considered “left-over” in neonates with a considerably shorter intestinal 
length. Timely handling of postmortem pediatric tissue is particularly challenging due 
to parents, who may need time to say goodbye when a child passes away, and the 
availability of autopsies only during the day. Furthermore, the availability of tissue may 
be limited compared to adults because the death rate among children is much lower 
than among adults, there may be reluctance on the part of parents to give consent for 
autopsy, and there are relatively few liver transplants from pediatric donors.
Ethical and practical challenges with performing nontherapeutic studies in minors
Research that does not potentially benefit the participating child (“nontherapeutic”) is 
subject to several limitations,[84] most importantly, the restrictions of minimal risk (a 
slight increase over what is ordinarily encountered in daily life) and minimal burden. 
These ethical limitations, which are intended to protect the individual child, limit the 
possibility of performing nontherapeutic pharmacokinetics and/or DDI studies related 
to drug transporters in minors. Giving a child a therapeutic dose of a drug solely for these 
purposes will, in many places, not be considered minimal risk. However, in some centers 
this approach is acceptable when the child will receive the drug later for therapeutic 
reasons. One solution is to study the disposition and effect of the drug in the context 
of clinical drug treatment. This may introduce unwanted complexity to studies, such 
as variation due to underlying disease and/or comedication, and the need for more 
sophisticated pharmacokinetic analyses. Microdosing may overcome these limitations, 
but can only be used for drugs that exhibit dose-linearity.[85] Other challenges include 
the need for repeated blood sampling as well as limitations with blood volumes. These 
can be overcome by using indwelling catheters already in place for clinical care, low 
volume drug assays, and population pharmacokinetic analyses.
Lack of transporter-specific probes to assess in vivo function
In vivo probes for individual drug metabolizing enzymes (e.g., midazolam for CYP3A4, 
dextromethorphan for CYP2D6/CYP3A4, and caffeine for CYP1A2) have facilitated 
investigations about the impact of growth and development, and the effects of phar-
macogenomics and disease, on drug metabolism. These critical tools have led to new 
knowledge. A similar approach is more challenging for drug transporters, as specific 
probes for individual transporters are lacking. Most drugs are substrates for multiple 
84 Chapter 4
transporters, which enable alternate transporter pathways to compensate in case the 
primary transporter is absent or has reduced activity. Nevertheless, pharmacogenomic 
studies on individual transporters have elucidated differences in drug disposition, 
efficacy, and safety in adults. This approach may aid in studying the developmental 
changes of these transporters in vivo. The use of microdosing in pediatric patients has 
been explored and may provide a basis for developing a better understanding of drug 
disposition and metabolomic profiling. While it is important to continue to analyze 
mRNA and protein expression levels of transporters in developing organs like the liver, 
kidney, and intestine, ultimately this must be related to physiological processes medi-
ated by these particular transporters. Because of unique safety concerns about using 
exogenous compounds as functional probes in the pediatric population, continued 
exploration of endogenous metabolites and other markers that can serve as surrogates 
for assessing transporter function during organ development and maturation is needed. 
The relevant sets of endogenous metabolites may be specific to each organ, and to 
particular developmental points, reflecting unique patterns of transporter expression 
and aspects of organ-specific physiology.
table 4. recommendations
•	 	Build	multidisciplinary,	international	collaborative	networks	to	facilitate	collection	and	sharing	of	data	
on pediatric transporters, including expertise in preclinical studies (e.g., knockout and in vitro models), 
pediatrics, clinical pharmacology, pharmacogenomics, pharmacometrics, and pharmacovigilance
•	 	Establish	central	(perhaps	regional)	tissue	repositories	where	surgical	and	postmortem	samples	can	be	
stored with clear guidelines for tissue collection and handling to preserve sample integrity
•	 	Continue	to	support	the	training	of	scientists	in	pediatric	clinical	pharmacology	with	expertise	in	
transporters, pharmacogenomics, pharmacometrics, and pharmacovigilance
•	 	Increase	the	awareness	of	clinicians	regarding	the	importance	of	transporters	in	pediatric	drug	disposition
•	 	Identify	examples	relevant	to	pediatric	pharmacotherapy	where	developmental	differences	in	transporter	
expression or activity could translate into clinically relevant effects
•	 	Work	with	professional	groups	to	develop	guidelines	on	how	drug	therapy	may	be	altered	due	to	
variations in transporter expression or activity
•	 	Identify	selective	and	specific	biomarkers	for	transporter	activity	in	pediatric	patients
•	 	Investigate	basic	developmental	mechanisms	regulating	transporter	expression	and	activity	in	the	
different organs in pediatric health and disease
•	 	Develop	pediatric-relevant	in vitro/in silico and systems biology models to predict transporter function in 
the context of overall drug disposition
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conclusion
Many fundamental and clinically relevant questions remain unanswered about the hu-
man ontogeny of drug transporters. As information highlighting the importance of drug 
transporters in adult medicine continues to emerge, this critical knowledge gap in the 
pediatric population becomes even more evident. In order to achieve safe and effective 
drug therapy for children, it is imperative that developmental patterns of transporter 
gene expression and protein abundance are elucidated, and that drug transporter func-
tion is defined across the age spectrum. Recommendations are provided (Table 4) to 
address some of the major challenges in obtaining this information. Fundamental and 
applied knowledge about the human ontogeny of drug transporters is absolutely es-
sential to ultimately achieve personalized pharmacotherapy in pediatric patients.
Additional Supporting Information may be found in the online version of this article.
Appendix 1 Literature Search Strategy
Appendix 2 Ontogeny of Rodent Kidney Transport Proteins
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AbstrAct
Membrane transporters play an essential role in the transport of endogenous and 
exogenous compounds, and consequently they mediate the uptake, distribution, and 
excretion of many drugs. The clinical relevance of transporters in drug disposition and 
their effect in adults have been shown in drug-drug interaction and pharmacogenomic 
studies in adults. Little is known, however, about the ontogeny of human membrane 
transporters and their roles in pediatric pharmacotherapy. As they are involved in the 
transport of endogenous substrates, growth and development may be important deter-
minants of their expression and activity.
This review presents an overview on our current knowledge on human membrane 
transporters in pediatric drug disposition and effect. Existing pharmacokinetic and 
pharmacogenetic data on membrane substrate drugs frequently used in children are 
presented and related, where possible, to existing ex vivo data, providing a basis for 
developmental patterns for individual human membrane transporters. As data for indi-
vidual transporters are currently still scarce, there is a striking information gap regarding 
the role of human membrane transporters in drug therapy in children.
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introDuction
Plasma membrane transporters play an essential role in the uptake of endogenous 
compounds into cells and their efflux from cells. They also mediate the absorption, 
distribution and excretion of a large number of drugs [1, 2]. In particular, two major 
transporter superfamilies are in the focus of pharmacological studies: the adenosine 
triphosphate (ATP)-binding cassette (ABC) transporters and the solute carrier (SLC) 
transporter superfamilies [3, 4]. The nomenclature is presented in Table 1. Numerous 
studies, mostly in adults, have investigated altered membrane transporter functions due 
to genetic variants or drug-drug interactions by co-medications [1, 5-9]. Studies on the 
role of membrane transporters in children are scarce, however. Still, growth and matura-
tion are likely to have an impact on activity of these transporters in light of their role in 
endogenous processes. Animal studies have indeed shown developmental changes in 
membrane transporter expression [10]. The aim of this review is to present an up-to-
date overview on our current knowledge on the role of human membrane transporters 
in pediatric drug disposition and effect. For this purpose, a short overview of ex vivo 
studies is presented after which results from pharmacokinetic and pharmacogenetic 
studies of relevant membrane transporters are reported that may broad our insight into 
developmental patterns for individual human membrane transporters.
Ex vivo stuDiEs on thE ontoGEny of huMAn MEMbrAnE trAnsPortErs
Ex vivo data from pediatric samples may be used to extrapolate existing adult phar-
macokinetic data to children, as is done using physiologically based pharmacokinetic 
(PBPK) modeling [11, 12]. Expression patterns of membrane transporters during human 
development have been studied in postmortem and surgical tissue samples with the use 
of different techniques such as immunohistochemistry to visualize tissue localization, 
reverse transcriptase polymerase chain reaction (RT-PCR) for messenger RNA (mRNA) ex-
pression, Western blotting and new liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) techniques to quantify transporter protein abundance. To the best of our 
knowledge, transporter activity studies using human pediatric tissue are non-existent. 
Although animal data may provide valuable insight, potential developmental patterns 
of membrane transporters in animals are likely to differ from those in humans, as studies 
on drug metabolizing enzymes (DMEs) have shown [13-15]. Moreover, animal studies 
do not provide any information when there are no direct orthologs in rodents, as is the 
case, for example, for human organic anion-polypeptide (OATP) 1B1 and OATP1B3.
From the embryonic and fetal period, most transporter data result from immunohis-
tochemistry and mRNA expression studies. These data, often covering a small age range 
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and/or small sample size, suggest transporter-specific maturation with a low fetal/neo-
natal or stable expression pattern, but quantification is lacking [16-19]. The ex vivo data 
from the first years of life consist mainly of hepatic and intestinal mRNA expression data, 
with the inherent limitation of a possible lack of correlation with protein expression 
[20-24]. In children from 7 years onwards, protein abundance data generated using LC-
MS/MS have been recently published [25-27]. Although a large pediatric age range was 
covered by this project, the younger age range, where most developmental changes are 
expected, is lacking in protein abundance data.
table 1. nomenclature of human membrane transporters: selection transporters discussed in this 
paper
Nomenclature of human membrane transporters: selection transporters discussed in this paper [source: 
NCBI Gene (http://www.ncbi.nlm.nih.gov/gene)]
ABC adenosine triphosphate (ATP)-binding cassette, ADRB2 β2-adrenergic receptor, FAAH fatty acid hydro-
lase, SLC solute carrier
Gene Protein
Name Locus Name Synonyms
ABC transporters
ABCB1 7q21.12 ABCB1 MDR1, P-glycoprotein (P-gp), CLCS, PGY1, ABC20, CD243, GP170
ABCC2 10q24 ABCC2 MRP2, CMOAT, DJS, cMRP, ABC30
ABCC3 17q22 ABCC3 MRP3, MOAT-D, cMOAT2, MLP2, ABC31, EST90757
ABCC4 13q32 ABCC4 MRP4, MOAT-B, MOATB
ABCG2 4q22 ABCG2 BRCP, MXR, MRX, ABCP, BMDP, MXR1, BCRP1, CD338, GOUT1, 
CDw338, UAQTL1, EST157481
SLC transporters
SLCO1B1 12p OATP1B1 OATP2, LST-1, OATP-C, HBLRR, LST1, SLC21A6
SLCO1B3 12p12 OATP1B3 OATP8, LST-2, LST3, HBLRR, SLC21A8, LST-3TM13
SLCO2B1 11q13 OATP2B1 OATP-B, SLC21A9
SLC3A2 11q13 4F2hc 4F2, CD98, MDU1, 4T2HC, NACAE, CD98HC
SLC22A1 6q25.3 OCT1 HOCT1, oct1_cds
SLC22A2 6q25.3 OCT2
SLC22A6 11q12.3 OAT1 PAHT, HOAT1, ROAT1
SLC22A7 6q21.1 OAT2 NLT
SLC22A8 11q11 OAT3
SLC15A1 13q32.3 PEPT1 HPEPT1, HPECT1
SLC47A1 17q11.2 MATE1
SLC47A2 17q11.2 MATE2-K MATE2, MATE2-B
Other
FAAH 1p35-p34 FAAH FAAH-1, PSAB
ADRB2 5q31-q32 ADRB2 BAR, B2AR, ADRBR, ADRB2R, BETA2AR
CDH17 8q22.1 HPT1 CDH16, LI cadherin
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The studies referenced above comprise the most significant studies investigating the 
maturation of human membrane transporters, with an emphasis on the clinically rel-
evant transporters ABCB1, ABCC2, OATP1B1 and OATP1B3. The best-studied transporter 
during human development is ABCB1 (Fig. 1). Interestingly, its developmental pattern 
seems organ-specific. In fetal intestinal samples (16th to 20th week of gestation), ABCB1 
could be visualized [16] and intestinal mRNA data suggests stable ABCB1 expression 
from the neonate up to the adult [22, 24]. In the liver, mRNA expression data suggest 
a pattern of low ABCB1 expression in fetuses, neonates, and infants until 12 months of 
age, after which it increases to adult levels [21, 22]. ABCB1 protein abundance measured 
using LC-MS/MS was quite variable (4.8-fold) in 64 subjects in the age range 7-70 years, 
but this variation could not be explained by either age or sex [25]. In fetal human brain 
samples ranging from 7 to 28 weeks of gestational age, ABCB1 immunostaining was 
detected in only one sample from a 28-week fetus [16]. In contrast, in postmortem 
central nervous system tissue from neonates (n= 28) of 22 - 42 weeks of gestational age 
and from adults (n=3), immunohistochemistry showed increasing ABCB1 staining with 
gestational age [28]. ABCB1 gene expression was also detected in the brain of fetuses of 
15, 27 and 42 weeks of gestational age [18]. Very recently, the ABCB1 protein was shown 
limited at birth and to increase postnatally to reach adult levels by 3-6 months of age 
[29]. Renal ABCB1 mRNA expression appears to be related to maturity of nephrons. A 
trend towards lower expression in fetuses and neonates than in adults was observed. 
ABCB1 protein has been identified as early as 5.5th of gestation [16, 17, 21].
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figure 1. suggested ontogeny of Abcb1 expression in intestine, liver, kidney and brain.
ABC adenosine triphosphate (ATP)-binding cassette
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ABCC2 ontogeny shows similarities to ABCB1. Small intestine ABCC2 mRNA expression 
is stable in neonatal surgical patients compared to adults. While, hepatic ABCC2 mRNA ex-
pression is much lower in the fetus, neonate and young infant (up to 200-fold lower) than 
the adult [22, 27], in children from 7 years onwards its protein expression appears stable 
[27]. On the protein level, both the localization pattern and intensity of ABCC2 protein 
staining appear to change during fetal life, in concert with fetal liver maturation [19, 23].
Hepatic mRNA expression of OATP1B1 and OATP1B3 appears to show a different de-
velopmental pattern than ABCB1 and ABCC2. Although fetal expression was 2- to 30-fold 
lower than adult expression, neonatal and infant expression appeared to be even lower 
(up to 600-fold) [19, 22]. This pattern appears to be supported by protein data (Western 
blotting) for OATP1B3 but not for OATP1B1. In one study, OATP1B1 protein expression 
already appears at adult levels in neonates, while in another OATP1B1 only increases 
after the age of 6 years [30, 31]. Again, for both OATP1B1 and OATP1B3, protein expres-
sion appears stable at adult levels from 7 years onwards [25].
PhArMAcoKinEtic AnD PhArMAcoGEnEtic stuDiEs of rElEVAnt 
MEMbrAnE trAnsPortEr substrAtEs
Pharmacokinetic and pharmacogenetic studies may provide insight into the impact 
of selected drug transporters in vivo. We identified 16 drugs frequently prescribed to 
children and that are known substrates of one or more specific membrane transporters 
(Table 2; see the Electronic Supplemental Material for the search strategy). Age-related 
differences in pharmacokinetic or pharmacogenetic studies may point to maturational 
changes in the transporter involved. On the other hand, concordance between adult 
and pediatric pharmacogenomic studies may support the presence and potentially 
similar expression of the involved transporters in children as in adults. To further sup-
port a potential developmental pattern, we compared the in vivo data with relevant ex 
vivo data of the individual transporters. As many drugs are also substrate of DMEs and/
or multiple transporters, the presented data must be interpreted in the context of the 
interplay with metabolizing enzymes. It can be speculated that when a specific DME is 
developmentally low at a certain age, while the transporter is already mature, this may 
impact the disposition of a drug, by potentially altering the absorption, distribution, 
metabolism, and excretion (ADME) pathway from largely DME based to transporter 
based. Where possible, we have only included data that are highly supportive of a role 
for the transporter(s) involved. Table 2 provides a summary of the pharmacokinetic stud-
ies in children and the relationship with transporters. For detailed genetic information 
on individual transporters, the reader is referred to the pharmgkb.org database (http://
pharmacogenetics.ucsf.edu/) and recent reviews [7, 8, 32-34]
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table 2. summary PK and PGx studies of relevant membrane transporter substrates.
ABC adenosine triphosphate (ATP)-binding cassette, AUC area under the plasma concentration-time curve, 
BRCP breast cancer resistance protein, GFR glomerular filtration rate, HPT human oligopeptide transporter, 
IV intravenous, M3G morphine-3-glucuronide, MATE multidrug and toxin extrusion protein, MPA mycophe-
nolic acid, mRNA messenger RNA, MRP multidrug resistance-associated protein, OAT organic anion trans-
porter, OATP organic anion-transporting polypeptide, OCT organic cation transporter, PGx pharmacogenet-
ics, PK pharmacokinetics, UGT uridine 5’-diphospho-glucuronosyltransferase
Drug relevant transporters 
involved in transport 
of drug
PK and PGx results in children
Digoxin ABCB1 Higher bodyweight-corrected digoxin clearance in term 
neonates and young children {Yukawa, 2007 #274;Yukawa, 2011 
#273;Hastreiter, 1985 #463}. Renal clearance of digoxin in young 
children may be more dependent on ABCB1 mediated tubular 
secretion than in adults {Ratnapalan, 2003 #285}.
Tacrolimus ABCB1 PGx studies of ABCB1 in relation to tacrolimus PK appear 
contradictory {Gijsen, 2011 #396;de Wildt, 2011 #286;Hawwa, 2009 
#97;Guy-Viterbo, 2014 #397}.
In pediatric liver transplant recipients, high intestinal ABCB1 mRNA 
expression was associated with a two-fold higher tacrolimus 
clearance {Fukudo, 2006 #7}.
Daptomycin ABCB1 Higher body-size corrected renal daptomycin clearance in neonates 
and younger infants {Bradley, 2014 #458;Woodworth, 1992 
#491;Cohen-Wolkowiez, 2012 #465}.
Fexofenadine OATP2B1,
ABCB1, MRP2
Apparent bodyweight corrected oral clearance was 1.5-fold lower 
in children 6 months to 6 years, than in children 6 to 12 years 
{Martinez, 2014 #461}.
Morphine OCT1, ABCB1, ABCC2, 
ABCC3, OATP1B1
Neonates and infants have low morphine clearance in the first 
10 days of life, increasing thereafter, largely due to immature 
UGT2B7 metabolism but transporters may contribute {Knibbe, 2009 
#277;Krekels, 2014 #429}. Neonates are more prone to morphine-
related respiratory depression. {Sadhasivam, 2014 #403}. ABCB1 
genotype was associated with respiratory depression in older 
children, in contrast to an adult study {Kharasch, 2003 #401}. Also 
ABCB1 genotype affects the M3G-formation and OCT1 genotype is 
associated with variation in morphine clearance and glucuronide-
metabolites formation {Venkatasubramanian, 2014 #430}.
Pravastatin OATP1B1, OATP2B1, 
OATP1B3, ABCB1, 
ABCC2
Children with hypercholesterolemia and the SLCO1B1 -11187GA 
variant had lower mean pravastatin AUCs than those with the wild 
type, in contrast to an adult study where opposite effect was found 
{Hedman, 2006 #259;Niemi, 2004 #433}. No age-related variability 
in pravastatin PK from children age 5 years onwards {Hedman, 2003 
#260}.
Atorvastatin OATP1B1, BCRP Atorvastatin PK in older children similar to adult PK {Knebel, 2013 
#347}.
Bosentan OATP1B1, OATP1B3, 
OATP2B1
In children, an exposure limit was found at a much lower dose than 
in adults, might be due to intestinal OATP2B1 saturation {Beghetti, 
2009 #438}.
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1. Digoxin – ABCB1
The cardiac glycoside digoxin is a well-known ABCB1 substrate (Fig. 2). Its US Food 
and Drug Administration (FDA) drug label warns about pharmacokinetic interactions 
with intestinal or renal ABCB1 inducers or inhibitors. Digoxin is mainly renally cleared 
as unchanged drug, 80 % by glomerular filtration and 20 % by tubular secretion [35]. 
Pharmacokinetic studies in children show clear age-related differences. In a population 
pharmacokinetic analysis in 71 neonates (age range 2-29 days), oral digoxin clearance 
table 2. summary PK and PGx studies of relevant membrane transporter substrates (continued)
Drug relevant transporters 
involved in transport 
of drug
PK and PGx results in children
Ondansetron OCT1 Ondansetron PK and clinical efficacy have been correlated with 
OCT1 genotypes in adults {Tzvetkov, 2012 #311}. Ondansetron 
clearance increased with age in children ages 1 to 48 months {Li, 
2013 #310}.
Metformin OCT, MATE1, MATE2K Metformin PK in children from 9 years of age onwards was 
comparable with adult PK, suggesting stable OCT and MATE activity 
{Sanchez-Infantes, 2011 #409}.
Cimetidine OCT2, MATE1, MATE2K, 
OAT2
In neonates and children cimetidine (and metabolites) renal 
clearance accounts for 80-90% of total clearance, whereas in 
adults it accounts for 60% of total clearance {Somogyi, 1985 
#419;Ziemniak, 1984 #418;Lloyd, 1985 #416}. The relatively high 
renal clearance suggests mature OCT2 activity at birth in the 
presence of immature GFR {Kurata, 2010 #477}.
Tramadol OCT1 In adults OCT1 genotype was related to metabolite plasma 
concentrations and prolonged miosis {Tzvetkov, 2011 #332}. 
Tramadol and metabolite PK show age-related changes in neonates 
{Allegaert, 2005 #335}
Methotrexate OATP1B1, ABCC2 Increased renal toxicity in children 0-3 months compared to infants 
7-12 months {Thompson, 2007 #481}. From 1 year of age onwards 
body-size corrected methotrexate clearance decreased linearly with 
age {Radtke, 2013 #492}. SLCO1B1 genotype was associated with 
increased AUC and was a predictor for toxicity {Radtke, 2013 #483}.
Mycophenolate 
mofetil
MRP2 In pediatric patients ABCC2 rs717620 allele has been associated 
with reduced exposure to MPA, more side effects and rejection 
{Fukuda, 2012 #375}.
Acyclovir/ 
valacyclovir
4F2hc, HPT1, OAT1, 
OAT3
In neonates, the IV acyclovir bodyweight-corrected clearance 
showed a 2-fold increase from 25 to 41 weeks of gestational 
age {Sampson, 2014 #364}. In older children, 1 month to 5 years, 
apparent oral clearance of valacyclovir in children less than 3 
months of age was 50% than that in older children {Kimberlin, 2010 
#453}.
Adefovir OAT1, MRP4 Adefovir is partly renally cleared (45%) {Maeda, 2014 #319;Imaoka, 
2007 #455}. In 45 children (age range 2 years – 17 years) receiving 
oral adefovir dipivoxil, weight-corrected mean apparent clearance 
and renal clearance were higher in younger children {Sokal, 2008 
#340}.
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increased non-linearly with increasing bodyweight and gestational age [36]. The esti-
mated clearance of digoxin in a term-born 3 kg newborn is 0.338 L/kg/h at a serum 
concentration of 1 ng/mL. A population pharmacokinetic study in older infants [n=117, 
mean age (range) 0.76 (0.08-4.43) years] also found increased oral digoxin clearance with 
increasing bodyweight [37]. In this study, the simulated apparent oral clearance (CL/F) 
of an 8 kg infant was 0.43 L/h/kg at a target concentration of 1 ng/mL. Interestingly, 
digoxin clearance normalized for bodyweight, appears much higher in term neonates 
figure 2. Membrane transporters in their relationship with common prescribed drugs to children: 
digoxin, tacrolimus, morphine, pravastatin and atorvastatin.
ABC adenosine triphosphate (ATP)-binding cassette, CYP cytochrome P450, OATP organic anion-transport-
ing polypeptide, OCT organic cation transporter, UGT uridine 5’-diphospho-glucuronosyltransferase
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and younger children than in adults (0.17 L/h/kg). This observation is also in line with 
higher (per kg) dosing recommendations in term neonates and infants. However, as the 
drug is mainly renally cleared, and glomerular filtration is still immature at birth, one 
would expect a lower body size-corrected clearance. This was indeed the case in preterm 
infants (<2.5 kg) whose digoxin bodyweight-corrected clearance was much lower than 
that of term infants (0.064 vs. 0.1 L/h/kg), in line with lower dosing recommendations 
for this age group [38]. Thus, in preterm newborns, both glomerular filtration rate (GFR) 
and ABCB1 may be immature at birth, while in term infants ABCB1 activity may already 
be more mature and compensate for developmentally low GFR.
Additionally, clearance decreases non-linearly with increasing concentrations in the 
range of 0.2 and 2 ng/mL in children up to 4.5 years of age, whereas non-linearity in 
adults is only found from a serum concentration of 7 ng/mL onwards. We can only 
speculate as to the underlying mechanism. Earlier transporter saturation due to im-
mature ABCB1 activity in intestine and kidney contradicts the observation of higher 
bodyweight-corrected clearance in young children than in adults.
A clinically relevant interaction was found in eight children who were co-administered 
the ABCB1 inhibitor carvedilol. Digoxin clearance decreased twofold, while the digoxin 
clearance to GFR ratio decreased by 45 %, supporting intestinal and renal ABCB1 medi-
ated inhibition [39]. In contrast, the same drug-drug interaction resulted in only a mild 
decrease in digoxin clearance in adults. These findings support our hypothesis that renal 
clearance of digoxin in young children may be more dependent on ABCB1-mediated 
tubular secretion than in adults.
Interestingly, the hypothesis of higher renal ABCB1 expression after birth is supported 
by a mouse study showing a relationship between renal Abcb1 expression and digoxin 
clearance in young mice, but not by the limited human data from neonates [21, 40].
2. Tacrolimus – ABCB1
The calcineurin inhibitor tacrolimus inhibits synthesis of cytotoxic lymphocytes and so 
prevents transplant rejection. Tacrolimus is a substrate for intestinal and hepatic ABCB1 
(Fig. 2) [41]. Weight-normalized oral tacrolimus clearance, which is also dependent on 
cytochrome P450 (CYP) 3A4/5 metabolism, is higher in infants between 1 and 6 years of 
age than older children and adults [42, 43]. CYP3A4 activity matures in the first year of 
life, while CYP3A5 activity, when present, appears stable from fetus to adult [44].
Pharmacogenetic studies of ABCB1 in relation to tacrolimus disposition appear 
contradictory [45]. In pediatric heart and kidney transplant recipients no relation was 
found between ABCB1 genotype and tacrolimus dosing requirements or concentra-
tion/dose ratio [42, 43]. In pediatric liver transplant patients, homozygous ABCB1 
1236TT/2677TT/3435TT carriers needed higher tacrolimus doses than non-carriers both 
early and later after transplantation [42, 46]. In a population pharmacokinetic analysis 
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in 114 pediatric liver transplant recipients, the ABCB1 2677G>T allele was associated 
with a higher pre-dose and concentration/dose ratio at day 1 after transplantation [47]. 
Such associations were not found for recipient or donor ABCB1 1199G>A and 3435C>T 
variants. These findings can be understood from a combined ex-vivo/population phar-
macokinetic study in 130 pediatric liver transplant recipients. High intestinal ABCB1 
mRNA expression was associated with an almost twofold higher tacrolimus clearance 
early after transplantation, indicative of a switch from primarily intestinal to hepatic 
tacrolimus clearance upon graft recovery [48].
The results from ex vivo studies suggesting stable ABCB1 mRNA intestinal expression 
and lower hepatic ABCB1 expression in young infants may explain the pharmacogenetic 
findings and the impact of the recipient intestinal ABCB1 on tacrolimus disposition [20, 
22, 24, 48].
3. Daptomycin – ABCB1
The antibacterial daptomycin is used to treat infections caused by Gram-positive bacte-
ria including methicillin-resistant Staphylococcus aureus (MRSA). Daptomycin is excreted 
primarily by the kidney and is an ABCB1 substrate. In 23 adult Caucasian patients, the 
ABCB1 3435T single nucleotide polymorphism (SNP) was associated with a higher intra-
venous daptomycin dose-normalized area under the plasma concentration-time curve 
(AUC) and lower steady state clearance [49, 50]. In 24 children (age range 3-24 months), 
intravenous daptomycin clearance in younger infants (approximately 20 mL/h/kg) was 
higher than previously reported for older children and adults (8-13 mL/h/kg) [51, 52]. 
Likewise, in 20 preterm and term infants (32-40 weeks of gestational age and 0-85 days’ 
postnatal age, the mean clearance was approximately 20 mL/kg/h) [53]. No relationship 
with gestational or postnatal age was found, possibly due to the small sample size. The 
maturation pattern of daptomycin pharmacokinetics resembles that of digoxin pharma-
cokinetics, with higher clearance values early in life. This pattern is not consistent with 
immature GFR, but may reflect a compensatory role of ABCB1-mediated renal tubular 
secretion in young children. As discussed earlier, this may be the result of increased renal 
ABCB1 expression in young infants, but these findings need to be confirmed [16, 18, 21].
4. Fexofenadine – OATP2B1
The antihistamine fexofenadine is mainly excreted through bile as parent drug. Only a 
minor part is metabolized by intestinal microflora and CYP3A4. Its disposition appears to 
be subject to membrane transport by the uptake transporter OATP2B1, the efflux trans-
porter ABCB1 and possibly ABCC2 [54-56]. In 14 healthy men, fexofenadine clearance 
was related to OATP2B1 polymorphisms and simultaneous apple juice ingestion [57]. This 
latter finding of a potential food-drug interaction concerning OATP2B1 substrates may 
be even more relevant for children, as heavy consumers of apple juice. In a population 
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pharmacokinetic study in 515 Japanese children (6 months to 16 years), CL/F was stable 
across the age groups (1 L/h/kg) with the exception of the 6- to 12-year olds, whose clear-
ance was 1.5-fold higher (1.5 L/h/kg) [58]. In another population pharmacokinetic study 
including 46 Caucasian and 31 Non-Caucasian children (6 months to 12 years) and 138 
adults, apparent bodyweight-normalized oral clearance was lower in children less than 1 
year of age than in older children and adults [59]. Interestingly when comparing ethnici-
ties, the CL/F was slightly higher in the 6- to 12-year-old Japanese children (1.5 L/kg/h) 
than in 14 non-Japanese children (0.8 L/h/kg) (13 Caucasian and one non-Caucasian), but 
this difference may be rather due to the small sample size than ethnicity [58].
Ex vivo data in these age groups are lacking, but OATP2B1 gene expression in 15 neo-
natal intestinal samples obtained during surgery was nearly three times higher than in 
adult samples [22]. This may imply higher oral absorption of fenofexadine in neonates 
and young infants.
5. Morphine – ABCB1 and OCT1
The opioid morphine is almost completely metabolized by uridine 5’-diphospho-gluc-
uronosyltransferase (UGT) 2B7 and UGT1A1 to morphine-3-glucuronide and morphine-
6-glucuronide. The disposition of both morphine and/or its metabolites is subject to 
membrane transport by the uptake transporters organic cation transporter (OCT) 1 
and OATP1B1 and by the efflux transporters ABCB1, ABCC2 and ABCC3 (Fig. 2) [60, 61]. 
Hepatic uptake of morphine appeared to be OCT1-mediated in an adult volunteer study 
and carriers of loss-of-function SLC22A1 gene polymorphisms showed higher morphine 
AUCs [61]. In other healthy adult volunteers, co-administration of the ABCB1 inhibitor 
quinidine altered both morphine pharmacokinetics and its opioid effects after oral but 
not after intravenous morphine administration, suggesting a limited role for ABCB1 in 
the disposition of morphine at the liver and blood-brain barrier [62]. In adult cancer 
patients receiving oral morphine, pain relief was more prominent in homozygous carri-
ers of the ABCB1 3435T/T SNP, probably due to higher intestinal uptake [63].
Age-related morphine clearance in neonates and infants is very low in the first 10 days 
of life and increases thereafter [64]. Although this pattern was explained by UGT2B7 
maturation, an impact of the maturation of the relevant transporters cannot be ruled 
out. Interestingly, in follow-up studies in which morphine doses were adjusted to the 
age-related clearance and similar exposure was reached across the first year of age, pain 
relief was adequate in neonates (<10 days of age), but the older children still needed 
high doses of rescue morphine [65]. Neonates are more prone to respiratory depression, 
which may be explained by increased exposure to morphine when doses are not ad-
justed to the age-related changes in its disposition. In addition, immature ABCB1 activ-
ity at the blood-brain barrier, as shown very recently, cannot be ruled out to contribute 
as well and deserves further study [29].
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Sadhasivam and co-workers [66, 67] have extensively studied the impact of genetics 
of transporters in a large cohort of infants and children receiving intravenous morphine 
for tonsillectomy. In 220 infants, OCT1 homozygous genotypes (SLC22A1 1365GAT>del 
/ 1498G>C) were associated with lower morphine clearance and lower morphine gluc-
uronide formation [68]. ABCC3 homozygous -211 CC carriers showed (approximately 
40 %) higher metabolite transformation, indicating increased efflux of metabolites into 
plasma. ABCB1 polymorphisms (3435 C>T) only affected morphine-3-glucuronide for-
mation, not morphine or morphine-6-glucuronide pharmacokinetics. It should be noted 
that only pharmacokinetic data up to 45 min post-dosing were available and, hence, the 
full pharmacokinetic profile of morphine and metabolites could not be determined. In 
263 children of the same cohort, the ABCB1 G allele of rs9282564 polymorphism was as-
sociated with respiratory depression, resulting in prolonged hospital stay (odds ratio 4.7 
(95 % confidence interval: 2.1-10.8, P=0.0002) [66]. This study contrasts the adult study 
in which ABCB1 inhibition did not influence the effect of morphine after intravenous 
administration [62]. In the extended cohort, now including 347 children, the interaction 
of genetic variants of ABCB1 and two other genes, the fatty acid hydrolase [FAAH, which 
has been associated with opioid use and addiction acting via cannabinoid receptors 
type 1, and the β2-adrenergic receptor (ADRB2, receptor blockade has been associated 
with pain and pain relief ), helped discriminate low and high risk for morphine-related 
postoperative respiratory depression [67].
As hepatic ABCB1 gene expression only appears to reach adult levels after the first year 
of life [20, 22, 24, 48], immature hepatic and possibly also blood-brain barrier ABCB1 ex-
pression may play a role in higher morphine plasma and brain exposure and the higher 
risk for respiratory depression in neonates.
6. Pravastatin – OATP1B1
Clearance of the cholesterol synthesis inhibitor pravastatin is mainly dependent on non-
CYP450-mediated drug metabolism and several uptake and efflux transporters, such as 
OATP1B1, OATP2B1, OATP1B3, ABCB1 and ABCC2 (Fig. 2) [69]. In adults, SLCO1B1, but not 
ABCC2, ABCB1, or ABCG2, gene variants were associated with inter-individual variability 
in pravastatin pharmacokinetics, suggesting a major role of SLCO1B1 in pravastatin 
disposition [70, 71].
Intriguingly, in one small pharmacogenetic study (n=20; mean ± standard deviation 
age 10.3 ± 2.9 years), children with familiar hypercholesterolemia with the SLCO1B1 
-11187GA genotype had lower mean pravastatin AUCs than children with the wild type 
[72]. The opposite effect was found in an adult study (n=41) [71]. These results, which 
should be interpreted with care in view of the small sample size, suggest age-related 
posttranslational differences in OATP1B1 expression. The pharmacokinetics of pravas-
tatin in children (aged 5-16 years) waere similar to adults, which suggests no major 
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impact of age-related variability in OATP1B1 or other transporter activity from 5 years 
onwards [73]. These results appear to be in line with the ex vivo results of stable hepatic 
OATP1B1 expression in older children [25].
7. Atorvastatin – OATP1B1
Another cholesterol synthesis inhibitor increasingly used in children is atorvastatin. Like 
the other statins (HMG-CoA reductase inhibitors), atorvastatin is extensively metabo-
lized, largely by CYP3A4, and is a substrate for OATP1B1 (hepatic uptake) and ABCG2 
(oral absorption) (Fig. 2). In a population pharmacokinetic study in pediatric hypercho-
lesterolemia patients aged 6-17 years, atorvastatin CL/F was described as a function of 
bodyweight. When scaled allometrically, CL/F was similar to values reported for adults 
[74]. Atorvastatin metabolism is probably mature from 6 years onwards. The stable 
clearance and the existing ex vivo data of OATP1B1 suggest similarly mature transporter 
activity, although an age-related change in the relative contribution of individual trans-
porters cannot be ruled out [25, 26]. We could not identify pediatric pharmacogenetic 
atorvastatin studies, although a comprehensive study in adults clearly indicated the 
SLCO1B1 variant 388A>G as a major determinant for atorvastatin PK [75].
8. Bosentan – OATP2B1
Bosentan is metabolized by CYP3A4 and CYP2C9, with both the parent compound and 
one metabolite being pharmacological active, but is also subject to hepatic uptake 
by OATP1B1, OATP1B3 and maybe OATP2B1 [76]. Next to the developmental pattern 
of CYP3A4, CYP2C9 already shows an increase prenatally, with stable, though variable, 
activity after the first week of postnatal age [77, 78]. Hence, the impact of the maturation 
of the transporters may be compounded by CYP3A4 and CYP2C9 maturation in the first 
year of life, but age-related variation as observed later in life may be more likely due 
to transporter maturation. At oral doses of approximately 2 mg/kg, bosentan plasma 
exposures for 19 children (aged 3-15 years) were similar to those for healthy adults [79]. 
In children [n=36, median (range) age 7.0 (2 - 11) years], plasma levels did not further 
increase at doses higher than 2 mg/kg (exposure limit), while in adults the exposure limit 
was 7 mg/kg, with no difference in the other pharmacokinetic parameters [80]. As bosen-
tan appears an OATP2B1 substrate, intestinal saturation due to immature OATP2B1, and 
perhaps other anatomical or physiological age-related differences in oral absorption, 
may explain this observation. This result does not correspond with the OATP2B1 mRNA 
expression results, suggesting higher expression in neonates than in adults [22]. In a 
pediatric population pharmacokinetic-pharmacogenetic study [n=46, mean (range) age 
3.8 (25 days – 16.9) years] no relation between bosentan pharmacokinetics and genetic 
polymorphisms of SLCO1B1, SLCO1B3, SLCO2B1 or CYP3A5 was found [81].
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9. Ondansetron – OCT1
The anti-emetic ondansetron is mainly metabolized by CYP2D6, which contributes to 
genetic variation in its disposition and effect. In addition to this CYP2D6 effect, the 
pharmacokinetics (n=45) and clinical efficacy (n=222) of ondansetron in adults (age 
range 18-83 years) have also been correlated with SLC22A1 genotypes [82]. OCT1 de-
ficiency potentially limits the hepatic uptake and increases plasma concentrations of 
ondansetron [82]. In a population pharmacokinetic analysis of 124 patients in the age 
range 1- 48 months, ondansetron bodyweight-normalized clearance was reduced by 
76% in a 1-month-old patient and by 31% in a 6-month-old patient, compared with 
the older children [83]. This contrasts evidence from both in vitro and in vivo studies 
suggesting maturity of CYP2D6 activity as early as 1-12 weeks postnatal [84-86]. Thus, 
we hypothesize that lower ondansetron clearance in the first year of life may be related 
to immature OCT1 activity.
10. Metformin – OCT1 and MATE1
Several transporters have been implicated in metformin elimination, tissue distribu-
tion and response. OCT1 is a major determinant of the hepatic uptake of metformin, 
while multidrug and toxin extrusion protein (MATE) 1 /MATE2K determine the efflux of 
metformin [7, 34]. Recently, the transcription factor hepatocyte nuclear factor 1 was 
found to regulate OCT1 expression and was related to metformin pharmacokinetics 
and pharmacodynamics [87, 88]. The combination of SLC22A1 (OCT1) and SLC47A1 
(MATE1) genotypes further explains variation in response to metformin in adults [8, 89]. 
In contrast, in 140 non-obese adolescent girls with androgen excess after precocious 
pubarche, SLC22A1 genotype was not related to metabolic response at 1 year of metfor-
min treatment [90]. In non-obese 9-year-old girls and diabetic patients aged 12-16 years, 
pharmacokinetics were comparable with those in adults [91, 92]. This suggests stable 
OCT1 or MATE activity from the age of 9 years onwards, but this needs further study, 
especially since data in younger children are lacking.
11. Cimetidine – OCT2
In adults, renal excretion of the histamine H2-receptor antagonist cimetidine and its me-
tabolites accounts for 60 % of total clearance, versus 80-90% in children and neonates 
[93-95]. Cimetidine is partially metabolized and is a substrate of the uptake transporters 
OCT2 and organic anion transporter (OAT) 2 and the efflux transporters MATE1 and 
MATE2-K [8, 34, 96, 97]. Cimetidine is a well-known OCT2 inhibitor and therefore could 
potentially counteract OCT2-driven cisplatin oto- and renal toxicity [98]. Although the 
drug is now rarely used in pediatric clinical care, this latter promise necessitates a full un-
derstanding of its disposition across the pediatric age range, as part of studies to confirm 
this new indication. The relatively high renal clearance in neonates and children suggests 
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an important role for renal tubular secretion and suggests mature activity already at 
birth. On the other hand, Ziemniak et al. [94] suggest that the unexplained gap between 
total and renal clearance in adults could be due to secondary metabolite formation in 
adults, which maybe missing in neonates due to immature metabolism. This is less likely, 
however, as the higher renal clearance was also observed in older children, whose drug 
metabolism is largely at adult levels. Moreover, in a rat study, bile duct ligation increased 
cimetidine renal tubular secretion by up-regulation of OCT2 (but not MATE1), supporting 
the hypothesis that the non-renal clearance in adults occurs through hepatic/bile excre-
tion and is not related to unknown secondary metabolite formation [99]. Nevertheless, 
as analytical methods to measure drugs and metabolites have become more sensitive 
since these early studies in the mid-1980s, new studies in children of different ages could 
help elucidate why renal clearance of cimetidine differs between children and adults 
and give insight in the role of OCT2 in cimetidine disposition.
12. Tramadol – OCT1
Tramadol is a prodrug of the µ-opioid receptor agonist O-desmethyltramadol. It is 
metabolized mainly by CYP2D6 to its active O-desmethyltramadol metabolite [100]. 
The variation in tramadol pharmacokinetics cannot solely be explained by variation 
in CYP2D6, as was shown by Tzvetkov et al. [101] who showed an additive effect of 
OCT1 on tramadol disposition variation. Loss-of-function SLC22A1 polymorphisms 
have been related to higher plasma concentrations of the active O-desmethyltramadol 
and prolonged miosis, as surrogate marker of the opioid effect. These effects are likely 
due to reduced OCT1-mediated hepatic uptake [101]. Allegaert and co-workers [102] 
showed that maturational clearance of tramadol, driven by CYP2D6 activity, is almost 
complete by 44 weeks post-menstrual age. In a pooled population pharmacogenetics-
pharmacokinetic study covering the age range from preterm to elderly, only part of the 
variability in O-desmethyltramadol formation clearance could be explained by CYP2D6 
genotype, further supporting a potential role for SLC22A1 genetic variation [86]. A re-
lationship between CYP2D6 genotype and tramadol metabolism was shown in young 
preterm infants, which is surprising as CYP2D6 is not fully mature at birth, especially not 
in preterm infants, and a genotype effect may have been obscured. It would be worth-
while, therefore, to study the impact of SLC22A1 genotype in this young population [10]. 
In a population pharmacokinetic/pharmacodynamic analysis of 104 older children (2-8 
years), age did not clearly contribute to variation in pharmacokinetics or the prediction 
of response [103].
13. Methotrexate – OATP1B1 and ABCC2
Methotrexate is a folic acid antagonist used to treat several forms of cancer and 
anti-inflammatory diseases. Methotrexate undergoes complex hepatic and intracel-
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lular metabolism [104]. Many membrane transporters are responsible for its uptake 
and excretion and for its metabolism to active polyglutamine metabolites and inactive 
7-hydroxy-methotrexate [104, 105]. Methotrexate is eliminated primarily by renal excre-
tion through glomerular filtration and renal tubular reabsorption and secretion. Ap-
proximately 70–90 % of a dose is excreted unchanged in urine. A small pharmacokinetic 
study showed only marginally lower methotrexate steady-state clearance (body surface 
area corrected), but increased renal toxicity, in 0- to 3-month-old infants than in 7- to 
12-month-old infants [106, 107]. From 1 year onwards methotrexate clearance (body 
surface area normalized) decreased linearly with age [107]. A 2014 review concluded 
that ”although there is no pharmacogenetic marker for MTX [methotrexate] in use in the 
clinic at present, polymorphisms in SLCO1B1 have an important role in MTX pharmaco-
kinetics and toxicity in pediatric ALL [acute lymphoblastic leukemia] patients and show 
the most consistent and promising results” [105]. For example, in a cohort of almost 
500 pediatric acute lymphoblastic leukemia (ALL) patients, methotrexate AUC from time 
zero to 48 h (AUC0-48h) increased by 26 % (P < 0.001) per SLCO1B1 rs4149056 C allele 
and was a significant predictor of overall toxic adverse events during methotrexate 
courses (R2 = 0.043; P <0.001), but no relationship was found for ABCC2 [107]. This study 
confirmed the results of a genome-wide association study (GWAS) in 434 ALL children, 
the first to identify SLCO1B1 as an important marker of methotrexate pharmacokinetics 
and clinical response, and recently validated by five different treatment regimens of 
high-dose methotrexate ALL treatment protocols at St Jude Children’s Research Hospital 
(Memphis, TN, USA) [108]. Moreover, a deep sequencing approach for SLCO1B1 demon-
strated that rare damaging variants contributed significantly to methotrexate clearance 
and had larger effect sizes than common SLCO1B1 variants [109, 110]. Other recent stud-
ies have detected a relationship between ABCC2 and methotrexate pharmacokinetics 
and toxicity. In 112 Han Chinese pediatric ALL patients, the ABCC2 -24T allele (rs717620) 
was associated with significantly higher methotrexate plasma concentrations at 48 h 
and with significant hematological and non-hematological toxicities. These findings 
are partially supported by other studies in 127 Lebanese and 151 Spanish pediatric ALL 
patients [111, 112].
14. Mycophenolate mofetil – ABCC2
Mycophenolate mofetil is the prodrug of the active mycophenolic acid (MPA). It is 
metabolized by carboxylesterase 2 (CES2), after which MPA is further metabolized by 
several CYPs and UGTs [113]. MPA-glucuronide is excreted in the bile primarily by ABCC2 
(encoded by ABCC2) and this transport is essential for enterohepatic circulation. The 
ABCC2 rs717620 A allele has been associated with reduced exposure to MPA in pediatric 
renal transplant recipients [114]. In a large multi-center cohort of pediatric heart trans-
plant recipients, ABCC2 rs717620 A allele was also associated with more gastrointestinal 
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intolerance, but with fewer short- and long-term rejection episodes [114]. As ABCC2 
is thought to excrete MPA-glucuronide in the bile, carriers of the active A allele, may 
have increased enterohepatic circulation with an increased concentration of free MPA 
in the intestine. This is potentially associated with more gastrointestinal intolerance, but 
simultaneously with higher exposure and efficacy. As SNPs in UGT1A9, UGT2B7, SLCO1B3 
and IMPDH have also been associated with altered MPA exposure, the combined effect 
of these SNPs and potentially interacting co-medication, may define high- and low- risk 
patients for MPA efficacy and toxicity. Full hepatic ABCC2 maturation appears to occur 
after infancy, suggesting a lower enterohepatic circulation of MPA, which may result in 
less gastrointestinal intolerance but potentially also with less efficacy in this age group 
[22]. This is merely a hypothesis without confirming pharmacokinetic data.
15. Acyclovir/Valacyclovir – OAT1 and OAT3
The oral bioavailability of the anti-viral agent acyclovir is poor, and therefore its prodrug 
valacyclovir was developed. A positive association was found between intestinal expres-
sion of 4F2hc (SLC3A2, amino acid transporter heavy chain, a membrane glycoprotein), 
and HPT1 (human oligopeptide transporter) and plasma levels of valacyclovir, but not 
peptide transporter 1 [PEPT1 (SLC15A1)] or any of the other investigated intestinal or-
ganic anion or cation transporters [115].
After hepatic metabolism, both drugs are mainly renally excreted by both glomerular 
filtration and renal tubular secretion, most likely by OAT1 and OAT3 [116, 117]. In preterm 
and term neonates (n=28, median age 30 weeks of gestation), the intravenous acyclovir 
bodyweight-corrected clearance showed a twofold increase from 25 to 41 weeks of ges-
tational age [118]. In children 1 month to 5 yearsold with or at risk for herpes infection, 
CL/F of valacyclovir (mL/kg/min) in those younger than 3 months was 50 % of that in 
older children, in whom bodyweight-corrected clearance remained stable [119]. A re-
cent study showed markedly increased acyclovir concentrations when co-administered 
with benzylpenicillin, which was shown to be due to OAT3 and possibly OAT1 inhibition 
[116]. This could be a very relevant interaction in septic newborns, who often receive 
both drugs, as increased acyclovir concentrations are associated with neurological 
adverse events as well as neutropenia.
16. Adefovir – OAT1 and ABCC4
Adefovir, the antiviral agent used for treatment of hepatitis B virus or HIV, is 45 % renally 
cleared through glomerular filtration and OAT1/ABCC4 renal tubular secretion [120, 121]. 
In 45 children in three age groups (2-6, 7-11, and 12-17 years) receiving oral treatment 
for hepatitis B virus with the prodrug adefovir dipivoxil bodyweight-corrected mean 
apparent clearance and renal clearance were decreasing with increasing age [122]. Simi-
larly, in a phase I study in children (n=13, age range 6 months to 18 years) receiving oral 
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adefovir dipivoxil for HIV treatment, systemic exposure was lower in children younger 
than 5 years [123].
suMMAry AnD Discussion
In summary, ex vivo, pharmacokinetic and pharmacogenetic studies suggest transport-
er-specific changes from the human fetus to the adult. At this time, data are very scarce 
and the impact of these changes on drug therapy in children is still largely unknown. 
However, despite data scarcity, our review may aid clinical pharmacologists and clini-
cians in rationale drug prescribing of the drugs presented, not only by showing how 
pharmacokinetics are probably similar in certain pediatric age groups compared to 
adults, but also by pointing out where potential age-related changes in individual trans-
porters could impact the drug’s efficacy and safety. It broadens our views on ontogeny 
of transporters by evaluation of the results of pharmacokinetic and pharmacogenetic 
studies on relevant transporters. Moreover, this review presents clear information gaps, 
which may guide future research efforts to elucidate the role of human membrane 
transporters in the developing child.
For most drugs, the in vivo data to support the ex vivo data in understanding the 
maturation of individual transporters are limited to older children, and, hence, their 
usefulness is limited. No clear transporter maturation pattern can be deducted from any 
of the available pharmacokinetic studies in children. This contrasts with our knowledge 
from individual DMEs. For example, using midazolam as phenotyping probe, the de-
velopmental expression of CYP3A4/5 from the preterm neonate to the adult has been 
extensively characterized [124, 125] or amikacin clearance to display the maturation 
of GFR in neonates [125]. Specific phenotyping probes to study individual membrane 
transporters are suboptimal and have only been validated in adults. For many drugs, 
multiple transporters are involved in their uptake and excretion, which in turn may also 
compensate for changes in individual transporter activity. In adults, knowledge has also 
been gained from pharmacogenetic and drug-drug interaction studies.
This review shows that pharmacogenetic variation in membrane transporter activity 
also impact drug disposition, effect and toxicity in children. Most pharmacogenetic 
studies in children are in line with adult data. However, these similar pharmacogenetic 
relationships should be interpreted with care, especially when it comes to translating 
these data across the whole pediatric age range. First, most pharmacogenetic study 
cohorts only contain older children, whereas pharmacokinetic studies in neonates and 
infants often show clear developmental changes up to 4-6 years of age. Hence, the 
impact of SNPs may be obscured by more prominent changes due to growth and devel-
opment. Second, the relationship between SLCO1B1 SNPs and pravastatin disposition in 
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adolescents was found to be the opposite of that in adults. If these results are validated 
in other studies, a potential impact of hormonal changes on individual transporters 
needs to be elucidated; this may also provide insight into the physiological role these 
transporters play during adolescence.
The limited data from ex vivo studies of postmortem or surgical samples support the 
notion of membrane transporter-specific maturational patterns. It is still difficult, how-
ever, to determine definitive patterns for the different transporters. One of the reasons 
for this is that most studies only used limited samples and limited age ranges. Most fetal 
and neonatal studies only applied immunohistochemistry or mRNA techniques, while 
the more quantitative protein expression data are mainly from older children, above the 
age range in which most developmental changes can be expected. In addition, the qual-
ity and interpretation is further challenged as the exact origin, handling, and storage 
of tissues, including detailed patient characteristics and exact procurement site from 
organ (e.g., where in the intestine?), is often unknown.
The mechanisms underlying maturational changes in transporters are largely un-
known. Recent studies on the CYP3A4 show maturational changes in methylation pat-
terns to mirror the maturational expression of CYP3A4, which may point towards similar 
mechanisms for the transporters [126].
Differences between ethnic groups in DME abundance or ethnicity have been de-
scribed, even in newborn infants [77, 85, 127]. Like in DMEs, it is credible to believe that 
ethnicity might have an effect on transporter activity or abundance. Nevertheless, for 27 
drug transporters in 95 pathologically normal kidney samples, the expression did not 
differ between European Americans or African Americans [128].
The interpretation of pharmacokinetic studies, to understand maturation of trans-
porters, is complicated by the fact that these transporters are part of the larger system 
of the ADME processes involved in the disposition of drugs. In contrast to DMEs, where 
clearance to a specific metabolite can be estimated to understand the DME maturation, 
studying a single transporter is more difficult. One may not be able to pinpoint one 
specific membrane transporter involved, and if the dominant transporter is still im-
mature early in life, other transporters may compensate, thereby obscuring individual 
transporter maturation.
futurE DirEctions
Several approaches are needed to increase our understanding of membrane transport-
ers in the fetus and child (Table 3). First, the impact of transporter maturation on efficacy 
and toxicity in daily clinical care needs to be elucidated.
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Pharmacogenetic studies can be a powerful tool to this aim, provided they have ad-
equate power and validation cohorts, the lack of which is a major limitation of currently 
published studies. Studies need to not only be powered to study the impact of a single 
SNP in one transporter gene, but at the least the interaction with age should be part of 
their designs. Preferably such studies are designed to study the disposition of a drug in 
the context of systems pharmacology, also including SNPs in other relevant pharmaco-
kinetic and/or pharmacodynamic genes, as well as pharmacokinetic sampling enabling 
the separation of different excretion pathways (e.g., GFR vs. tubular secretion vs. bile 
secretion vs. metabolism). In addition to pharmacogenetic studies, well-designed stud-
ies reflecting clinical drug-drug interaction scenarios may improve our understanding of 
transporter maturation, such as pharmacokinetic studies in which patients’ samples are 
taken before/during/after co-medication with a potentially interacting drug. For example, 
the carvedilol-digoxin study [39] or the older cimetidine studies in neonates in which 
renal clearance by glomerular filtration could be separated from renal tubular secretion 
[94], have, by their design, provided support for age-related differences in specific renal 
transporters. We also noted a specific lack of in vivo data from younger children.
Ethical challenges have limited studies in infants and neonates. However, many drugs 
in our overview are regularly prescribed, even for these young children. Therefore, op-
portunistic sampling or biobanking of left-over samples from children who take these 
drugs for therapeutic reasons may aid to overcome these ethical barriers.
table 3. Approaches to future transporter studies
LC-MS liquid chromatography-mass spectrometry, PD pharmacodynamics, PGx pharmacogenetic, PK phar-
macokinetic
Ex vivo research
-  Build multidisciplinary research teams for tissue collection and study design, e.g., surgeons, pathologists, 
clinical study staff, basic researchers
-  Use optimal age distribution, e.g., tissues samples from fetuses, neonates and young infants, where most 
developmental changes can be expected, as well as sample number to ensure adequate power to detect 
age-related changes
-  Establish high-quality tissue collections with detailed tissue handling description and detailed description 
of patient characteristics
-  Use protein quantification techniques (e.g., LC-MS) and develop tools to study activity with minimal 
human tissue amounts
PK studies
- Phenotyping studies with drugs that are clinically used, and consider microdosing studies
- Blood sampling at similar times as clinical blood draws (opportunistic sampling)
- Perform population PK analyses
- Design drug-drug interaction studies
PGx studies
- In pediatric populations, test genetic variants in transporters known to affect PKs or PDs in adults
- Take into account PGx variation in affected drug-metabolizing enzymes as added variants
- Include relevant age ranges: e.g., younger children and neonates
- Design adequately powered studies
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At this time, endogenous markers to phenotype the activity of individual transport-
ers are lacking. With the increased availability of metabolomics, specific metabolites 
or metabolite ratios may be identified to reflect transporter activity in vivo. A recent 
GWAS-metabolomics study detected specific metabolites/metabolite ratios for selected 
transporters such as OCT1. [129-133]. The feasibility of this approach was recently shown 
for CY2D6 phenotyping in children [129]. To design drug-dosing regimens in children, 
increasingly, population PBPK models are being used [134]. Modeling and simulation 
can be used in different ways to increase our understanding and to design dosing 
regiments. Using a systems approach, modeling of the disposition of a substrate model 
drug, can result in a mathematical description of maturation of the specific transporter. 
This maturational description can then be used to simulate dosing guidelines for other 
transporter substrates. The feasibility of this approach has been used to describe matu-
ration of selected DMEs and GFR clearance [133, 135]. Secondly, PBPK modeling, which 
incorporates available drug property and physiological information, could be used to 
simulate the impact of maturation of specific transporters, preferably with actual ex vivo 
data on transporter expression/activity [134]. An example is a mechanistic PBPK model 
to predict morphine levels in breast-fed neonates of codeine treated mothers [136]. A 
major limitation of these models is the lack of high quality ex vivo data on transporter 
activity across the pediatric age range and the lack of in vivo validation of these models.
In the design of new studies the following issues should be considered. The collec-
tion of these data can only be achieved by an international effort to collect high-quality 
tissue in collaboration with surgeons, pathologists, ethicists, clinical researchers, and 
experts in drug transporter research. The limitations of current tissue collections have 
been described here and good protocols for tissue collection, preferably in the context of 
internationally accessible biobanks, should be developed. Newer laboratory techniques 
should be strongly considered to minimize tissue amounts needed, for example, for 
laser capture and LC-MS/MS to determine protein abundance. Moreover, a multi-omics 
approach, including not only genomics but also transcriptomics, proteomics, metabolo-
mics, and microbiomics, may provide greater power to predict drug efficacy and adverse 
drug reactions [137, 138]. Also, with the fast developments in tissue engineering, the 
current ethical and practical issues regarding tissue sampling and storage could be 
overcome using pediatric-engineered tissues. This may even enable transporter activity 
studies, which are now not available in pediatric tissue.
Additional Supporting Information may be found in the online version of this article
Appendix 1 Literature search strategy
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AbstrAct
introduction
Many drugs prescribed to children are drug transporter substrates. Drug transporters 
are membrane-bound proteins that mediate the cellular uptake or efflux of drugs, and 
are important to drug absorption and elimination. Very limited data are available on the 
effect of age on transporter expression. Our study assessed age-related gene expression 
of hepatic and intestinal drug transporters.
Methods
Multidrug resistance protein 2 (MRP2), organic anion transporting polypeptide 1B1 
(OATP1B1), and OATP1B3 expression was determined in postmortem liver samples 
(fetal n=6, neonatal n=19, infant n=7, child n=2, adult n=11) and multidrug resistance 
1 (MDR1) expression in 61 pediatric liver samples. Intestinal expression of MDR1, MRP2, 
and OATP2B1 was determined in surgical small bowel samples (neonates n=15, infants 
n=3, adults n=14). Using real time reverse-transcritption polymerase chain reaction, 
we measured fetal and pediatric gene expression relative to 18S rRNA (liver) and villin 
(intestines), and we compared it to adults using the 2-∆∆Ct method.
results
Hepatic expression of MRP2, OATP1B1, and OATP1B3 in fetuses, neonates and infants 
was significantly lower than in adults. Hepatic MDR1 mRNA expression in fetuses, neo-
nates and infants was significantly lower than in adults. Neonatal intestinal expressions 
of MDR1 and MRP2 were comparable to those in adults. Intestinal OATP2B1 expression 
in neonates was significantly higher than in adults.
conclusion
We provide new data that show organ- and transporter-dependent differences in 
hepatic and intestinal drug transporter expression in an age-dependent fashion. This 
suggests that substrate drug absorption mediated by these transporters may be subject 
to age-related variation in a transporter dependent pattern.
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introDuction
Drug transporters are membrane-bound proteins whose primary function is to facilitate 
the trafficking of drugs and their metabolites across a biologic membrane. Expressed 
in structural cells that compose the organs of importance to drug disposition, such as 
enterocytes and hepatocytes, they are involved in the active uptake and elimination 
of orally administered drugs. In adults, drug transporters are recognized as key deter-
minants of variation in the pharmacokinetics of many drugs, as shown in studies using 
primary cell and ex vivo organ cultures as well as clinical studies [1]. In contrast, such 
data in children are scarce and clinical studies are absent [2-7].
Pharmacokinetics in children is known to be affected by developmental changes with 
age [8]. Drug metabolizing enzyme activity, for example, changes significantly from fetal 
to adolescent age associated with alterations in metabolic clearance of many drugs [9]. 
Notably, hepatic and intestinal expression of cytochrome P450 subfamily CYP3A4 shows 
a clear developmental pattern, and systemic clearance of midazolam, a known substrate 
of CYP3A, changes with age [10-12]. Similarly, compared with adults, differences in body 
composition and renal function in children affect drug tissue distribution and renal drug 
excretion, respectively.
As a consequence, it has become apparent that simply extrapolating drug doses 
from adults to children based on body weight is likely inaccurate owing to our lack 
of our understanding of age-dependent differences in the maturation of the drug 
absorption and elimination processes involved in drug disposition. As the expression 
of drug metabolizing enzymes appears to be age-related, it is also likely that this is the 
case for drug transporter expression. Data from animal studies report occurrence of 
transporter-specific maturation [13]. In humans, several efflux transporters that belong 
to the ATP-binding cassette family (ABC), including the multidrug resistance protein 1 
(MDR1/ABCB1), multidrug resistance-associated protein 2 (MRP2/ABCC2), and breast 
cancer resistance protein (BCRP/ABCG2), were found to be expressed in fetal liver or 
intestine, but otherwise little is known of the developmental patterns of individual 
drug transporters [6, 14, 15]. Systematic characterization of age-related differences in 
transporter expression will aid the selection of the most appropriate dose for substrate 
drugs in children.
In a first step towards elucidating the developmental changes, this study determined 
the gene expression of clinically relevant hepatic and intestinal drug transporters across 
the pediatric age range. We focused on transporters with well-defined roles in drug 
pharmacokinetics in adults [1] (Fig. 1). These included the efflux carriers MDR1 and MRP2 
in liver and intestine, and uptake carriers of the organic anion transporting polypeptide 
(OATP/solute carrier organic anion [SLCO]) family, including the liver-specific transport-
ers OATP1B1 and OATP1B3, and OATP2B1 in the intestine.
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1. tissue samples
Autopsy liver tissue samples from fetuses and from children up to 18 years of age were 
obtained from the Erasmus MC Tissue Bank. An opt-out clause was in place for use of 
tissue from the tissue bank. The Erasmus MC research ethics board provided a waiver 
for ethics approval according to the Dutch Law on research in humans. Fresh intestinal 
tissue was collected during surgery at the time of resection. Intestinal samples from 
children were derived from other research projects, and informed consent was previ-
ously obtained for the use of this tissue in the context of these studies approved by 
Erasmus MC research ethics beoard. After resection, all liver and intestinal tissues were 
immediately snap frozen in liquid nitrogen, stored at −80°C and processed on ice for 
mRNA isolation.
Healthy human adult liver samples were obtained from the Liver Tissue Cell Distri-
bution System at the University of Minnesota under National Institues of Health (NIH) 
contract N01-DK-7-0004/HHSN267200700004C. Adult intestinal samples were obtained 
from the University of Western Ontario, and the use of these samples was approved by 
the research ethics board.
Additional pediatric tissue specimens for MDR1 analyses were obtained from the 
NIH-supported tissue programs: the Liver Tissue Cell Distribution System (LTCDS) from 
the Minnesota and Pittsburgh collection centers; the University of Maryland Brain and 
Tissue bank for Developmental Disorders (Baltimore, MD); and the Laboratory of De-
velopmental Biology at the University of Washington (Seattle, WA). Additional samples 
were from Xenotech, LLC (Lenexa, KS). The use of these tissues was declared nonhuman 
subjects research by the Children’s Mercy Hospitals and Clinics pediatric institutional 
review board.
The sources of the obtained samples are listed in Table 1.
figure 1. transporters in enterocyte and hepatocyte.
Only transporters in enterocyte (A) and (B) hepatocytes were selected for this study.
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2. mrnA isolation and cDnA synthesis
Frozen human tissue samples were mechanically homogenized on ice. Homogenate 
was applied to a QiaShredder column (Qiagen) and RNA was extracted using the RNeasy 
Mini Kit (Qiagen, Valencia, CA) according to the instructions provided by the manu-
facturer. RNA was treated with DNase to digest genomic DNA remnants. The quantity 
and integrity of RNA were determined by microfluidics-based analyses using the 2100 
BioAnalyzer (Agilent, Santa Clara, CA). Samples with an RNA integrity number (RIN) of 
<5 were excluded from this study. Complementary DNA (cDNA) was synthesized using 
the High-capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) and random 
priming.
3. real time reverse transcription Polymerase chain reaction
The mRNA expression was measured by SYBR green quantitative real-time polymerase 
chain reaction with the ABI 7500 sequence detection system (Applied Biosystems). Previ-
ously optimized primers were used (Supplemental Material) [16]. Modified primers were 
used for villin and OATP2B1 (reverse primer only), and primer sequences were obtained 
via qPrimer Depot (http://primerdepot.nci.nih.gov/). After each polymerase chain reac-
tion, a melting curve analysis was performed to confirm product specificity. Eukaryotic 
18S rRNA was assessed as the endogenous control with the use of a TaqMan VIC/MGB 
probe (4319413E, Applied Biosystems). Transporter transcript levels were normalized 
to18s rRNA, and relative expression was determined using the 2-ΔΔCt method comparing 
pediatric samples to adult liver or intestine (calibrator samples) [17]. The adult target 
gene value was determined by using the median of the adult threshold cycle (Ct) values.
For comparison, all 96-well plates analyzing liver samples included a specific liver con-
trol sample to normalize expression for the gene of interest and 18S rRNA, if appropriate. 
Similarly, a specific intestinal sample was added to plates to normalize for the genes of 
interest, 18S rRNA, and villin if appropriate.
4. statistics
All data were analyzed by Kruskal-Wallis analysis, followed by group comparisons using 
a nonparametric Mann-Whitney test and post-hoc Bonferroni multiple comparison test. 
All statistical analyses were performed using GraphPad Prism version 5.00.2 and IBM 
SPSS Statistics software (SPSS Statistics for Windows, Version 21.0; IBM, Armonk, NY). 
P<0.05 was considered statistically significant. Data are presented as median and range, 
unless indicated otherwise.
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sample characteristics
Characteristics of all samples are provided in Table 1. Forty-one liver samples from 
anonymous donors were collected from the Erasmus MC Tissue Bank. Seven samples 
were excluded because of poor mRNA quality, with 34 samples remaining for analysis. 
The causes of death were the following: congenital disorders (n=9), [including hydrops 
fetalis (n=2), ruptured giant omphalocele, hemangioendothelioma, extended congeni-
tal abnormalities, trisomy 7 or 8, cardiac, osteogensis imperfecta], cardiac failure (n=6), 
respiratory disorders (n=6), sepsis (n=4), gastrointestinal disorders (n=4), neurological 
disorders (n=3), and unknown causes (n=2). Adult liver samples (n=11) were derived 
from histologically normal parts of transplanted livers. Death was related to anoxia 
(n=5), trauma (n=3), neurologic disorders (n=2), or unknown cause (n=1), and ages were 
unknown. The RIN median of fetal, pediatric, and adult liver samples was 7 (range 5 - 10). 
The MDR1 mRNA expression was also measured in additional pediatric liver samples: 
three fetuses, 1 neonate, 4 children age 1 month to 12 months, and 17 children aged 12 
months to 17 years. Thus, the total set of liver samples in which MDR1 mRNA expression 
was measured consisted of 9 fetal samples and 52 neonatal/pediatric samples. Cause of 
death of the additional pediatric donors was unknown.
Twenty-eight intestinal resection samples were obtained, of which 10 were excluded 
due to poor mRNA quality. The main reasons for resection were necrotizing enteroco-
litis and intestinal atresia (n=11); other reasons (n=7) were volvulus, persistent ductus 
omphaloentericus, Meckel’s diverticulum, meconium peritonitis and ileostomy closure. 
Resection areas were aimed at the most proximal part of the intestine. Adult intestinal 
samples (n=14) were endoscopic biopsy samples and negative for any pathology. RIN 
median of pediatric intestinal samples was 7 (range 5 - 9). The RIN values of samples from 
adult intestinal donors were not measured. In pediatric and adult intestinal samples, 18S 
was significantly correlated with villin mRNA (n=32, r=0.6110, p<0.05). We also deter-
mined CYP3A4 gene expression. The mRNA expression of CYP3A4 is well reported in the 
literature. Patterns of intestinal and hepatic CYP3A4 mRNA expression were the same as 
those reported in the literature (data not shown) [3].
Information about medication use by the donors was not available.
transporter-specific ontogenetic Profile of MDr1, MrP2, oAtP1b1 and 
oAtP1b3 mrnA Expression in liver
Hepatic transporter expression was significantly associated with age: MDR1 H(4) = 
35.3, P<0.05; MRP2 H(4) = 18.0, P<0.05; OATP1B1 H(4) = 27.4, P<0.05; OATP1B3 H(4) = 
28.1, P<0.05. Fetal, neonatal, and infant (up to 12 months of age) gene expression of all 
hepatic transporters was lower than in adults. In the age group 1 to 7 years, only two 
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samples were assessed for the hepatic transporters MRP2, OATP1B1, and OATP1B3, as a 
result of which median mRNA expression could not be determined and comparison with 
adult expression was not possible.
MDR1 mRNA expression in fetal [0.061 (0.027 - 0.792)] and neonatal [0.036 (0.011 - 
0.364)] age groups was 20- to 30-fold lower than in adults (Fig. 2). MDR1 mRNA expres-
sion in infants was slightly lower [0.248 (0.010 - 1.46)] than in adults (Fig. 2). Median 
MDR1 gene expression in children aged 1 to 7 years was not different from adults [0.777 
(0.012 - 8.928); P=0.663]. Interindividual variability in all age groups was large.
MRP2 mRNA expression was about 30-fold lower in fetal liver samples [0.074 (0.004 - 
0.162)], 200-fold lower in neonates [0.012 (0.001 - 0.238)], and 100-fold lower in infants 
[0.022 (0.008 - 0.357)] than in adult liver samples (Fig. 2). Compared with adult liver, 
OATP1B1 mRNA expression was 20-fold lower in fetal liver samples [0.042 (0.0004 - 
0.683)], 500-fold lower in neonates [0.002 (0.0003 - 0.018)], and 90-fold lower in infants 
[0.010 (0.001 - 0.086)] (Fig. 2). Expression profiles of OATP1B3 in the liver samples were 
similar to those of OATP1B1. Expression of hepatic OATP1B3 was 30-fold lower in fetuses 
[0.046 (0.001 - 1.910)], 600-fold lower in neonates [0.002 (0.0004 - 0.0187)], and 100-fold 
lower in infants [0.010 (0.001 - 0.021)] than in adults (Fig. 2).
similar MDr1 and MrP2 mrnA Expression in neonatal and Adult intestines, 
and higher oAtP2b1 in neonatal intestines
Intestinal transporter expression was statistically significantly associated with age for 
MRP2 H(2) = 9.1, P<0.05 and OATP2B1 H(2) = 15.8, P<0.05, but not for MDR1, H(2) = 
1.3, P=0.5. MDR1 expression in intestinal samples of neonates was 0.838 (0.370 - 97.0; 
P=0.395) and of infants was 1.454 (0.409 - 3.174; P=0.413) and hence similar to adults 
(Fig. 3). Expression of MRP2 mRNA in the intestinal samples of neonates [1.262 (0.338 - 
9.266); P=0.248] was similar to the adult expression (Fig. 3). In infant intestinal samples, 
however, MRP2 mRNA expression was significantly lower [0.038 (0.023 - 0.074); P<0.05] 
than in adult samples. Interestingly, the uptake transporter OATP2B1 showed a higher 
mRNA expression in neonates [2.86 (1.212 - 34.45); P<0.0001]. In infants up to 12 months 
of age, OATP2B1 was expressed at the same level as in adult intestinal samples [1.21 
(0.328 – 2.288); P=0.147] (Fig. 3).
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figure 2. transporter gene expression in liver.
Relative mRNA expression of MDR1 (A) MRP2 (B) OATP1B1 (C) OATP1B3 (D) from fetal, pediatric and adult 
liver samples, normalized to 18S mRNA expression and adult expression using the 2-ΔΔCt method. Lines 
represent median and interquartile range.
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figure 3. transporter gene expression in intestine.
Relative mRNA expression of MDR1 (A) MRP2 (B) OATP2B1 (C) from pediatric and adult intestine samples, 
normalized to villin mRNA expression and adult expression using the 2-ΔΔCt method. Lines represent median 
and interquartile range.
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Discussion
Little is known about transporter gene expression in children. Our study used samples 
from fetal to adult age, to examine the gene expression of hepatic transporters MDR1, 
MRP2, OATP1B1, and OATP1B3; they were found to be age-related, as their expression 
was lowest in fetal and pediatric liver samples. In contrast, intestinal OATP2B1 expres-
sion in neonates was higher than in adults. Intestinal MDR1 and MRP2 expression was 
similar between neonates and adults.
ontogeny in hepatic transporters
Hepatic MDR1 expression is already detectable in early human fetal life. The maturation 
pattern found in our study is consistent with previous data on hepatic MDR1 mRNA 
expression [3, 15, 18]. Our findings are also supported by immunohistochemical staining 
showing that MDR1 expression followed the architectural changes during fetal develop-
ment [18]. We show that MDR1 expression changes after birth, with low mRNA expres-
sion until 12 months of age whereupon it increases to adult levels. In a recent study 
that used a novel liquid chromatography with tandem mass spectrometry method to 
estimate protein expression, from 7 years onwards, MDR1 was stable up to 70 years of 
age in a cohort of more than 50 patients [19].
Low fetal MRP2 expression in humans has been reported earlier in two small studies 
(n=10, 14-20 weeks’ GA; and n=3, 20-21 weeks’ GA) [5, 14]. In the latter, however, two of 
five control adult liver samples were from normal tissue in patients with hepatocellular 
carcinoma. Because organic cation transporter 1 (OCT1) expression has been shown to 
be lower in nontumor hepatocellular carcinoma liver than healthy liver, a similar phe-
nomenon with other transporters cannot be excluded [20]. Using immunohistochemical 
staining, distinct canalicular expression of MRP2 in adult liver was observed but a fuzzier 
canalicular occurrence in fetal liver, which may suggest immaturity of the localization 
pattern [5]. In addition, fetal human liver tissues obtained at 19 weeks’ gestational age 
showed higher MRP2 signal intensity than tissues obtained at 14 weeks [21] In our study, 
neonatal MRP2 gene expression was lower than in adults. From 7 years onwards, MRP2 
protein expression was stable. [22].
The observed lower fetal OATP1B1 and OATP1B3 mRNA expression levels in the pres-
ent study are also in line with human data derived of three fetal (21-23 weeks’ gestational 
age) and three adult livers [14]. In our study, OATP1B1 and OATB1B3 expression was 
also low in neonates. In contrast, the reported neonatal OATP1B1 and OATP1B3 protein 
expression (n=5), was similar in adults [23]. In 80 human pediatric liver samples ranging 
from age 2 months to 12 years, OATP1B1 was low until 6 years of age, whereas OATP1B3 
protein levels were high at birth then rapidly decreased in the first year to then increase 
again from 8 years of age onwards to adult levels [24]. From 7 years onwards, OATP1B1 
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and OATP1B3 protein expression was stable, with only genotype related to OATP1B1 
abundance [19].
ontogeny in intestinal transporters
We observed stable intestinal MDR1 expression from neonatal to adult age, a finding 
that fills a gap between currently available fetal and pediatric data. Previously, fetal 
intestinal tissue obtained after induced abortion, showed no or minimal MDR1 mRNA 
expression in samples after 11, 13, and 14 weeks, but clear expression at 16 and 20 
weeks’ gestational age [18]. Another study reported similar small intestinal MDR1 
mRNA expression in fetuses (14- 20 weeks’ gestational age), neonates, and adults [3]. 
However, a limitation is the small sample size [n=5, n=12 (fetus plus neonates)] [3, 18]. 
Stable MDR1 mRNA expression in children from 1 month to adulthood was shown in 
nondiseased duodenal biopsy and jejunal tissue from liver donor recipients [2, 4]. We 
also found stable intestinal MRP2 expression but higher expression levels of OATP2B1 in 
neonates compared to adults.
The transporter maturation we observed likely reflects physiological roles of these 
transporters in organ development. Epigenetic mechanisms such as DNA methylation 
are thought to be involved in the maturation of drug metabolizing enzymes. For ex-
ample, DNA methylation seems to partly explain a developmental switch from expres-
sion of CYP3A7 to CYP3A4 in human fetal and adult liver [25]. Epigenetic mechanisms 
may be also involved in the developmental regulation of drug transporter expression, 
but studies are currently lacking.
Due to mediation by transcription factors (which in their turn can be induced by 
chemicals or pathological conditions), some transporters show relatively high whereas 
others show low expression [13]. For example, expression of the steroid- and xenobiotic-
sensing pregnane X receptor (PXR) was shown to correlate with intestinal breast cancer 
resistance protein (BCRP), MRP2 and MDR1 mRNA in many different human tissues 
(e.g., intestine and liver) [3, 26, 27]. We may further speculate that the ontogeny of 
transporters is a combined function of developmental changes, genetic heterogeneity, 
and exposure to substrates (drug or environmental) that induce or inhibit expression 
and/or activity. For example, CYP1A2 and CYP3A4 activity, assessed by phenotyping 
caffeine and dextromethorphan, respectively, was shown to be affected by the type 
of infant feeding (breast milk or formula) [28]. Dietary supplements in infant formula 
decreased MDR1 expression in colon cell cultures [29]. Moreover, the effect of feeding is 
more variable when a child’s diet is expanded, as specific nutrients can influence MDR1 
expression [30, 31].
This study is one of the first exploratory studies characterizing developmental changes 
in hepatic and intestinal transporters. Some limitations of the data should be addressed. 
First, most fetal liver samples were obtained in the second trimester of gestation, thus 
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results might not be representative for the entire range of gestational age. Second, the 
variation in fetal transporter mRNA expression may be partly due to the small number 
of samples representing ages more distant from the median age. Given the small num-
ber per age group, the range of expression might not be representative for the entire 
population.
Third, all liver samples were collected within 24 hours after death, but the exact time is 
unknown. Still, RNA stability was minimized by RNA integrity determination.
Also, our samples may display disease-dependent variability in transporter expression. 
Inflammation has been shown to affect drug metabolism and transport. Decreased mid-
azolam clearance in critically ill children is likely a result of reduced CYP3A activity [32]. 
Inconsistency has been reported from studies assessing the effect of proinflammatory 
cytokines on intestinal MDR1 expression in vitro and in animal models, but they sug-
gest a trend towards decreased expression [33]. In children with Crohn disease, MDR1 
expression was higher in both inflamed and nonnflamed duodenal biopsies compared 
with healthy age-matched controls [34]. Inflammation was also shown to affect the ex-
pression of other transporters in primary human hepatocytes (i.e., OATP1B1, OATP1B3, 
MDR1, MRP2), resulting in reduced mRNA expression, protein, and activity [35]. Thus, 
evidence exists that the potential effects of underlying disease should be considered 
when interpreting age-related changes in transporter expression.
Finally, transporter genetic polymorphisms likely contribute to the observed vari-
ability in gene expression [1]. Recently, Nies et al. and Prasad et al. showed that hepatic 
expression of OATP1B1, but not OATP1B3, is significantly affected by genetic variants 
[19, 36].
The observed age-dependent maturation and large interindividual variability in drug 
transporter expression may have implications for oral drug absorption and hepatic 
drug excretion. The question whether posttranscriptional modifications occur and if 
expressed mRNA level can be extrapolated to protein expression and ultimately in vivo 
activity remains to be answered [4, 11]. Human hepatic OATP1B1 and OATP1B3 protein 
expression showed a trend with high interindividual variability in the first year of life 
followed by lower variability until the age of 8 years, when variability increases again 
[24]. This typical age-related change in variability at younger age is also reflected by 
our findings on OATP1B1 and OATP1B3 mRNA expression. In contrast, others could not 
correlate protein levels with OATP1B1 or MDR1 mRNA expression [37]. Further protein 
expression and transporter activity studies are needed to confirm these mRNA expres-
sion results.
In conclusion, hepatic MDR1, MRP2, OATP1B1, OATP1B3 and intestinal MDR1, MRP2, 
OATP2B1 drug transporter expression show organ- and transporter-specific maturation 
patterns during childhood. Therefore, the disposition of drugs substrates for these 
transporters may be subject to age-related changes other than that in body size alone.
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AbstrAct
introduction
The intestinal influx oligopeptide transporter PEPT1 (SLC15A1) is best known for 
nutrient-derived di- and tripeptide transport. Its role in drug absorption is increasingly 
recognized. To better understand the disposition of PEPT1 substrate drugs in young 
infants, we studied intestinal PEPT1 mRNA expression and tissue localization across the 
pediatric age range.
Methods
PEPT1 mRNA expression was determined using real time RT-PCR in small intestinal tis-
sues collected from surgical procedures (neonates, infants) or biopsies (older children, 
adolescents). PEPT1 mRNA relative to villin mRNA expression were compared between 
neonates/infants and older children and adolescents. PEPT1 was visualized in infant 
tissue using immunohistochemical staining. Other transporters (MDR1, MRP2 and 
OATP2B1) were also stained to describe the localization in relation to PEPT1.
results
22 intestinal samples (n=20 neonates/infants, n=2 pediatric, n=4 adolescents) were ana-
lyzed. The young infant samples were collected at a median (range) gestational age at 
birth of 29.2 weeks (24.7 - 40) and postnatal age of 2.4 weeks (0 – 16.6). The PEPT1 mRNA 
expression of the neonates/infants was only marginally lower (0.8-fold) than the older 
children (p<0.05). Similar and clear apical PEPT1 and MRP2 staining, apical and lateral 
MDR1 staining, and intra-epithelial OATP2B1 staining at the basolateral membrane of 
the enterocyte was detected in 12 infant and 2 adolescent samples.
conclusion
Although small intestinal PEPT1 expression tended to be lower in neonates than in older 
children, this difference is small and tissue distribution is similar. This finding suggests 
similar oral absorption of PEPT1 substrates across the pediatric age range.
Intestinal peptide transporter PEPT1 expression and tissue distribution across the pediatric age range 147
7
introDuction
The influx oligopeptide transporter PEPT1 (SLC15A1) is a member of the solute carrier 
(SLC) superfamily and is situated on the apical membrane of the enterocyte. Its expres-
sion in the human adult jejunum is at least more than 2 to 10 times higher than that 
of other transporters such as from the ABC-transporter family (MDR1, MRP2, or BCRP) 
or from the solute carrier (SLC) family (OATP’s) [1]. In histologically normal intestinal 
biopsies from 10 adults, PEPT1 was expressed most abundantly in duodenum and ileum 
with a mean relative mRNA expression of 4 compared to <0.5 in colon [2]. In 6 adult 
intestine organ donors the PEPT1 protein expression accounted for approximately 50% 
of the total expression of all transporter proteins in the small intestine. In colon, PEPT1 
represents 5% of all transporter proteins [3].
PEPT1 is best known for its function as a nutrient-derived di- and tripeptide trans-
porter, but may also have a role in (pro)drug transport because it is the most abundant 
peptide transporter in the gut and drug properties mimicking di- and tripeptides may 
allow uptake by the peptide transporter [4]. Its role as intestinal transporter has been 
demonstrated for several (pro)drugs. In PepT1 (orthologue of human PEPT1) knock-out 
mice, the small intestinal uptake of the pro-drug valacyclovir was attributed for 90% to 
the PepT1 transporter [5]. Consequently these mice had a delayed Tmax and decreased 
Cmax of acyclovir (active metabolite of valacyclovir) relative to wild type mice [6].In 
human adults, however, PEPT1 mRNA expression was not correlated with valacyclovir 
pharmacokinetic parameters, even though, in vitro, valacyclovir was a PEPT1 substrate 
[7]. This suggests that valacyclovir may be not be a PEPT1 substrate in human adults, or 
that PEPT1 mRNA expression may not correlate to PEPT1 activity. The role of PEPT1 in 
valacyclovir pharmacokinetics in humans may differ from that in animals and remains to 
be elucidated. Several β-lactam antibiotics appeared to be PEPT1 substrates in Caco-2 
cells with varying affinities: e.g. ceftibuten, cyclacillin, cefadroxil, cefaclor, benzylpenicil-
lin, and cephalexin. Their structure resembles the tripeptide structure with additional 
groups [8]. The ACE-inhibitor fosinopril is a PEPT1 substrate; other ACE-inhibitors might 
be substrates, although this needs to be confirmed [8].
Most drugs prescribed to children are administered orally. Some PEPT1 substrates are 
dosed to children even very early in life. Considering the wide age-related variation in the 
processes affecting oral drug absorption, including gastric pH, gastric motility and drug 
metabolizing enzyme activity, age-related changes in membrane transporters are also 
very likely [9]. Earlier we showed a transporter-dependent maturation in gene expression 
in young infants for MDR1, MRP2 and OATP2B1 [10], but overall data on the intestinal ex-
pression of membrane transporters during growth and development are very scarce [11].
To the best of our knowledge, studies on the development of intestinal PEPT1 in hu-
mans are even lacking. From a pharmacological point a view, it is important to elucidate 
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the development of PEPT1 expression for known substrates. But this may also be for the 
development of new drugs in which PEPT1 could enhance oral absorption.
PEPT1 developmental changes have been studied in several animal species. A devel-
opmental pattern of PepT1 mRNA and protein expression has been shown in the duo-
denum, jejunum, ileum and colon of rats [12]. In the small intestine of newborn rats the 
expression peaked 3-5 days after birth, after which it rapidly decreased and increased 
again by the time animals were weaning. The authors ascribed the increase postpartum 
to suckling. in another study in rats, PepT1 small intestinal mRNA expression was stable 
from postnatal day 4 till day 21, and then decreased from postnatal day 50 onwards [13]. 
In neonatal miniature pigs, PepT1 mediated dipeptide (3H-glycylsarcosine) disappear-
ance in the ileal segment was highest in the youngest age group (1 week) , but PepT1 
expression in post-weaned pigs was higher than in sucklings [14]. These data suggest 
that in the first weeks of life, intestinal PEPT1 is important for nutritional intake and later 
for diet transition following weaning
Comparative mRNA expression of various peptide transporters in mice, rats and hu-
man adults shows a PEPT1 expression in all species, but expression levels varied in rela-
tion to that of other peptide transporters (HPT1, PEPT2) [15]. This suggests that animal 
data cannot be directly extrapolated to humans and that human studies are needed.
To our knowledge expression or activity of PEPT1 in human fetal or pediatric popu-
lation has not been described thus far, let alone a developmental expression pattern. 
To better understand the disposition of PEPT1 substrate drugs in neonates and young 
infants, we aimed to compare intestinal PEPT1 mRNA expression and tissue localization 
in these age groups with those in older children and adolescents. To describe PEPT1 
protein staining in relation to other transporters with known mRNA expression data, we 
also aimed to detect MDR1, MRP2 and OATP2B1 protein in intestine.
MAtEriAl AnD MEthoDs
1. tissue samples
Intestinal tissue samples were obtained surgically at time of resection (neonates/in-
fants/adolescents) or as biopsies during duodenoscopies (older children/adolescents). 
For mRNA isolation, post-resection, tissue was snap frozen in liquid nitrogen and stored 
at −80°C. For immunohistochemical analysis, tissue was immediately put in 4% formal-
dehyde in PBS and processed to paraffin cubes.
Collection of neonatal/infant intestinal tissue and the use of left-over material was 
approved by the “Central Committee of Research involving Human Subjects” (the Hague, 
Netherlands) [16]. The Erasmus MC research ethics board in two other protocols ap-
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proved collection of intestinal residual tissue from adolescent patients and endoscopy 
biopsies of older children and adolescents.
Informed consent was obtained from all parents/care-givers and children older than 
12 years of age for use of left-over tissue and clinical data.
2.  real-time reverse-transcription Polymerase chain reaction (real time rt-
Pcr)
Isolation and cDNA synthesis has been previously described [10]. In brief, frozen tissue 
samples were mechanically homogenized on ice. RNA was extracted using the RNeasy 
Mini Kit (Qiagen). To digest genomic DNA remnants, RNA was treated with DNase. The 
RNA integrity numbers (RIN) of the samples were analyzed using the 2100 BioAnalyzer 
(Agilent, Santa Clara, CA), and a value <5 was considered poor quality and reason to 
discard the sample. The mRNA expression was measured by SYBR green quantitative real 
time RT-PCR with 7900 Sequence Detector (Applied Biosystems, ABI prism).
Primers were used for PEPT1, villin and GAPDH, and sequences were designed using 
Oligo 6.22 software. Primer sequences were: GAPDH forward 5’-GTCGGAGTCAACG-
GATT-3’, GAPDH reverse 5’-AAGCTTCCCGTTCTCAG-3’; villin forward 5’-TGCCAACAC-
CAAGAGACT-3’, villin reverse 5’-TCCCAATCCAGAAGAAGAC-3’; PEPT1 forward 5’-TTG-
GCCCAATGTCTCA-3’, PEPT1 reverse 5’-GGCCCTGCTTGAAGTC-3’. The melting curve was 
analyzed after every PCR to confirm product specificity. GAPDH and villin mRNA expres-
sion were used as the endogenous control. PEPT1 transcript levels were normalized to 
villin transcript levels (ratio PEPT1/villin), and relative expression was compared across 
the age groups (neonates/young infants vs children/adolescents)
3. immunohistochemistry
Intestinal sections were dewaxed for immunohistochemistry (IHC), and endogenous per-
oxidases were quenched with 3% H2O2 in methanol for 20 min. Antigens were retrieved 
using Pepsin (0.1% in 0.01N HCL) pretreatment for 7 min at 37°C stove. The sections were 
blocked for 1h in 10% normal human serum and 10% normal rabbit serum diluted in 
Teng-T (10 mMTris (pH 8), 5 mM EDTA (pH 8), 0.15 M SodiumCl, 0.25% gelatin and 0.05% 
Tween-20). Primary antibodies goat anti-PEPT1 C-20 (Santa Cruz Biotechnology Inc., 
Heidelberg, Germany) were incubated over night at 4°C in 2% human serum. Immunore-
active sites were detected with biotinylated secondary rabbit anti-goat serum using the 
Vectastain ABC Elite Kit (Vector Laboratories, Burlingame, CA), and 3,3 diaminobenzidine 
tetrahydrochloride (DAB) solution (Sigma-Aldrich, Zwijndrecht, Netherlands). The nuclei 
were counterstained with hematoxylin (Vector Laboratories). A negative control staining 
lacking the primary antibody was performed for every slide. A matched goat-antibody 
negative control was performed to assess background staining. Images were acquired 
and analyzed with Leica microscope and LAS-AF image acquisition software.
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IHC was also performed, on the same tissue samples for three other membrane 
transporters with known intestinal mRNA expression data, MDR1, MRP2 and OATP2B1, 
to compare tissue distribution of PEPT1 with these transporters. In case of MDR1 and 
OATP2B1 staining, microwave pretreatment in citrate buffer (10 mM, pH6.0) was used to 
retrieve antigens. In case of MRP2, pepsin pretreatment, similar as for PEPT1, was used. 
Primary antibodies mouse anti-MDR1 and mouse anti-MRP2 were obtained from EMD 
Millipore, and rabbit anti-OATP2B1 from Abnova.
4. statistical analysis
Data are presented as median and range, unless indicated otherwise. Group comparison 
(neonates/young infants – older children/adolescents) was made using nonparametric 
Mann-Whitney U test. All statistical analyses were performed using GraphPad Prism ver-
sion 5.00.2 and IBM SPSS Statistics software (SPSS Statistics for Windows, version 21.0; 
IBM, Armonk, NY). The level of significance was set at P<0.05.
rEsults
Descriptive results
Twenty-six samples (n=20 neonates/infants, n=2 children, n=4 adolescents) were collected 
(Table 1). The ages of the young infants ranged from gestational age at birth [median (range) 
GA] 29.2 weeks (24.7 - 40) and to postnatal age (PNA) 2.4 weeks (0 – 16.6). The main reasons 
for resection were stoma closure (in patients with history of necrotizing enterocolitis (NEC) 
(n=5), current NEC (n=6) and intestinal atresia (n=5). Other reasons were intestinal volvulus 
(=3), and Meckel’s diverticulum (n=1). Samples of two children (9 and 10 years old) and two 
adolescents (16 and 17 years old) who underwent endoscopy for suspicion of inflamma-
tory bowel disease, were histologically normal. The two samples for immunohistochemistry 
were collected from two children who underwent an ileocecal resection (age 15 years, his-
tory of Crohns disease, active disease at time of surgery) and ileoanal pouch surgery (age 17 
years, history of ulcerative colitis, active disease at time of surgery), respectively.
mRNA was analyzed on samples of which snap frozen tissue was available; i.e. 17 young 
infant, 2 pediatric, and 2 adolescent samples. Immunohistochemistry was performed on 
samples of which paraffin-embedded tissue was available; i.e. 12 young infant and two 
adolescent samples (Table 1).
GAPDH mRNA strongly correlated with villin mRNA in all intestine samples (n=21, 
r=0.6182, p<0.01). One sample was excluded due to low mRNA expression of villin and 
GAPDH suggesting loss of enterocytes. Twenty samples remained for mRNA expression 
analysis.
No information on concomitant medications or nutritional intake was available.
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PEPt1 gene expression
PEPT1 mRNA was detected in all samples. The relative intestinal PEPT1 mRNA expression 
(PEPT1/villin) in young infants slightly varied (0.15-fold) (Fig 1). In the neonatal/infant group 
the PEPT1 expression was 0.8 fold lower than in the older age group (p=0.01), with median 
relative mRNA expression of 0.80 (range 0.77 – 0.92) and 1.02 (1.01 – 1.04), respectively.
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figure 1. relationship of age with intestinal PEPt1 gene expression
Relative mRNA expression of PEPT1 in relation to age normalized to villin mRNA expression.
Presence of PEPt1 protein in enterocytes
Clear PEPT1 staining was present at the apical membrane in the brush border of the 
enterocyte in all samples (Fig 2). Microscopically, PEPT1 staining intensity seemed to 
vary among samples, but we did not quantify staining. PEPT1 apical localization was 
similar in neonatal and adolescent intestinal samples. No PEPT1 staining was detected 
in Goblet cells, most likely due to the artificial effect of enlargement of Goblet cells 
during the process of paraffin embedding. No staining was observed at the basolateral 
membrane or at the tight junctions.
figure 2. Age and PEPt1 protein localization in enterocyte.
Immunohistochemical detection of PEPT1 in paraffin-embedded intestinal sample. From left to right: pedi-
atric intestinal sample, negative control; intestinal sample from adolescent; negative control. Apical stain-
ing of PEPT1 on enterocyte. Black arrows indicate PEPT1 detection, grey arrows indicate artifacts.
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Presence of MDr1, MrP2 and oAtP2b1 protein in enterocytes
MDR1 staining was visible at the apical and lateral surfaces of the enterocyte (Fig 3). 
The lateral MDR1 staining is clearly visible in figure 4. OATP2B1 staining was present 
intra-epithelial at the basolateral membrane (Fig 3). MRP2 was localized only in the 
brush border at the apical surface (Fig 3). Specific transporter staining was present in all 
neonatal, infantile and adolescent samples.
figure 4. MDr1 protein localization in enterocyte.
Immunohistochemical detection of MDR1 in paraffin-embedded intestinal samples. From left to right: 40x 
magnification of pediatric intestinal sample. Clear apical and lateral MDR1 staining (black arrows). Grey ar-
rows indicate non-specific signal.
figure 3. Age and MDr1, oAtP2b1 and MrP2 protein localization in enterocyte.
Immunohistochemical detection of MDR1, OATP2B1, and MRP2 in paraffin-embedded intestinal samples. 
From left to right: pediatric intestinal sample, negative control; intestinal sample from adolescent; negative 
control. Apical and lateral MDR1 staining, intra-epithelial OATP2B1 staining at the basolateral membrane, 
and apical MRP2 staining in the enterocyte. Black arrows indicate transporter detection, grey arrows indi-
cate artifacts.
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Discussion
PEPT1 mRNA expression and protein expression were found in neonatal and young 
infant intestinal tissues immediately postnatally. The PEPT1 mRNA expression in young 
children was slightly lower than in older children, although the clinical relevance of this 
difference is probably negligible. This study is the first to demonstrate intestinal gene 
expression of the PEPT1 transporter across the pediatric age range. The gene expression 
of PEPT1 in neonatal intestine samples was confirmed by immunohistochemical staining 
showing protein PEPT1 expression in the brush border of the enterocyte. Localization of 
PEPT1 in the apical part along the brush border of villus epithelial cells was comparable 
with staining in human adolescents (this study) and adults, rat and mice [17-20].
Based on the clear developmental expression patterns of intestinal drug metabolizing 
enzymes and hepatic transporters, with in general low expression at birth and increasing 
with postnatal age, we anticipated lower PEPT1 transporter expression in neonates [11]. 
However, our results suggest slightly lower PEPT1 expression and similar localization as 
in adolescents. Hence the uptake of PEPT1 substrates in neonates and young infants is 
likely not to be affected by growth and maturation and dose-adjustments for PEPT1 ac-
tivity therefore do not seem necessary. Attention should lay at other factors that govern 
drug disposition in children, e.g. GFR or drug metabolism, do not seem necessary.
Stable mRNA expression of small intestinal MDR1 from neonatal age onwards was 
also found in other studies [10, 21-23]. In a previous study from our group, MRP2 mRNA 
expression in the small intestines was also stable during infant age, but OATP2B1 
expression in neonates was about three times higher than in adults [10]. This suggests 
that intestinal membrane transporters show stable or higher expression during child-
hood and that a developmental expression might occur before birth. These findings 
are supported by our immunohistochemistry data, which show clear localization of 
PEPT1 and the other transporters studied. Immunohistochemical staining of MDR1, 
MRP2 and OATP2B1 was done to compare the localization of PEPT1 in relation to the 
other transporters. MDR1 was stained at the apical border of the enterocyte, similar 
to MDR1 staining in 59 duodenal biopsies from infants up to 7 years of age and from 
fetuses from a gestational age of 16 and 20 weeks [22, 24]. MRP2 apical staining 
matches to staining in human colorectal cancer tissue, as well as intestinal tissue from 
horse, rabbits and rats [25-27]. Intraepithelial OATP2B1 staining at the basolateral 
enterocyte border was similar to staining in human colonic biopsies from adults [28]. 
The localization corresponds with the function of MDR1, MRP2 and PEPT1 to facilitate 
uptake of substrates in the enterocyte, whereas OATP2B1 facilitates excretion from the 
enterocyte to blood [29].
Our data do not contradict previous data from juvenile animal studies. In rats, PepT1 
expression was increased on days 3 to 5 after birth, after which it rapidly decreased 
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and then increased at the time animals were weaning [12]. If we would extrapolate this 
data to neonates, we would expect a PEPT1 elevation several days after birth, and time 
of weaning might be translated to infant age at the time of introducing food next to 
breastfeeding of formula. The slightly higher PEPT1 expression in older children and 
adolescents than in young infantss might be compared to weaned rats from the animal 
study. Still, a clinical impact of slightly lower infantile PEPT1 expression is questionable.
PEPT1 has been studied in relation to feeding and nutrition [30]. Interestingly, the 
PEPT1 transporter expression seems sensitive to nutritional status. In adult short-
bowel syndrome patients, small intestinal and colonic mRNA expression of PEPT1 was 
upregulated compared to healthy controls [17]. Studies in several animal species have 
further explored the impact of nutrition on intestinal PEPT1 expression. After maternal 
overnutrition during pregnancy (but not after maternal undernutrition), PepT1 mRNA 
expression was significantly increased in jejunum of newborn or weaned piglets [31]. 
In contrast, maternal protein restriction in rats also led to higher duodenal PepT1 
mRNA expression in 3- and 16-week-old offspring. Irrespective of feeding, PepT1 mRNA 
expression in 16-week-old rats was higher than in 3-week-old rats [32]. In another 
study in adult rats on a protein-rich diet, PepT1 mRNA and protein expressions, as well 
as transporter activity were increased [33]. In low-birth-weight piglets colonic PepT1 
activity (measured by flux of cephalexin) was increased after high- instead of normal-
protein formula feeding [34]. The effects of feeding and nutrition may in part explain 
the observed interindividual variability in PEPT1 gene expression in young infants in the 
present study. Unfortunately we have no detailed clinical nutritional data to prove this.
Several limitations of this study should be addressed. One, most samples were ob-
tained during the first few weeks of life, and pediatric samples after the age of 4 months 
up to 9 years are lacking. Therefore the expression in this age range is still unknown. Sec-
ond, variability in our samples might be due to co-medication, nutritional differences, 
disease or extent of inflammation. Still, most samples were obtained during surgery of 
stoma closure and therefore the intestinal tissue can be expected to be relatively nor-
mal. Third, variability might be due by genetic polymorphisms in SLC15A1 gene causing 
a change in PEPT1 expression. Thus farno polymorphism has been proven to be clinically 
relevant, however, and therefore we did not genotype our samples [35].
In conclusion, although small intestinal PEPT1 expression was slightly lower in 
neonates than in older children, this difference is small and tissue distribution is similar. 
Therefore, this finding suggests similar oral absorption of PEPT1 substrates across the 
pediatric age range.
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AbstrAct
introduction
Human hepatic membrane-embedded transporter proteins are involved in trafficking 
endogenous and exogenous substrates. Even though impact of transporters on phar-
macokinetics is recognized, little is known on maturation of transporter protein expres-
sion levels, especially during early life. We aimed to study the protein expression of 10 
transporters in liver tissue from fetuses, infants and adults.
Methods
Transporter protein expression levels (ABCB1, ABCG2, ABCC2, ABCC3, BSEP, GLUT1, 
MCT1, OATP1B1, OATP2B1, and OCTN2) were quantified using UPLC-MS/MS in snap-
frozen post mortem fetal, infant and adult liver samples. Protein expression was quanti-
fied in isolated crude membrane fractions. The possible association between postnatal 
and postmenstrual age versus protein expression was studied.
results
We studied 25 liver samples: 10 fetal [median gestational age 23.2 weeks (range 16.4-
37.9)], 12 infantile [gestational age at birth 35.1 weeks (27.1-41.0), postnatal age 1 week 
(0-11.4)], and 3 adult. Four patterns emerged. ABCB1, OATP1B1, and OATP2B1 expres-
sion levels were stable from fetal to adult age. ABCC2, ABCC3, and BSEP were low in fetus 
and infant compared to adults, while ABCG2, GLUT1, OCTN2 protein levels were higher 
early in life than in adults. MCT1 expression levels were highest in infants compared to 
fetus and adult. These patterns were also found for postmenstrual age within the fetal/
infant groups.
conclusion
The impact of growth and development on human membrane transporter protein 
expression is transporter-dependent. The age-related differences in transporter protein 
expression aid our understanding of normal growth and development, and also may 
impact the disposition of substrate drugs in neonates and young infants.
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introDuction
Membrane-embedded transporter proteins are involved in the transport of a myriad of 
endogenous and exogenous substances. These transporters can be found in various cell 
types, such as enterocytes, hepatocytes, brain and kidney cells. By trafficking exogenous 
substrates, they have an important impact on drug absorption, distribution and excre-
tion of drugs and their metabolites, thereby determining drug efficacy and toxicity. In 
the hepatocyte, transporters have been identified on both basal and canalicular mem-
branes regulating the uptake and excretion of drugs and their metabolites into and from 
the systemic circulation as well as excretion into bile [1].
The international transporter consortium has identified a large set of clinically rel-
evant membrane transporters, subdivided in families with similar peptide sequences 
[2]. Transporters belonging to the ATP-binding cassette (ABC) family are multidrug 
resistance protein 1 (ABCB1/MDR1/P-gp), multidrug resistance-associated protein 2 
and 3 (ABCC2/MRP2, ABCC3/MRP3), breast cancer resistance protein (ABCG2/BRCP), 
and bile salt export pump (ABCB11/BSEP). To the solute carrier organic anion (SLCO) 
family belong organic anion transporting polypeptide 1B1 and 2B1 (SLCO1B1/OATP1B1, 
SLCO2B1/OATP2B1), and are acknowledged to be the most clinically relevant. Other 
transporter proteins taken along in the current study are glucose transporter 1 (SLC2A1/
GLUT1), monocarboxylate transporter 1 (SLC16A1/MCT1), and organic cation/carnitine 
transporter (SLC22A5/OCTN2) which belong to the solute carrier (SLC) family. This selec-
tion of transporters were chosen because, they have proven to be important in drug 
disposition in adults or have shown a large abundancy in human adult liver [3].
Children’s growth and maturation importantly impact the processes involved in the 
disposition of drugs such as absorption, metabolism and renal excretion [4]. It is there-
fore likely that expression and activity of transporters are also subject to age-related 
changes, as has been convincingly shown for the drug metabolizing enzymes [5]. In-
deed, animal studies have shown transporter-specific maturation profiles in transporter 
expression [1, 6]. For example, hepatic mRNA expression of mouse Oatps gradually 
increases after birth until adult levels at 6 weeks of age [7]. In spite of the maturation 
in animal studies, interspecies differences prevent us to translate animal maturation 
data to humans [8]. For humans, only few transporters have been studied and a clear 
information gap remains on the developmental trajectory of individual transporters in 
fetuses and young children and the related impact on drug disposition [6, 9]. Recently, 
we showed a transporter dependent maturation profile in mRNA expression of hepatic 
ABCB1, ABCC2, OATP1B1 and OATP1B3 [10]. To predict drug disposition on the basis of 
these results is a challenge since posttranscriptional variation may result in a discrep-
ancy between mRNA and protein levels, as has been shown for some transporters in 
human adults [11, 12]. Protein expression data in children are limited. For example, a 
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selection of transporters (ABCC2, ABCG2, ABCB1, OATP1B1, OATP1B3 and OATP2B1) has 
been quantified in children using quantitative LC-MS methods, but the younger age 
range (<7 years of age) where most developmental changes occur was not included 
in these studies [12-14]. Moreover, other pediatric transporter protein data are derived 
from non-quantitative immunohistochemistry studies [6].
With the aim to further elucidate developmental changes in human membrane 
transporters, especially during early life, we conducted an exploratory study using 
quantitative LC-MS/MS to determine the hepatic protein abundance of a large selection 
of transporters in liver samples from fetuses, neonates and young infants and relate the 
findings to adults.
MAtEriAl AnD MEthoDs
1. tissue samples
Post mortem liver tissue samples from autopsy of fetuses and infants were collected by 
the Erasmus MC Tissue Bank. Tissue was procured at the time of autopsy within 24 hours 
after death and snap-frozen at −800C for later research use. The Erasmus MC Research 
Ethics Board waived the need for ethics approval according to the Dutch Law on Medical 
Research in Humans. The tissue was collected after parental written informed consent 
was obtained for both autopsy and the explicit use of the tissue for research, in line with 
the Dutch guidelines on the secondary use of human tissue. Human adult liver tissue 
samples (n=3) were a kind gift from Prof. G.M.M. Groothuis, University of Groningen, The 
Netherlands. They were collected anonymously as surgical waste material from patients 
after partial hepatectomy because of liver metastasis.
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figure 1. Age distribution in fetal and infantile samples.
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The cohort of selected samples reflected a widespread gestational age, in second and 
third trimester of pregnancy, as well as postnatal age (up to three months) (age distribu-
tion is displayed in figure 1).
2.  Membrane isolation and liquid chromatography-tandem Mass 
spectrometry
Isolation of crude membrane fractions from tissue samples was conducted as described 
by Wisniewski et al., with some minor adaptations [15]. In brief, approximately 10 mg 
of liver tissue was homogenized in a hypotonic buffer (0.5 mM sodium phosphate, 0.1 
mM EDTA, and a cocktail of protease inhibitors containing 2 mM phenylmethylsulfonyl-
fluoride, aprotinin, leupeptin, and pepstatin) using a Potter-Elvehjem homogenizer. The 
homogenate was centrifuged at 100,000g for 30 minutes at 4°C using a LE-80k Centri-
fuge with SW28 rotor (Beckman Counter, USA). The pellet, containing crude membrane 
protein fraction, was resuspended in 500 µL SDT-lysis buffer (0.1 M Tris pH 7.6, 0.1 M 
DTT, 4% SDS). Approximately 50 µL of cell lysate, corresponding to 1 mg tissue, was 
incubated at 95°C for 5 minutes and briefly sonicated on ice, mixed with 200 µL of 8 M 
urea and loaded onto a 30K Amicon Ultra-0.5 centrifugal filter device (Millipore, Darm-
stadt, Germany) and centrifuged at 14,000g for 15 minutes. After adding another 200 
µL 8 M urea the tubes were centrifuged again at 14,000g for 15 minutes. Subsequently, 
100 µL of 0.05 M iodoacetamide in 8 M urea in 0.1 M Tris-HCl, pH 8.5 was added and 
the samples were incubated for 20 minutes at room temperature, and centrifuged at 
14,000g for 15 minutes. The resulting concentrate was diluted with 100 µL 8 M urea 
in 0.1 M Tris-HCl, pH 8.5 and centrifuged (14,000g for 15 minutes) again. This step was 
repeated twice. Subsequently, 100 µL 0.05 M ammoniumbicarbonate was added to the 
concentrate and centrifuged (14,000g for 15 minutes). This step was also repeated twice. 
Proteins were digested into peptides by incubating the samples overnight at 37°C in a 
0.05 M ammoniumbicarbonate solution containing 0.5 µg/µL trypsin. The digests were 
collected into a new collection tube by centrifugation (14,000g for 10 minutes,) and the 
filter device was rinsed with 50 µL 0.5 M NaCl and centrifuged (14,000g for 10 minutes). 
The combined filtrate was acidified with 25 µL 0.1% CF3COOH, desalted on a 7 mm/ 3 mL 
extraction disk cartridge (3M Empore, Zoeterwoude, The Netherlands) and eluted with 
70% acetonitrile. Subsequently, the samples were vacuum dried (SpeedVac) until the 
solution was vaporized and stored < −70°C until further analysis.
All samples were analyzed using a UPLC coupled to a 6500 QTrap mass spectrometer 
(AB Sciex). The crude membrane fractions were injected on an Acquity C18 BEH UPLC 
column and separated using gradient elution. During analysis, the column was main-
tained at 50°C and the samples were kept at 10°C. The mass spectroscope was operated 
in selective reaction mode using electrospray ionization in positive ion mode, with a 
capillary voltage of 3.3 kV, a source temperature of 150°C, and a desolvation tempera-
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ture of 600°C. Cone voltage and collision energy were optimized for each compound 
individually. The multiple reaction monitoring transitions were determined from tan-
dem mass spectra obtained by direct infusion of 0.5 µg/mL. Per peptide three transitions 
were chosen (Q3-1, Q3-2 and Q3-3) for quantitation and confirmation. The transitions for 
the different proteins are listed in Table 1. A peptide labeled with 15N and 13C (AQUA pep-
tide) was synthesized (Sigma Aldrich, Steinheim DE) and used as an internal standard 
for quantification (Table 1). Peak identification and quantification was performed using 
Analyst software version 1.6.
3. statistics
Data are presented as median and range, unless indicated otherwise. To describe the 
variation in protein expression, the relative difference between the lowest and highest 
observed value was calculated per transporter. Median (range) protein expression per 
age group (fetuses, infants and adults) was calculated to describe the fold-change in 
table 1. Multiple reaction monitoring (MrM) transitions of the used peptides and the corresponding 
internal standards (AQuA)
name labelled Peptide sequencea Molecular
weight
Q1 Q3-1 Q3-2 Q3-3 Q3-4
ABCB1 unlabeled NTTGALTTR 934.0 467.7 719.4 216.1 618.4
AQUA NTTGAlTTR 950.0 471.2 726.5
ABCC2 unlabeled VLGPNGLLK 910.1 455.8 698.5 185.3 213.3
AQUA VLGPNGLlK 926.1 459.2 705.4
ABCC3 unlabeled ALVITNSVK 944.1 472.8 760.4 661.4 548.4
AQUA ALVITNSVK 950.1 475.8 766.5
ABCG2 unlabeled SSLLDVLAAR 1.044.2 522.8 644.3 757.5 529.4
AQUA SSLLDVlAAR 1.060.2 526.3 651.3
BSEP unlabeled STALQLIQR 1.029.2 515.3 657.4 841.6 529.4
AQUA STALQlIQR 1.045.2 518.8 664.3
GLUT1 unlabeled VTILELFR 990.2 495.8 790.5 677.4 201.2
AQUA VTILELfR 1.000.2 500.8 800.5
MCT1 unlabeled SITVFFK 841.0 421.2 173.2 641.3 201.1
AQUA SITVFfK 851.0 426.2 651.3
OCTN2 unlabeled WLISQGR 859.0 430.2 560.3 272.2 300.2
AQUA WLiSQGR 875.0 433.7 567.3
OATP1B1 unlabeled LNTVGIAK 815.0 408.2 399.4 588.3 228.2 702.3
AQUA LNTVGiAK 831.0 411.7 402.9
OATP2B1 unlabeled SSISTVEK 849.9 425.7 563.3 676.3 175.1
AQUA SSISTVEK 855.9 428.7 569.3
a AQUA: Amino acid presented in bold is labelled with 13C and 15N.
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protein expression. The possible relation between transporter protein levels and age 
was assessed using scatter plots. As these plots suggested a monotonic relationship for 
almost all transporters, the association between transporter protein levels and age was 
assessed using Spearman’s rank correlation coefficient. In addition, in the fetal and infant 
samples, the association between transporter protein expression and postmenstrual 
age was also assessed using Spearman’s rank correlation.
All statistical analyses were performed using IBM SPSS Statistics software (SPSS Statis-
tics for Windows, version 21.0; IBM, Armonk, NY) and a significance level of P<0.05 was 
used throughout the study.
rEsults
Descriptive results
We studied 25 liver samples: 10 of fetuses [median gestational age (GA) 23.2 weeks 
(range 16.4-37.9)], 12 of infants [postnatal age 1 week (0-11.4), GA at birth 35.1 weeks 
(27.1-41.0)] and 3 of adults. Patient characteristics are listed in Table 2. The clinical diag-
noses of the fetuses and infants were: therapeutic abortion for severe genetic disorders 
(non-metabolic diseases) (n=7), fetomaternal transfusion (n=1), hydrops fetalis (n=1), 
and intrauterine death for unknown reason (n=1). The clinical diagnoses of the infants 
were congenital malformations (n=5), viral/bacterial infections (n=4), necrotizing en-
terocolitis (without liver insufficiency) (n=2), and benign liver tumor (n=1). The adult 
liver tissue was histologically normal tissue. Information about diagnosis, reason for 
biopsy or medical history of the three adult patients concerned was not available.
table 2. hepatic protein expressions
fetuses
N = 10
infants
N = 12
Adults
N = 3
Profile i
‘stable’
OATP1B1 17.6 (5.4-35.6) 22.8 (9.5-47.9) 34.6 (21.5-57.5)
OATP2B1 42.2 (29.3-59.3) 38.5 (27.2-46.3) 44.9 (30.1-48.9)
ABCB1 79.2 (23.2-117.7) 107.9 (60.6-150.6) 96.9 (93.5-103.4)
Profile ii
‘low to high’
ABCC2 8.8 (5.5-9.9) 12.6 (5.3-43.9) 19.8 (15.5-22.2)
ABCC3 5.4 (1.6-9.9) 21.9 (3.6-32.8) 23.1 (15.9-23.7)
BSEP 18.4 (11.4-33.7) 35.9 (10.6-49.8) 47.7 (40.3-67.0)
Profile iii
‘high to low’
ABCG2 4.0 (2.2-7.0) 2.7 (1.5-4.2) 1.7 (0.8-2.2)
GLUT1 434.2 (49.1-1413.3) 108.7 (39.0-255.4) 5.2 (5.1-7.7)
OCTN2 6.3 (4.1-8.9) 4.4 (1.9-6.6) 3.0 (2.2-4.8)
Profile iV
‘non-linear’
MCT1 12.9 (10.0-20.0) 20.3 (10.8-39.0) 9.8 (8.9-12.4)
Data are expressed as median (range) protein expressions in pmol/g tissue
168 Chapter 8
Following the Dutch guideline on secondary use of human tissue, the Tissue Bank only 
provided the following clinical data: gestational age, postnatal age, gender and main 
clinical diagnoses. Consequently, data on nutrition or medication use prior to death 
were unavailable.
transporter protein expression from fetus to adult
The selected hepatic transporter proteins could be detected in all samples. There was 
a 10 to 300-fold relative difference in transporter protein abundance between the pa-
tients with the lowest and the highest protein expression (Fig. 2). The highest variability 
was seen in GLUT1 protein expression with a nearly 300-fold relative difference. Table 3 
shows the median abundance of studied transporters in fetal, infant and adult samples. 
With exploration of the relationship between age and protein expression the following 
four developmental patterns emerged. Table 4 shows the four developmental profiles in 
relation to previous results from other studies on transporter mRNA and protein expres-
sion.
  
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 
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
figure 2. Variability in protein expression
Each dot represents an individual liver sample, the bars present median and range
First, in profile I (‘stable’), ABCB1, OATP1B1, and OATP2B1 protein expression levels were 
similar across age groups (postnatal age) (ρ=0.33, p=0.11; ρ=0.18, p=0.39; and ρ=−0.11, 
p=0.59 respectively), but also within the fetal and infant groups (postmenstrual age) 
(ρ=0.18, p=0.43; ρ=0.23, p=0.31; and ρ=0.05, p=0.84 respectively) (Fig. 3 and 4).
Next, in profile II (‘low to high’), ABCC2, ABCC3, and BSEP protein expression levels 
were low early in life and high in adulthood (ρ=0.56, p<0.01; ρ=0.59, p<0.01; and 
ρ=0.60, p<0.01 respectively) (Fig. 3). Median protein levels of ABCC2, ABCC3, and BSEP 
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were approximately 2-fold, 4-fold, and 3-fold lower in fetuses and infants than in adults 
respectively. ABCC3, and BSEP, but not ABCC2 protein expression, increased with post-
menstrual age (ρ=0.53, p<0.05; ρ=0.55, p<0.01; and ρ=0.34, p=0.12, respectively Fig. 4).
The opposite pattern holds in group III (‘high to low’), for ABCG2, GLUT1, and OCTN2, 
higher protein abundance early in life and low at adult age was observed (ρ=−0.48, 
p<0.01; ρ=−0.59, p<0.01; and ρ=−0.78, p<0.001 respectively) (Fig. 3). Median protein 
levels were approximately 2-fold, 86-fold and 2-fold higher in fetuses and infants than 
adults, respectively (Table 3). Similarly, ABCG2, GLUT1, and OCTN2 protein expres-
sion decreased with increasing postmenstrual age within the fetal and infant groups 
(ρ=−4.55, p<0.05; ρ=−0.72, p<0.001; and ρ=−0.58, p<0.01 respectively) (Fig. 4).
Lastly, in profile IV (‘non-linear’) the MCT1 protein expression had a curvilinear re-
lationship with postnatal age, with a 2-fold higher expression in infants than in both 
fetuses and adults (Fig. 3). Within the fetal and infant groups, the MCT1 protein expres-
sion increased with postmenstrual age (ρ =0.52, p<0.05, Fig. 4).
correlation analysis of transporter protein abundances
To explore potentially shared expression regulation, Spearman correlations of trans-
porter protein expression levels between transporters were performed. In total, the 
expression levels of 16 transporter-pairs were significantly correlated to each other 
(Table 5). The strongest correlations were found for the pairs: GLUT1/ABCG2, GLUT1/
ABCC2, ABCB1/ABCC2, and ABCG2/OCTN2 (ρ=0.70, p<0.0001; ρ=−0.65, p<0.001; ρ=0.69, 
p<0.001; and ρ=0.67, p<0.001)(Table 4 and fig. 5).
table 4. correlations of transporter protein expressions
oAtP1b1 oAtP2b1 Abcb1 Abcc2 Abcc3 bsEP AbcG2 Glut1 octn2 Mct1
Profile i
‘stable’
OATP1B1 1 – 0.43* 0.46* – 0.52** −0.56** −0.49** – –
OATP2B1 1 – – – – – – – –
ABCB1 1 0.69*** 0.47* 0.55** – – – 0.47*
Profile ii
‘low to high’
ABCC2 1 0.63** 0.62** – −0.65*** – –
ABCC3 1 0.58** – −0.61** – –
BSEP 1 – −0.58** – –
Profile iii
‘high to low’
ABCG2 1 0.70*** 0.67*** –
GLUT1 1 0.59** –
OCTN2 1 –
Profile iV
‘non-linear’
MCT1 1
*P<0.05, ** P<0.01, *** P<0.001
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Discussion
This study reveals important age-dependent differences in protein abundance of ten 
clinically relevant hepatic membrane transporters. Four different developmental pro-
files of protein abundancy could be distinguished in liver samples from fetuses, young 
infants and adults. These results and existing data from the literature are summarized in 
Table 4.
stable expression of hepatic transporters: Profile i
Protein expression of ABCB1, OATP1B1, and OATP2B1 transporters was similar in fetuses, 
infants and adults. This adds to current LC-MS/MS data on patients between 7-70 years 
of age (n=64), in which ABCB1, OATP1B1, and OATP2B1 protein expressions were also 
stable [13].
ABCB1 is the most studied transporter in fetuses and children. Examples of ABCB1 
substrate drugs are digoxin, dexamethasone, tacrolimus, and morphine [16-19]. Inter-
estingly, our finding that ABCB1 protein expression data is consistent in the investigated 
age-ranges is in line with other protein studies using immunoblotting in pediatric post-
mortem and living donors, in which stable protein expression was found from 0.3-12 
years of age (abstract only) [20]. This apparent stable ABCB1 protein expression differs 
from the previously reported immature ABCB1 mRNA expression in the first year of 
life [10, 21-24]. In a study in adults absence of correlation between ABCB1 mRNA and 
protein expressions was also found [11].
In contrast to our finding, stable OATP1B1 protein expression during childhood was 
not found in 78 liver samples from children aged 0-12 years, in which the OATP1B1 pro-
tein expression by Western blotting was low from birth until 6 years of age and increased 
thereafter (abstract only) [25]. Yet, a smaller protein study using Western blotting on liver 
samples from neonates (n=5) and adults (n=5) confirms our finding regarding OATP1B1 
[26]. OATP1B1 mRNA expression data from several other cohorts do not correspond to 
our protein data, with low expression in fetuses and infants up to 1 year of age (n=32) 
[10, 24, 27].
Stable OATP2B1 protein expression in infants and adults contrasts to lower OATP2B1 
mRNA expression in samples of fetuses (n=3) from the second trimester of pregnancy 
than in samples from adults (n=3) [27].
low to high expression of hepatic transporters: Profile ii
The ABCC2, ABCC3, and BSEP transporters showed increasing protein expression from 
fetus to infant and highest expression in adults. We found increasing ABCC2 protein ex-
pression with age in the first months of life, confirming the results of protein expression 
using Western blotting in children from 0-12 years of age (abstract only) [20]. In addition, 
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other studies found lower ABCC2 mRNA expression in samples from fetuses and infants 
up to 1 year of age than in samples from adults [10, 24]. From 7 years onwards, ABCC2 
absolute protein expression levels, also quantified with LC-MS/MS, was stable [14].
The BSEP protein expression profile confirms results from the few available mRNA 
expression studies. One showed approximately 3-fold increasing expression from fetal 
(n=3) to adult (n=3) liver samples; a second study, found lower expression in neonates 
than in children older than 7 years of age [1, 27]. BSEP protein was immunohistochemi-
cally detected in second trimester fetuses [28].
Lower expression of ABCC3 early in life is not seen in a small study using liver samples 
of 5 neonates and 5 adults, in which relative ABCC3 protein expression using Western 
blotting was similar in both groups [26]. In contrast, mRNA expression of ABCC3 in 3 
fetal liver samples was significantly lower than that in 3 adult liver samples [27] and in 
perinatal/neonatal liver samples (prenatal to postnatal day 30, n=6; and 0-4 years, n=8) 
compared to liver samples from children older than 7 years [1].
high to low expression of hepatic transporters during childhood: Profile iii
The ABCG2, GLUT1, and OCTN2 transporters showed high protein expression early in life 
and lower expression at adult age. This adds to current data of stable protein expression 
from 7 years onwards [12 ].
The higher ABCG2 protein expression early in life does not correspond to the stable 
ABCG2 protein expression found using Western blotting in 5 neonatal livers and 5 adult 
livers [26]. ABCG2 protein visualized by immunohistochemistry staining showed weak 
coloring in first trimester fetal hepatocytes, while adult liver showed strong ABCG2 
staining [29]. On the other hand, stable ABCG2 mRNA expression with age was found in 
two studies; in fetal, pediatric, and adult (n=90) liver samples and a study comparing 3 
fetal and 3 adult livers [24, 27].
To the best of our knowledge, there are no human developmental expression data 
available for GLUT1 and OCTN2. The same holds for MCT1, which forms the fourth 
developmental profile group with non-linear expression profile amongst the three age 
categories.
Variability in transporter expression
This exploratory study confirms earlier reports of transporter-specific discrepancy be-
tween mRNA and protein expression. Our ABCB1, ABCG2, OATP1B1, OATP2B1 protein 
developmental patterns do not seem to correspond to earlier mRNA expression data 
[10, 26, 27]. This discrepancy shows the relative weakness of relying solely on mRNA 
expression data to understand transporter maturation. An explanation could be post-
transcriptional changes – for example mediated by microRNAs – on account of which 
mRNA does not correspond to protein expression [30]. Recently, developmental changes 
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in hepatic miRNA expression have been shown, and for some, miRNA expression was 
correlated to mRNA expression of drug disposition genes [24]. The interpretation of 
protein data should also be done with care, as transporter protein expression itself may 
not necessarily translate to transporter activity. Glycosylation, phosphorylation, and 
ubiquination, might alter proteins into active or non-active forms [1].
It can be speculated that the maturation of transporter expression is in line with the 
physiological transporter function with respect to growth and development. For ex-
ample, transporters that are involved in energy supply in fetal life may be up regulated 
in fetuses and early in life. Glucose transporter GLUT1 and L-carnitine (molecule that 
shuttles long-chain fatty acids to the mitochondria for oxidation) transporter OCTN2, are 
probably both essential for fetal energy supply, which seems to tally with our findings 
of high protein expression in fetuses and early in life. On the other hand, transporters 
involved in the uptake and efflux of steroids and bilirubin (i.e. OATPs, ABCC2), may show 
less variability throughout life.
We hypothesized that pairwise-correlation in transporter expression might reveal a 
common developmental origin and point towards interlinked physiological processes. 
We found strong correlations for the following pairs: GLUT1/ABCG2, GLUT1/ABCC2, 
ABCB1/ABCC2, and ABCG2/OCTN2. Similarly, in adult liver samples correlations between 
multiple CYP and UGT protein expression were demonstrated [31-33]. To our knowl-
edge, these inter-transporter correlations at the protein level have not been described 
previously. Many drugs have been shown to be substrates for multiple transporters, 
which may result in compensatory pathways in case a specific transporter is inactive 
due to genetic variation or drug-drug interactions. In addition, hepatocyte-hopping of 
substrates using different transporters may enhance efficient hepatic drug clearance 
[34]. Therefore, when using transporter expression data to predict drug disposition it is 
recommended to consider drug transport, and also drug metabolism as an interrelated 
biological system.
Variability in transporter expression may also be explained by other factors than 
age, such as disease, genetic heterogeneity, gender, drug-drug and drug-food interac-
tions. This may explain some of the discrepancy between studies, as the sample origin 
and clinical characteristics are often only sparsely described. In human hepatocytes, 
inflammation via interferon-γ resulted in reduced mRNA expression of ABCB1, ABCC2, 
OATP1B1 and OATP2B1 [35]. More specifically in pediatric patients (1-2 months of age) 
with biliary atresia, hepatic ABCC2, BSEP, ABCB4, OATP1B1, OATP1B3, but not ABCC3 
mRNA expression differed significantly from that in both fetuses and adults [36]. Genetic 
polymorphisms are well known to govern drug efficacy and toxicity; variants in OATP1B1 
and ABCG2 encoding genes, for example, were found to influence statin efficacy/toxicity 
[37]. Gender did not impact protein expressions of ABCG2, ABCB1, ABCC2, OATP1B1, 
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OATP1B3 and OATP2B1 [12-14]. Due to the limited sample size and the lack of detailed 
clinical data, we could not incorporate other co-variates than age in our study.
While this explorative study adds importantly to existing pediatric transporter data 
by studying protein levels in the age group where most developmental changes are ex-
pected for 10 transporters, some limitations are present. The sample size was small and 
most samples are from young infants up to 3 months, so that possible effects of matura-
tion later in pediatric life could not be studied. On the other hand, most developmental 
changes are expected in the first year of life. Second, all liver samples were collected 
postmortem, within 24h, but the exact time was unknown, the time gap might have 
influenced the quality of tissue. Further studies should be aimed to extend the pediatric 
age range, extend the selection of transporters, preferably involve larger sample size, 
and combining transporter expression with regulator proteins and genotyping.
Eventually, transporter maturation profiles and their interrelation may serve as input 
for physiologically-based pharmacokinetic (PBPK) models, which can be applied to 
use existing juvenile infant and human adult pharmacokinetic information to predict 
pharmacokinetics and drug response in children [38, 39].
In conclusion, we revealed age-dependent differences in absolute protein expression 
levels of ten different hepatic transporter proteins. Namely, profile I ‘stable’ (OATP1B1, 
OATP2B1, ABCB1), profile II ‘low-to-high’ (ABCC2, ABCC3, BSEP), profile III ‘high-to-low’ 
(ABCG2, GLUT1, OCTN2) and profile IV ‘non-linear’ (MCT1). These findings are important 
as they strongly suggest that disposition of drugs and endogenous transporter sub-
strates will be subject to age-related changes, that could impact the efficacy and safety 
of drugs in the first months of life.
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AbstrAct
rationale
Pediatric drug development is hampered by practical, ethical, and scientific challenges. 
Microdosing is a promising new method to obtain pharmacokinetic data in children with 
minimal burden and minimal risk. The use of a labeled oral microdose offers the added 
benefit to study intestinal and hepatic drug disposition in children already receiving an 
intravenous therapeutic drug dose for clinical reasons.
objective
The objective of this study was to present pilot data of an oral [14C]paracetamol [ac-
etaminophen (AAP)] microdosing study as proof of concept to study developmental 
pharmacokinetics in children.
Methods
In an open-label microdose pharmacokinetic pilot study, infants (0-6 years of age) 
received a single oral [14C]AAP microdose (3.3 ng/kg, 60 Bq/kg) in addition to intrave-
nous therapeutic doses of AAP (15 mg/kg intravenous every 6 h). Blood samples were 
taken from an indwelling catheter. AAP blood concentrations were measured by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) and [14C]AAP and metabolites 
([14C]AAP-Glu and [14C]AAP-4Sul) were measured by accelerator mass spectrometry.
results
Ten infants (age 0.1 to 83.1 months) were included; one was excluded as he vomited 
shortly after administration. In nine patients, [14C]AAP and metabolites in blood samples 
were detectable at expected concentrations: median (range) maximum concentra-
tion (Cmax) [14C]AAP 1.68 (0.75-4.76) ng/L, [14C]AAP-Glu 0.88 (0.34-1.55) ng/L, and [14C]
AAP-4Sul 0.81 (0.29-2.10) ng/L. Dose-normalized oral [14C]AAP Cmax approached median 
intravenous average concentrations (Cav): 8.41 mg/L (3.75-23.78 mg/L) and 8.87 mg/L 
(3.45-12.9 mg/L), respectively.
conclusions
We demonstrate the feasibility of using a [14C]labeled microdose to study AAP pharma-
cokinetics, including metabolite disposition, in young children.
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introDuction
Up to 70% of drugs prescribed to children are unlicensed or off-label, which brings 
risk of drug toxicity or therapeutic failure [1, 2]. However, pediatric drug studies face 
important ethical, practical, and scientific challenges [3]. A major challenge – against the 
background of developmental changes in drug absorption, distribution, metabolism, 
and excretion – is appropriate dose selection [4]. Simple size- or weight-based extrapo-
lations from adult to pediatric doses do not suffice, particularly in neonates and infants. 
Current strategies include simulations using population pharmacokinetic (popPK) and 
physiologically based pharmacokinetic (PBPK) models [5-9]. The usefulness of these 
models may be limited, as relative little pediatric pharmacokinetic and physiological 
data are available to validate them. Hence, new data are needed to support these mod-
els, as well as alternative methods to collect pharmacokinetic data without the inherent 
risks of toxicity when a therapeutic dose is given for the first time in a specific age group.
Microdosing is an interesting alternative. The European Medicines Agency (EMA) and 
the US Food and Drug Administration (FDA) define a microdose as one-hundredth of 
the No Observed Adverse Effect Level (NOAEL) or predicted pharmacologic dose based 
on animal data or as 100 µg of the new drug, whichever dose is lower [10, 11]. Dose 
linearity between the microdose and therapeutic dose is a prerequisite to extrapolate 
pharmacokinetic data to dosing guidelines [12]. The extremely low dose concentrations 
call for highly sensitive measurements. Accelerator mass spectrometry (AMS) can mea-
sure low attomolar to zeptomolar isotope ratio ranges, to quantify [14C]labeled drug or 
metabolite levels in urine or plasma samples, even after at least five half-lives following 
a microdose [13]. [14C] Labeling of a microdose is associated with very low radiation 
exposure, i.e., less than 10 µSv in adults, when compared to the yearly background expo-
sure of 2.5 mSv/year in The Netherlands [14]. Hence, microdosing is safe to use to study 
pharmacokinetics in children. In clinical care, [14C]urea has been safely used to test for 
Helicobacter pylori infection [15]. A [14C]ursodiol microdose study in preterm infants was 
briefly described in an excellent review on the potential for use of AMS in children [16]. 
Administering a labeled oral microdose to children already receiving a therapeutic drug 
dose for clinical reasons intravenously offers the added possibility to study oral bioavail-
ability [12, 17]. This approach may also serve to delineate developmental changes in the 
drug-metabolizing enzymes involved in intestinal and hepatic drug metabolism [17, 18].
Paracetamol (acetaminophen; AAP), is much used in children and is an interesting 
study drug for several reasons. First, its metabolism shifts from primarily sulphation 
(AAP-sulphate [AAP-Sul]) to glucuronidation (AAP-glucuronide [AAP-Glu]) in the first 
year of life, as reflected by urinary metabolite kinetics [19, 20]. The relative contribution 
of intestinal and hepatic drug metabolism has not been studied to date. Second, dose 
linearity under normal conditions and after probenecid glucuronidation inhibition was 
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shown in adults [18]. We therefore selected oral [14C]AAP to study the developmental 
changes in AAP glucuronidation and sulphation in children already receiving the 
non-labeled or ‘cold’ drug intravenously for analgesia [14]. This paper presents our first 
pilot data as proof of concept of this promising, safe method to study developmental 
pharmacokinetics in children.
MEthoDs
study Design
This proof-of-concept study is part of a larger phenotyping study in 60 children delineat-
ing developmental changes in AAP to metabolite clearance (EudraCT 2011-005497-28). 
The Dutch Central Committee on Research Involving Human Subjects (The Hague, The 
Netherlands) approved the larger study. Parents or legal guardians gave informed con-
sent. Radiation exposure was explained during the informed consent procedure in rela-
tion to background exposure and exposure from medical imaging. The Dutch Nuclear 
Research and Service Group estimated individual exposures at approximately 1 µSv for 
a 0-2-year-old child, well below the minimal risk category 1 (100 µSv) of the International 
Commission of Radiological Protection and the yearly background exposure (2.5 mSv). 
Category 1 risk studies are considered minimal risk and are allowed when they provide 
new scientific knowledge [11].
subjects
Patients admitted to the Intensive Care of the Erasmus MC-Sophia Children’s Hospital 
(Rotterdam, The Netherlands) were considered for inclusion. Inclusion criteria were age 
between 0 and 6 years, gestational age >36 weeks, medical need for intravenous AAP, 
and an indwelling central venous or arterial line in place. To reduce pharmacokinetic 
variability due to underlying disease, patients with kidney and liver injury or the use of 
more than one vasopressor drug were excluded, as well as children intolerant to enteral 
nutrition.
study Procedures
A single oral [14C]AAP microdose (3.3 ng/kg, 60 Bq/kg, 0.25 ml/kg) followed by 1 ml of 
saline (to ensure rinsing of the enteral feeding tube) was administered in addition to the 
intravenous therapeutic dose of AAP (15 mg/kg intravenously every 6 h) prescribed by 
the treating physician to provide analgesia. The [14C]AAP oral dose also contained 1.7 
µg/kg non-labeled AAP, but this amount was negligible in relation to the therapeutic 
intravenous dose and thus considered irrelevant for the pharmacokinetic estimations. 
The microdose was based on a previous adult [14C]AAP microdose study using 100 
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μg/7.1 kBq/individual and was normalized for weight [21]. Blood samples (0.5 mL) were 
taken from the indwelling catheter before and at 10-30 min, 1, 2, 4, 6, 12, and 24 h after 
dosing. Blood samples were centrifuged and plasma was stored at −80 0C until analysis.
Medicinal Products
The AAP formulation (10 mg/mL) was purchased from Fresenius Kabi, Schelle, Belgium. 
[14C]AAP was purchased from Moravek Biochemicals (Brea, CA, USA).
radiopharmaceutical Preparation
The formulation for oral administration [14C]AAP was prepared by adding [14C]AAP to 
an AAP formulation for intravenous use at the good manufacturing practice (GMP) 
radiopharmaceutical production laboratories of the Department of Radiology and 
Nuclear Medicine at the VU University Medical Center (Amsterdam, The Netherlands) 
(GMP license no. NL/H 11/0005) at final concentrations of 13 ng/mL for [14C]AAP and 6.7 
µg/mL for non-labeled AAP. The mixed formulation was passed over a Millex - GV 0.22 
µm filter and dispended in 20 mL sterile vials. Radiochemical purity was > 99%; chemical 
purity >98%. The radiopharmaceutical was heat sterilized and was shown to be stable 
for 2 months.
Non-specific binding was tested by running the [14C]AAP formulation followed by 1 
mL of saline through enteral feeding tubes. Radioactive recovery measured by liquid 
scintillation was greater than 95%.
Paracetamol (Acetominophen; AAP) analysis
AAP concentrations were measured in the Hospital Pharmacy laboratory of Erasmus MC 
with a clinically used enzyme multiplied immunoassay technique (EMIT, Abbott Labora-
tories®) with a lower limit of quantification (LLOQ) of 2.8 mg/l.
[14c]AAP and Metabolite Analysis
Plasma Sample Extraction and Ultra Performance Liquid Chromatography Separation
Using 175 μL 100% v/v methanol containing 6.6 μg/mL APAP in 96-well protein pre-
cipitation plates, 45 μL of plasma was extracted. The pellet was washed with 100 μL 
0.9% NaCl:100% methanol (1:4 v/v). Resulting filtrates were evaporated to dryness, and 
re-dissolved in 30 μL 10 mM ammonium phosphate pH3.4 (Eluent A) of which 25 μL 
was used for ultra- performance liquid chromatography (UPLC) analysis. An AAP solution 
with a specific radioactivity of 4,100 Bq [14C]AAP /100 μg AAP in blank pooled plasma was 
used to prepare eight calibrators levels and three quality control (QC) sample levels from 
0.4 to 180 mBq/mL, and from 1.7 to 131 mBq/mL, respectively. Calibrators (duplicate), 
QCs (triplicate), and sample extracts were injected onto a UPLC coupled to a photodiode 
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array (PDA). Chromatographic conditions can be found in Table 1. AAP in 100% methanol 
was added to each collected fraction to increase the carbon-12 content to 25 μg.
Accelerator Mass Spectrometry Analysis
[14C]AAP and metabolites were determined as described recently [22]. A novel AMS 
sample introduction method was used in this study to allow the routine analysis of 
biomedical samples. The method consists of an automated carbon diaoxide (CO2) 
combustion device online coupled to an AMS. Briefly, dried fractionated samples are 
placed in a tin foil cup and subsequently combusted using an elemental analyzer (EA) 
(Vario Micro, Elementar, Germany). The resulting CO2 was captured on a zeolyte trap at 
the interface, connecting the EA to the AMS. CO2 was released by heating of the trap 
and transferred to a vacuum syringe using helium. The resulting 6% v/v gas mixture of 
CO2 with helium was infused at a pressure of 1 bar at 60 μL/min into the titanium target 
in the SO110 ion source of a 1 MV Tandetron AMS (High Voltage Engineering Europe 
B.V., Amersfoort, The Netherlands) [23]. Within the source, CO2 is converted into negative 
carbon ions. The validation for the liquid chromatography (LC) + AMS analysis was based 
on the recommendation of the European Bioanalytical Forum. Three QC concentration 
table 1. uPlc conditions AAP
Eluent A 10 mM ammonium phosphate pH 3.4
Eluent B 100 % v/v methanol
UPLC column (Waters Acquity) BEH C18 1.7 μm 2.1x100 mm column
Flowrate 0.3 mL/minute
Column temperature 30oC
Pressure 700 Bar
Chromatography conditions 0-1 min 100% A and 0% B
1-10 min linear gradient from 100% A and 0% B
to 95% A and 5% B
10-12 min 95% A and 5% B
12-15 min linear gradient from 95% A and 5% B
to 0% A and 100% B
15-20 min 0% A and 100% B
20-20.10 min linear gradient from 0% A and
100% B to 100% A and 0% B
20.10-20.50 min 100 %A and 0% B
20.50-28 min 100% A and 0% B at a flowrate of
0.4 ml/min
28-29 min 100% A and 0% B
Collected fractions [14C]AAP-Glu (3.8-5.3 min)
[14C]AAP-4Sul (6.1-7.9 min)
[14C]AAP (8.1-9.8 min)
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levels were included, QC High 145 mBq/ml, QC Medium 14.5 mBq/ml and QC Low 2.4 
mBq/ml. The accuracy of QC High, Medium, and Low analysis corresponded to 104, 103 
and 90%, respectively. The precisions, defined by a coefficient of variation, were 9.1%, 
6.7% and 6.9% respectively. All values are well within the requirements for LC + AMS 
analysis [24]. The LLOQ of the method was 0.58 mBq/mL.
Data analysis
Data were summarized as median (range), unless noted otherwise. The plasma [14C]
AAP and metabolite concentrations were calculated by converting measured Bq/L to 
ng/L based on the dose given (3.3 ng/kg contained 60 Bq/kg) and for the metabolites 
corrected for molecular weight ([14C]AAP 151 g/mol, [14C]AAP-Glu 237 g/mol and [14C]
AAP-4Sul 231 g/mol). To compare the disposition of oral [14C]AAP microdose to the 
intravenous therapeutic doses, the microdose concentrations were dose normalized to 
15 mg/kg by multiplying with 5 x 10E6.
rEsults
Patients
Between 13 January and 31 May 2014, 32 patients were eligible. Nine patients were 
excluded for logistical reasons and 13 for refusal of informed consent. Parents’ informed 
consent was received for ten patients who were subsequently dosed according to the 
protocol. One patient vomited within 15 min post-dose and was excluded from pharma-
cokinetic analysis. Table 2 provides a summary of patient characteristics.
Detection of [14c]AAP and Metabolites in Plasma
Time profiles of [14C]AAP, [14C]AAP-Glu and [14C]AAP-4Sul metabolite plasma concentra-
tions of two representative patients are shown in Fig. 1. These patients were chosen as 
figure 1. [14c]AAP and metabolite plasma concentrations
[14C]AAP and metabolite plasma concentrations after oral 3.3 ng/kg [14C]AAP dose (LLOQ 0.03 ng/L).
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they represent the youngest and the oldest age group. The Electronic Supplementary 
Material shows graphs of all patients. The median time to maximum concentration (tmax) 
and maximum concentration (Cmax) median (range) for [14C]AAP were, respectively, 153 
min (10-245 min) and 1.68 ng/L (0.75-4.76 ng/L), for [14C]AAP-Glu were 248 min (161-382 
min) and 0.88 ng/L (0.34-1.55 ng/L), and for [14C]AAP-4Sul were respectively 193 min 
(115-343 min) and 0.81 ng/L (0.29-2.10 ng/L). Sample collections were not complete 
for all patients as the arterial line was prematurely removed or access to the line was 
restricted for clinical reasons.
Dose-normalized [14c]AAP and AAP Disposition
Semilog plots of the same two patients of dose-normalized 3.3 ng/kg oral [14C]AAP and 
15 mg/kg every 6 h intravenous AAP concentrations are shown in Fig. 2. Individual graphs 
of all patients are displayed in the Electronic Supplemental Material. Dose-normalized 
median [14C]AAP Cmax concentrations approached median intravenous average concen-
trations (Cav) [median (range)]: 8.41 mg/L (3.75 to 23.78 mg/L) and 8.87 mg/L (3.45 to 
12.9 mg/L), respectively.
table 2. Patient characteristics
Patient Postnatal age
(months)
Gender
(male/female)
Primary diagnosis Intervention
1 3.6 Male Post necrotizing enterocolitis 
sigmoïd stenosis
Postoperative partial proximal 
colon resection
2 10.6 Female Scaphocephaly Postoperative craniofacial 
correction
3 1.7 Female Congenital cystic adenomatoid 
malformation of the lung
Postoperative partial lung 
resection
4 0.3 Male Congenital diaphragmatic hernia Postoperative hernia correction
5 53.8 Male Scaphocephaly Postoperative craniofacial 
correction
6 28.9 Male Germ cell tumor Respiratory insufficiency due to 
mediastinal pressure
7* 83.1 Male Increased intracranial pressure Postoperative craniofacial correction
8 0.1 Male Congenital cardiac disease Monitoring respiratory 
insufficiency
9 6.2 Male Scaphocephaly Postoperative craniofacial 
correction
10 5.6 Male Duodenal web Postoperative 
duodenoduodenostomy and 
placing gastrostomy tube
* Patient 7 excluded from results after vomiting within 15 minutes after microdose intake.
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Discussion
This proof-of-concept study shows the practical and ethical feasibility of a [14C]micro-
dose study in children to study developmental pharmacokinetics.
The concentrations of [14C]AAP are in the expected range, when compared to dose-
normalized concentrations previously reported in neonates and children [25-27]. The 
average [14C]AAP and metabolite Cmax values are also similar to those in a previous 
adult study: 1.64 vs 1.68 ng/ml for [14C]AAP, 0.88 versus 0.92 ng/ml for [14C]AAP-Glu, 
and 0.62 versus 0.88 ng/ml for [14C]AAP-4Sul [18]. The apparent lack of an age-related 
difference in metabolite disposition is easily explained by our small sample size and the 
even smaller number of neonates in our cohort. This is supported by our observation 
that in the 4-day-old neonate [14C]AAP-4Sul concentrations are much higher than the 
[14C]AAP-Glu concentrations, while the opposite is observed in the 2.4-year-old, in line 
with developmental changes in AAP metabolism. In the follow-up study up to 50 ad-
ditional patients will be included to study developmental changes in AAP disposition 
with enough statistical power. Interestingly, the average tmax values in our patients are 
much later than in the adult study: 0.25 versus 2.6 h for [14C]AAP, 0.25 versus 4 h [14C]
AAP-Glu, and 0.5 versus 3.2 h for [14C]AAP-4Sul. A possible explanation for this finding 
may be slower oral absorption due to maturation and the underlying critical illness or 
post-operative state in our patients [26, 28].
The major barrier to a [14C]microdosing study in children has been the perceived risk 
of radiation in the context of a non-therapeutic trial [29, 30]. Still, radiation exposure in 
this study was extremely low (<1 μSv), much lower than yearly background exposure 
(2.5 mSv/year in The Netherlands), a continental flight (>4 μSv), exposure from chest 
X-ray (10 μSv) or computed tomography scans (100 μSv) [7, 14]. To overcome parental 
ethical barriers to the study, we added a letter from the Dutch collaborative patients’ 
figure 2. Dose-normalized plasma concentrations
Dose-normalized plasma concentrations after oral [14C]AAP (3.3 ng/kg) and intravenous AAP (15 mg/kg/ 
q6h) dose (dose-normalized LLOQ AMS 0.03 mg/L; LLOQ LC-MS/MS 2.8 mg/L). AAP IV administration time 
points are indicated with black arrows. Patient 6: at latter two timpoints insufficient blood collected to also 
analyze AAP levels in plasma.
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organization for rare and genetic diseases (VSOP) to the patient information leaflet, 
explaining the need for pediatric drug research and the minimal risk involved in this 
study. Surprisingly, from the informed consent conversations it appeared that most 
parents perceived there was minimal risk involved. Fear for harmful radiation exposure 
was not the main reason to deny informed consent. Parents of the other children refused 
informed consent for reasons relating to the burden of additional procedures and/or 
blood sampling.
Very sensitive LC-tandem mass spectrometry (LC-MS/MS) techniques to measure 
pharmacokinetics of an unlabeled microdose may be an alternative to using a radio-
labeled microdose in general [31]. Nevertheless, while low drug concentrations can be 
measured with LC-MS/MS, this analytical method has not reached the very low limits of 
detection of AMS. Hence, a larger unlabeled dose may be needed, which may increase 
the risk of a therapeutic or toxic effect [13]. Moreover, the use of an unlabeled micro-
dose would also prohibit the separation of the disposition of an oral and intravenous 
dose given at the same time. This could be overcome by using a stable isotope-labeled 
probe drugs, which has successfully been used to study oral bioavailability using 15N3-
midazolam in adults [32]. This method also has the important disadvantage that a much 
higher labeled drug dose is needed with similar or even higher risk of therapeutic or 
toxic effect.
conclusion
We have shown proof of concept for the practical and ethical feasibility of a [14C]labeled 
microdose to study pharmacokinetics in young children. This approach offers innovative 
possibilities to perform phase I first-in-child studies, especially for drugs with a small 
therapeutic window and high toxicity. In addition, it enables studies in vulnerable 
populations such as critically ill neonates and studies on developmental pharmacoki-
netics using probe drugs for specific elimination pathways such as drug-metabolizing 
enzymes and renal excretion.
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suPPlEMEntAl fiGurEs
 
 
figure 1. [14c]AAP and metabolite concentrations in plasma
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figure 2. AAP concentrations following iV therapeutic dose and [14c]AAP dose normalized concen-
trations following an oral microdose
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introDuction
Important information gaps remain on efficacy and safety of drugs in children. Pediatric 
drug development encounters several ethical, practical and scientific challenges. One 
barrier to the evaluation of medicines for children is a lack of innovative methodologies 
that have been adapted to the needs of children. This article presents our successful 
experience of pediatric microdose and microtracer studies using 14C-labeled probes in 
Europe to illustrate the strengths and limitations of these approaches.
Microtracer / microdose studies in pediatric drug development
Dose selection for pediatric phase I/II studies is usually based on extrapolation from 
human adult and juvenile animal data, increasingly using population pharmacokinetic 
(PK) and physiology-based pharmacokinetic modeling to simulate dosing regimens. 
These methods have important limitations. Critical information gaps remain on the 
developmental changes in the processes involved in the disposition of drugs [1]. Es-
pecially for drugs with complex metabolism and/or poor understanding of ontogeny, 
a useful model is lacking. PK studies with a 14C-labeled drug at a subtherapeutic dose 
may aid to close these information gaps while overcoming many limitations associated 
with regular pharmacokinetic studies in children. This can contribute to systems-level 
understanding (e.g., information about ontogeny) and drug-level understanding (e.g., 
population PK studies during drug development).
When a radiolabeled drug is administered concomitantly with a therapeutic dose of 
the same unlabeled drug via either the same (for example, for mass balance studies) or 
another route (for example, for absolute bioavailability studies), this is referred to as a 
microtracer dose [2]. For example, a radiolabeled probe administered enterally can gen-
erate information about enteric and hepatic metabolism distinguishing between the 
two routes. A microdose is a subtherapeutic dose in the absence of other dosing with 
the drug of interest. Following a microdose the disposition will reflect the microdose per 
se. The European Medicines Agency (EMA) and the US Food and Drug Administration 
(FDA) defines a microdose as 1/100th of the No Observed Adverse Effect Level (NOAEL) 
or predicted pharmacologic dose based on animal data, with a maximum of 100 µg of 
the new drug. Microdosing has been used in adult drug development.
A prerequisite of both microtracer and microdosing is the availability of sensitive 
analytical techniques to measure the low plasma concentrations. Very sensitive liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) techniques have been used 
to measure PK of an unlabeled subtherapeutic dose. However, these techniques are 
not sensitive enough to detect the low concentrations of metabolites seen during the 
elimination phase following the administration of a microdose. LC-accelerator mass 
spectrometry (AMS) can measure low attomolar to zeptomolar range and quantify 14C-
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labeled drug or metabolite levels in urine or plasma samples [3]. The exquisite sensitivity 
of AMS allows extremely low doses of drugs to be given, which minimizes the amount of 
14C administered. The administration of doses that have no pharmacological effect and 
thus no concerns about toxicity would allow a microdose study to be conducted early 
in pediatric drug development. In addition, AMS uses very small samples of plasma (<20 
µL) that are compatible with sampling limits during research involving children.
As a result of the 2006 EU [4] regulation on medicinal products for pediatric use, both 
European (Era-NET) and national (ZonMW Priority Medicines for Kinderen) funding 
opportunities encouraged drug studies in children. Two projects: PAMPERS (Paediatric 
Accelerator Mass Spectrometry Evaluation Research Study) and PEDMIC (Pediatric mi-
crodosing: elucidating age-related changes in oral absorption to guide dosing of new 
formulations) were funded to study the use of 14C-labeled probes in children to elucidate 
PK. The first results of these studies were published recently, showing the feasibility of 
the approach, including acceptable dose linearity [5, 6].
PAMPErs and PEDMic project study aims
The PAMPERS project aims to show the feasibility of microdose and microtracer stud-
ies for drug development in children. 14C-Paracetamol and 14C-midazolam, frequently 
prescribed to children and probes for UGT and CYP3A metabolism, were chosen to show 
feasibility [6].
The PEDMIC study was designed on the premise of dose-linearity of oral absorption, 
as shown in adults, and aimed to study developmental pharmacology. By administering 
an oral microtracer (14C-paracetamol or 14C-midazolam) while the patient received the 
drug for therapeutic reasons i.v., in children from 0 to 6 years of age, the developmental 
change in intestinal and hepatic drug metabolizing enzymes, specific for these drugs, 
can be elucidated [5].
Details of both projects can be found in Table 1.
Perceived risks of radioactivity
In discussions with colleagues, we found that the major concern about 14C-labeled 
microtracer and microdose PK studies in children lay in the perceived risk of adverse 
effects related to radioactive exposure from a 14C-labeled drug. While this hesitancy is 
understandable, it is unfounded. Radioactive dose calculations were performed using a 
worst-case half-life scenario of 40 days, which for an 111Bq/kg 14C-dose gave a radioac-
tive exposure between 0.33 and 0.8 microSV. This is much lower than yearly background 
exposure (2.5 mSv/year in the Netherlands), a regional European flight (1-15 microSv), a 
computed tomography (CT)-scan of the head (1200 microSv) or chest x-ray (12 microSv) 
(Figure 1). The International Committee on Radioactivity Protection (ICRP) considers 
an effective radioactive dose of <100 microSv for a healthy adult volunteer as risk 
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table 1. study details of PAMPErs and PEDMic projects
PAMPEr PEDMic
Study design Microdosing and
Microtracer studies
1) i.v. microtracer mixed with i.v. 
therapeutic dose
2) i.v. microtracer while patient 
concomitantly receives enteral 
therapeutic dose
3) Enteral microdose in the absence 
of therapeutic dose
4) i.v. microdose in the absence of 
therapeutic dose
Microtracer study:
Enteral microtracer while patient 
concomitantly receives i.v. therapeutic 
dose for clinical reasons
Compound 14C-APAP and 14C-midazolam 14C-APAP and 14C-midazolam
Objective To study feasibility of microdosing and 
microtracer studies in children
To study ontogeny of intestinal and 
hepatic drug metabolism
Study partners UK, Estonia, Poland, The Netherlands The Netherlands
Clinical study sites UK, Estonia The Netherlands
Grant awarded Priomedchild ZonMw
Drug purchase 14C-APAP acquired from Moravek 
Biochemical Inc, USA, purified to >99% 
radiochemical and chemical purity at 
the Pharmaceutical Research Institute, 
Warsaw, Poland
(2 months once specification was 
agreed)
14C-APAP acquired from ARC (St. Louis, 
MO, USA)
Drug development In MHRA GMP registered 
Radiopharmacy, Addenbrookes 
Hospital, Cambridge, UK (MHRA 
Licence Holder MS 12854). Here the 
high specific radioactivity 14C-APAP 
was diluted in 5% w/v dextrose, 
filter sterilized and released to the 
paediatric clinics by a Qualified 
Person and QC work (1 month once 
specification was agreed)
In GMP registered Department of 
Radiology & Nuclear Medicine, VUmc, 
Amsterdam, NL: 300ng (3700 Bq) of 
14C-APAP was mixed with APAP I.V. 
solution and added to saline (0.3% w/v of 
14C-APAP and 100 µg/mL of paracetamol 
solution in saline). The drug product was 
heat-sterilized. Quality control showed 
purity and that the product was sterile 
and pyrogen free. (one month once 
specification was agreed)
Awarded REB consent September 2012 September 2013
Radiation Safety Protocol No Yes
CTIMP No Yes
Assay development Method transfer, development and implementation based on extant metabolite 
profile
Validation according to EBF recommendation (parent drug)
(2 months once specification was agreed)
Age range studied 36 weeks to 127 weeks corrected 
gestational age
0.1-83.1 months postnatal age
Dose of labeled drug 4.5 ng/kg (111 Bq / kg) 2 ng/kg (60 Bq/kg)
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table 1. study details of PAMPErs and PEDMic projects (continued)
PAMPEr PEDMic
Included patients 14C-APAP: n= 34.
Oral microdose (n=4); i.v. microdose 
(n=6); oral therapeutic microtracer 
(n=6) and i.v. therapeutic microtracer 
(n=18).
14C-APAP: n=10 (pilot data)
PK sampling schedule Maximum of 6 blood samples 
including a pre-dose baseline sample 
and at least two from a series of 
optimal time points between 5 min 
and 8 hrs postdose.
8 blood samples (1mL each) over 24 
hrs, 24-hr urine collection from urinary 
catheter
Handling biomaterials Normal handling of blood / urine Normal handling of blood/urine. Protocol 
regarding handling was needed for 
radiation safety office.
AMS Sample analysis TNO, Zeist, NL
AMS
Cost ratio of LC-AMS 
compared to LC-MS/MS 
analysis
Method transfer development and implementation (assuming a metabolite 
profiling method is available) 1; Validation 1; Sample analysis (only parent drug, 
price per sample) 3; Each additional metabolite (price per sample) 3.
Preliminary findings Feasibility of microdosing/microtracer 
studies Acceptable dose linearity
Feasibility of microtracer studie and 
appaerent dose linearity
Published 14C-APAP (14C-Paracetamol) study details are provided, 14C-midazolam studies are ongoing, more 
data can be provided upon request.
figure 1. A comparison of radiation exposure
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category 1. Thus, the doses of radiation that can be administered during studies that use 
AMS pose no increase above minimal risk.
Ethics
With this explanation about the dose of radioactivity, approval by Ethics Committees 
(equivalent to Independent Review Boards (IRBs)) was unproblematic. The study designs 
in PAMPERS and PEDMIC for the microdosing arms involve administering a medicine 
without a direct therapeutic benefit to the individual child. These studies administered 
a background dose of radioactivity with a medicine in common use and took blood 
samples through available vascular access. Ethics Committees in three countries deemed 
this compatible with minimal risk and burden for children receiving pediatric intensive 
care. Similarly, a neonatal 14C-ursodiol microdose study was approved in the U.S. [7]. All 
these studies met the criteria of minimal risk and burden in the specific patient popula-
tion studied. But for each study an evaluation of the balance between risks and benefits 
in the specific context needs to be made. For example, a microdose study with urine 
sampling only may be evaluated as minimal risk and burden in healthy children, while 
repeated blood sampling may only be allowed in children with available vascular access. 
Hospital staff also understood the concept of microdosing and supported the studies at 
all three sites.
consent
The concept and safety of these studies appeared easy to explain to parents. The recruit-
ment rate in both projects was around 50% of eligible patients. This is comparable to 
other interventional studies in the Intensive Care Units at Erasmus MC Sophia, Alder Hey 
Children’s Hospital and Tartu Children’s Hospital. For most parents who did not consent, 
information overload during critical illness or the perceived burden of repeated blood 
sampling were the main reasons not to let their child participate [8]. Fear of radiation 
was cited as a reason not to consent by a small minority of parents in all three centers.
Dose linearity
A major prerequisite for a microdose to study pharmacokinetics is a linear relationship 
in PK from the microdose to the therapeutic dose range. 14C-paracetamol and 14C-
midazolam show dose-linear pharmacokinetics in the dose range from the microdose 
to a therapeutic range in healthy adults [9, 10]. For other drugs, microdosing studies 
in children should preferably be preceded by adult microdosing studies to show dose-
linearity, as otherwise extrapolation of data from microdosing studies to pediatric 
therapeutic doses may be incorrect.
210 Chapter 10
regulatory issues
A major challenge was the preparation from the commercially available chemical 
compound 14C-paracetamol into a formulation suited for human use according to Good 
Manufacturing Practice (GMP) guidelines. This challenge was overcome by the addition 
of a very small amount of 14C-paracetamol acquired from a commercial supplier to saline 
or glucose with (PEDMIC) or without (PAMPERS) unlabeled i.v. solution paracetamol. 
Solubility in itself was not an issue considering the extremely low concentrations. Exten-
sive GMP quality control showed the drug product to be pure, sterile, and pyrogen free.
In The Netherlands, a single microtracer to study pharmacokinetics was considered a 
drug so that the study was a clinical trial of an investigational medicinal product (CTIMP). 
This was not the case in the UK and Estonia, where it was considered a well-characterized 
probe in a physiological experiment (a study involving a less well-characterized probe 
would be a CTIMP in the UK). In The Netherlands, the hospital’s Radiation Safety Officer 
considered the formulation radioactive and requested a Radiation Safety training by the 
junior researcher, as well as a study-specific radiation handling protocol, in contrast to 
the UK and Estonia, were it was not considered radioactive. Body fluids and blood/urine 
samples were considered radioactive only in The Netherlands. The radiation dose, how-
ever, was such a low dose that no special handling was required in all three countries.
costs
14C AMS studies may be costly. First, the 14C-labeled probe needs to be manufactured 
and formulated according to GMP, without loss of its unique chemical property. The 
costs are probe-specific. Second, the AMS analyses are usually more costly than LC-MS/
MS analyses. Finally, additional adult studies may be needed to show dose-linearity 
across the full dose range and possibly also in inhibition and/or induction scenarios. 
Nevertheless, timely information about disposition will accelerate the development of 
safe and effective pediatric products, outweighing the financial cost of such studies.
conclusion
We have shown the ethical, practical and scientific feasibility of microtracer and micro-
dose studies in children. Microtracer studies could be a valuable tool in pediatric drug 
research. Taking the challenges such as dose-linearity and costs into account, we believe 
that microdosing/microtracer trials are of added value for pediatric drug development. 
Microdosing may be of specific value during the early evaluation of new drugs when 
metabolism is likely to be complex and the timely determination of the pharmacokinet-
ics of a new drug is critical to the risk-benefit analysis of a new medicine in the pediatric 
population.
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AbstrAct
background
We aim to study the feasibility for [14C]microdosing to study the impact of age on drug 
disposition pathways, more specifically, glucuronidation and sulfation, using [14C]
paracetamol (AAP).
Methods
Infants admitted to the pediatric intensive care received a single oral [14C]AAP microdose 
while receiving intravenous therapeutic AAP q6h. The plasma AUC0-inf and urinary re-
covery ratios ([14C]AAP and metabolites measured with accelerator mass spectrometry) 
were related to age as surrogate markers of metabolism.
results
50 children [median age 6 months (range 3 days - 6.9 years)] received a microdose (3.3 
[2.0-3.5] ng/kg; 64 [41-71] Bq/kg). Plasma [14C]AAP CL/F was 0.4 (0.1-2.6) L/h/kg, Vss/F 
was 1.7 (0.9-8.2) L/kg, T1/2 was 2.8 (1-7) h. With age, plasma and urinary AAP-glu/AAP and 
AAP-glu/AAP-sul ratios significantly increased by 4-fold, while the AAP-sul/AAP ratio 
significantly decreased.
conclusion
Using [14C]labeled microdosing, the effect of age on orally administered AAP metabo-
lism was successfully elucidated in both plasma and urine.
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introDuction
Drug disposition in children may differ largely from that in adults due to age-related 
changes in drug absorption, distribution, metabolism and excretion [1, 2]. Drug me-
tabolism is one of the main determinants of variation in drug disposition. While several 
knowledge gaps on the ontogeny of drug metabolizing enzymes (DMEs) have already 
been elucidated (e.g. cytochrome (CYP) 3A family) much is still unknown, especially on 
the ‘phase II’ drug metabolizing enzymes [3, 4].
Phenotyping studies can be used to elucidate in vivo drug metabolism pathways but 
in the pediatric population these studies pose several challenges in children. For one, 
when a validated phenotype probe for the pathway of interest is available [5], it is often 
a marketed drug with potentially therapeutic and toxic effects, which may not be ac-
ceptable to ethics committees, physicians, parents and their children. Second, repeated 
blood sampling for pharmacokinetic analyses may be difficult in light of blood volume 
limits (<5% of estimated circulating volume) and repeated painful punctures. The alter-
native method, urinary sampling, is technically challenging in young children especially 
without urinary catheter and results often in unreliable collections.
To overcome some of these challenges, microdosing with carbon-14 labeled drugs 
may be an interesting alternative to classic pharmacokinetic phenotyping studies in 
children [6-8]. A very low drug dose is not expected to be toxic or result in any therapeu-
tic effect. Also, only very small blood volumes are needed for highly sensitive analytical 
methods, such as accelerator mass spectrometry (AMS) [9]. A microdose is defined as a 
maximum of 100 micrograms or 1/100th of the No Observed Adverse Effect Level (NO-
AEL) or animal-based predicted pharmacologic dose [10, 11]. Microdosing has been ac-
cepted by the US Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) as a tool to study pharmacokinetics in adults [9]. If pharmacokinetics shows dose 
linear behavior, pharmacokinetic data can be extrapolated to therapeutic exposure [12-
14]. Moreover, when an labeled oral dose is given simultaneously with a therapeutic 
intravenous dose (or routes are reversed), bioavailability can easily be determined. The 
microdose is then referred to as a microtracer. Two recent proof-of-concept studies in a 
limited number of patients, have shown the ethical and practical feasibility of pediatric 
microdosing/microtracer studies using [14C]paracetamol (AAP) [13, 14]. Dose linearity 
was shown in adults for paracetamol from microdose to therapeutic dose under stan-
dard and inhibition conditions [15, 16]. Our own proof-of-concept study supported this 
dose linearity of pharmacokinetics in children [13].
Paracetamol, also known as acetaminophen or N-acetyl-p-aminophenol, is a common 
analgesic and antipyretic agent. Its main metabolism pathways are glucuronidation and 
sulfation. Glucuronidation occurs mainly via uridine 5’-diphospho-glucuronosyltransfer-
ase (UGT) 1A1, 1A6, 1A9 and 2B15 and sulfation is catalyzed by sulfotransferase (SULT) 
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1A1, 1A3, 1A4, and 2A1 [17]. Although not specific for individual enzymes, paracetamol 
pharmacokinetic studies have provided valuable insight in the relative contributions 
of glucuronidation and sulfation to the disposition of paracetamol. Paracetamol me-
tabolism in young children differs from that in adults. In neonates, a higher proportion 
of urinary paracetamol sulfate than glucuronide suggested immaturity of the involved 
UGTs, compensated for by more mature sulfotransferases [18]. Other studies showed a 
significant increase in urinary AAP-glu/AAP-sul ratio from 0.27 in 23-week-old preterm 
neonates to 0.75 in 3 to 9-year-olds and 2 in adults [19]. Despite these studies, gaps 
remain in the knowledge on the ontogeny of paracetamol metabolism, especially for 
children with bodyweights between 3 and 7 kg as well as between 25 and 50 kg [20, 21]. 
Most developmental changes in drug metabolizing enzymes occur in the first months 
of life, a better insight in the exact pattern of the age-related change paracetamol me-
tabolism may provide valuable novel information. Moreover, studies on exclusive oral 
paracetamol and metabolite disposition are scarce, while population pharmacokinetic 
studies using multiple study cohorts have often combined administration routes [20, 
21] [22]. Bioavailability of oral and rectal administration differs, hence phenotyping of 
combined small intestinal and hepatic drug metabolism may be less precise, through 
by-pass of the liver after rectal administration [23]. Even though the oral bioavailability of 
paracetamol approaches 90% in adults, data in children are lacking and therefore a con-
tribution of intestinal metabolism on oral paracetamol disposition cannot be excluded 
(Tylenol ® product information). Finally, most studies used the urinary metabolite ratio 
as surrogate marker for paracetamol metabolism. This method has limitations due to 
the difficult nature of complete and prolonged urine collections in young children, with 
incomplete or short collection intervals. Hence, these data may have unexplained large 
inter-individual variation reducing the power to detect more subtle age-related variation.
Previously, we showed that microdosing is practically and ethically feasible to study 
AAP pharmacokinetics in children. Now, using this innovative [14C] microdosing method, 
we aim to study the impact of age on paracetamol disposition exclusively after oral ad-
ministration, with plasma and urine analyses including metabolites (AAP-glu, AAP-sul), 
over the whole age range from 0 to 6 years. In this way, we aimed to further elucidate the 
exact developmental pattern of glucuronidation and sulphation in young children and 
to ultimately narrow the information gap on phase II drug metabolism.
MEthoDs
1. subjects
Patients admitted to the pediatric intensive care unit of the Erasmus MC-Sophia Chil-
dren’s Hospital were considered for inclusion. Inclusion criteria were age from 0 through 
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6 years, medical need for intravenous paracetamol, an indwelling arterial or central 
venous line in place and written informed consent from parents or legal guardians. 
To reduce the impact of critical illness or bowel disease on the pharmacokinetics of 
paracetamol, patients with kidney and liver failure, more than one vasopressor drug, in-
flammatory bowel disease, or intolerant to enteral nutrition, or concomitantly receiving 
co-medication known to interact with paracetamol (according to Micromedex ® www.
micromedexsolutions.com) were excluded.
2. study design
The study design has been previously described in detail [13]. The Dutch Central Com-
mittee on Research Involving Human Subjects (The Hague) approved the study (EudraCT 
2011-005497-28). Purchase of [14C]AAP formulation and radiopharmaceutical prepara-
tion have been previously described [13]. A single [14C]AAP microdose (3.3 ng/kg, 60 Bq/
kg, 0.25 ml/kg) was given by mouth or enteral feeding tube. The [14C]AAP oral dose also 
contained 1.7 µg/kg non-labeled AAP, which is negligible in relation to the therapeutic 
intravenous dose and considered irrelevant for pharmacokinetic estimations. Enteral 
feeding tubes were flushed with 2 ml saline to ensure complete rinsing. Patients would 
simultaneously receive therapeutic AAP as part of clinical care, dosed according to the 
Dutch Pediatric Handbook (www.kinderformularium.nl): 20 mg/kg loading dose, fol-
lowed by 10 mg/kg every 6 h (<1 month of age) or 15 mg/kg q6h (≥ one month of age).
Blood samples (1.0 ml) were taken from the indwelling catheter immediately before 
administration; at around 10, and 30 min; and at 1, 2, 4, 6, 12, 24 hrs after dosing or until 
the catheter was removed. After centrifuging, plasma was stored at −80 0C until analysis. 
Urine was collected in patients who needed a urinary catheter for clinical reasons. It was 
collected for a maximum 24 hrs or until the urinary catheter was removed. Urine volume 
was entered by the nurses in the clinical electronic patient record. One sample (2 mL) 
was taken from the 24h-urine collection and stored at −80 0C until analysis.
3. Analytical procedures
Previously a method has been qualified to quantify [14C]AAP, [14C]AAP-glu and [14C]AAP-
sul levels in human plasma, using liquid chromatography (LC) in combination with AMS 
[13, 24]. The LC+AMS qualification was performed in accordance with the recommenda-
tion of the European Bioanalytical Forum [25], qualification results are summarized in 
Mooij et al. [13].
In short the experimental outline was as follows; a 45 µL aliquot of plasma was ex-
tracted using 175 µL100% v/v methanol containing 6.6 µg/ml AAP, 8.10 µg/mL AAP-glu, 
10.0 µg/mL AAP-sul and 6.6 µg/mL 3-acetamidophenol in 96-well protein precipitation 
plates. The pellet was washed with 100 µL 0.9% NaCl:100% methanol (1:4 v/v). The 
filtrates were combined and after evaporation, redissolved in 30 µL 10 mM ammonium 
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phosphate pH3.4 (Eluent A). For each sample 25 µL is injected on the UPLC. Calibra-
tion standards at 8 different levels, ranging from 0.4-180 Bq/L were prepared by spik-
ing an [14C]AAP solution (SA 4100 Bq [14C]AAP /100 µg AAP) to blank pooled plasma. 
Similarly quality standards were prepared at 3 levels, from 1.7 to 131 Bq/L respectively. 
For the calibration and quality standards only 15 µL of sample was used for extraction. 
Chromatographic conditions can be found in Table 1 of Mooij et al.[13]. The extraction 
recovery per sample is determined by the AUC of spiked AAP, AAP-glu and AAP-sul ver-
sus the AUC of the corresponding compounds after a direct injection of the extraction 
solution. The collected fractions of AAP, AAP-glu and AAP-sul were supplemented with 
25 µg carbon-12, by adding 25 µL 1.97 mg/mL AAP. Fractions were transferred to a tin 
foil cup and evaporated to dryness prior to AMS analysis.
Urine samples were processed similarly, with a few exceptions. Urine samples were 
diluted 20 fold with MilliQ prior to extraction. Like for plasma samples, 45 µL of the 20 
fold diluted urine samples was extracted. The extraction solution was spiked with 6.6 
µg/mL 3-acetamidophenol only, which was used as an internal standard to determine 
the recovery of the extraction. As relatively high concentrations of cold AAP, AAP-glu 
and AAP-sul were present in urine samples due to the therapeutic dose the patients re-
ceived, recoveries could not be determined from spiked AAP, AAP-glu and AAP-sul. Each 
analytical run included the duplicate analysis of the calibrators and triplicate analysis of 
quality standards, and passed based on the acceptance criteria [25].
Tin foil cups were combusted on an elemental analyzer (Vario Micro, Elementar, 
Germany). Generated CO2 was transferred to a home-built gas-interface, composed of a 
zeolite trap and syringe [24]. CO2 adsorbed to the trap on the interface, after heating of 
the trap the CO2 was transferred to a vacuum syringe using helium. A final CO2/helium 
mixture of 6% was directed to the AMS ion source, at a pressure of 1 bar and a flow of 60 
µL/min. A 1 MV Tandetron AMS (High Voltage Engineering Europe B.V., The Netherlands) 
[26] was used.
4. Pharmacokinetic analysis
The maximal concentration of [14C]AAP in plasma (Cmax) and time to reach Cmax (Tmax) were 
extracted from the plasma concentration versus time curve. Area under the concentra-
tion-time curve from time zero to the last sampling time point (AUC0-t) was calculated 
using the log-linear trapezoidal method. The apparent volume of distribution (Vss) and 
total plasma clearance (Cl) were calculated by using standard non-compartmental tech-
niques. Pharmacokinetic parameters of [14C]AAP-glu and [14C]AAP-sul were determined 
as described above for [14C]AAP. All pharmacokinetic parameters were estimated using 
the Excel PKsolver add-in software [27].
The plasma AUC0-inf and urinary recovery ratios of [14C]AAP/[14C]AAP-glu, [14C]AAP/
[14C]AAP-sul, and [14C]AAP-glu/[14C]-AAP-sul were calculated to serve as ‘surrogate’ 
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markers for glucuronidation and sulfation and their relative activity, respectively. Since 
AUC-ratios were used for the primary outcomes, individual AUC’s were not corrected for 
individual dose. For clarity, the AUC0-inf ratios of [14C]AAP/[14C]AAP-glu are denoted as 
‘AAP/AAP-glu’ etc., and the urinary recovery ratios are denoted as ‘U-AAP/AAP-glu’ etc.
Criteria for excluding study patients from all pharmacokinetic analyses were inade-
quate intake or too few blood samples (less than 4). If Cl/F, Vss/F or t1/2 were not predicted 
due to non-negative estimated λz, they were excluded for respectively Cl/F, Vss/F or t1/2 
analyses. If the part of AUC0-inf that was extrapolated beyond the last observation was 
larger than 20% of the actual AUC0-t, then the AUC0-inf was excluded from the analyses as 
it would introduce unreliable overestimation of the AUC0-inf.
5. statistics
The [14C]AAP and metabolite concentrations were measured using Bq/L and converted 
to ng/L based on the exact dose given (3.3 ng/kg contained 60 Bq/kg). For the me-
tabolites, Cmax was corrected for molecular weight (AAP-Glu/AAP 2,165 and AAP-Sul/
AAP 1,530). To compare the disposition of oral [14C]AAP microdose to literature data of 
therapeutically dosed AAP, the microdose concentrations were dose-normalized to 15 
mg/kg (assuming bioavailability is dose-linear) by multiplying the plasma [14C]AAP and 
metabolite concentrations (in ng/L) by 5*106.
Descriptive statistics of all variables are presented as medians and ranges. Nonpara-
metric Spearman’s rank correlation was used to describe the relationship between plas-
ma and urinary metabolite ratios. Univariable linear regression analyses were performed 
with postnatal age as independent variable and the pharmacokinetic parameters (Cmax, 
Tmax, t1/2, AUC0-inf, weight-corrected Cl/F, and weight-corrected Vss/F), including the AUC 
ratios as dependent variables. If necessary, dependent and independent variables were 
log-transformed to ensure normality of the residuals and an adequate model fit. The 
Cmax was compared between the different modes of oral administration (oral, gastric/
duodenal tube, or gastrostomy) using the Mann-Whitney test. All statistical tests were 
two-sided and used a significance level of P=0.05.
rEsults
Patients
From January 13 2014 till July 1 2015, 50 patients (41 boys) with a median gestational age 
at birth of 40 (30-42) weeks, and a median postnatal age of 6 months (3 days till 6 years 
and 11 months) participated in the study (see flowchart Figure 1 and Table 1). The main 
reason for admission was postsurgical care (38 out of 50 patients). One patient needed 
mechanical ventilation. Patients received one oral [14C]AAP microdose (median[range] 
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3.3 [2.0-3.5] ng/kg; 64 [41-71] Bq/kg) and up to four intravenous AAP doses during the 24 
hours study period as per clinical protocol. Variation in dose was introduced by round-off 
errors and in one case a bodyweight-error was found in the health record and rectified 
after microdose administration leading to a dose of 2.0 ng/kg, 41 Bq/kg. In some cases 
the route of administration was switched from IV to rectal for clinical reasons after the 
microdose was given. In two cases, the blood sampling was discontinued the patient 
vomited shortly after administration of the microdose, potentially resulting in inad-
equate [14C]AAP intake. Three patients received potentially interacting co-medication 
(phenytoin, phenobarbital and pentobarbital) after administration of the study drug for 
clinical reasons. For nine patients the number of blood samples taken was too small (less 
than 4) to accurately estimate all pharmacokinetic parameters and these patients were 
excluded from the pharmacokinetics analysis. Of the 39 patients for [14C]AAP pharma-
cokinetics analysis, nineteen received the microdose [14C] AAP via a gastric tube, 10 via 
oral administration (in buccal cavity) 8 via duodenal tube, and 2 via gastrostomy. For an 
additional patient, AUC0-t, Cmax, and Tmax could be estimated but not CL/F, Vss/F, t1/2.
Pharmacokinetics
The exemplary plasma concentration – time curves for [14C]AAP, [14C]AAP-glu, and [14C]
AAP-sul of two individual patients are depicted in Figure 2, and the pharmacokinetics 
are summarized in Table 2. Apparent paracetamol CL/F was 0.4 (0.1-2.6) L/h/kg, Vss/F was 
1.7 (0.9-8.2) L/kg, and T1/2 was 2.8 (1.0-7.0) h. Cmax for [14C]AAP, [14C]AAP-glu, and [14C]
AAP-sul equivalent for the parent compound were respectively 34.9 (3.8-89.6) Bq/L, 8.6 
232 eligible patients
AAP IV and access for blood sampling
114 patients approached
60 excluded
      22 <24 hours IC admission
      22 gastrointestinal disorder
      6 ECMO treatment
      4 unable to inform parents
      2 hepatic failure
      2 <24h arterial line
      1 renal failure
      1 anticipated death <48 hours
21 study drug not available
37 patient already participate in another study 
50 reveived [14C] AAP
48 completed study
64 refused to participate
2 vomited shortly after microdose intake; 
study ceased
figure 1. flowchart
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(0.8-38.1) Bq/L, and 10.0 (1.0-41.0) Bq/L. Tmax for [14C]AAP, [14C]AAP-glu, and [14C]AAP-sul 
were respectively 1.0 (0.2-6.2)h, 4.1 (0.8-12.6)h, and 3.0 (0.3-12.6)h. Tmax  for [14C]AAP was 
similar for all routes of administration, but with large variability (Table 2).
Dose-normalized (mg/kg dose) Cmax for [14C]AAP, [14C]AAP-glu, and [14C]AAP-sul were 
respectively 8.4 (0.9-23.0) mg/L, 3.8 (0.4-16.0) mg/L, and 4.6 (0.5-20.5) mg/L.
One outlier could be identified, but was kept in the analysis; this patient had very low 
plasma [14C]AAP and metabolites concentrations, even though no abnormalities were 
noticed during oral dose administration. The patient may have partially spit out the 
buccally given microdose.
table 1. Patient demographics
Age group 
(birth – 1 month)
Age group
(1 month – 6 months)
Age group 3
(6 months – 2 years)
Age group 4
(2 years- 6 years)
Number 9 15 14 12
Postnatal age in weeks 0 (0-1) 23 (7-25) 35 (26-98) 197 (112 – 361)
Gestational age at birth 38.1 (34.9 – 40.7) 39.8 (33.1-42) 39.9 (30-41.7) 40 (36-40)
Weight (kg) 3 (2 – 3.5) 7 (3.5-9.2) 7.5 (6.1-12.8) 16.1 (12.9-25)
Weight (z-score) −1.12 (−2.1 - 0.1) −0.63 (−2.5-1.5) −1.3 (−2.5-0.9) −0.02 (−2.9-2.1)
Gender (M/F) 8/1 14/1 10/4 9/3
Ethnicity (Caucasian/
African /Asian/Other)
5/1/2/1 11/1/1/2 12/0/0/2 11/0/0/1
Reason for admission
(surgical/medical)
8/1 12/3 12/2 6/6
Mechanical ventilation at 
start study (yes/no)
1/8 0/15 0/14 0/12
Enteral/tube feeding (yes/
no)
3/6 10/5 9/5 6/6
PELOD (study day) 11 (1-11) 10 (0-30) 6.5 (0-30) 10 (0-20)
Number of failing organs 
(study day)
2 (1-3) 2 (1-2) 2 (1-3) 2 (1-2)
PRISM 16 (0-31) 18 (4-41) 17 (0-34) 6 (0-44)
PIM (%) 4 (0-20) 1 (0-10) 0 (0-9) 2 (0-33)
PIM II (%) 5 (1-15) 0 (0-17) 0 (0-6) 1 (0-29)
Paracetamol dosing
[14C]AAP dose (ng) 9.8 (6.5 – 11.7) 22.8 (11.7-29.9) 23.4 (15.6-41.6) 52 (41.6-81.2)
[14C]AAP dose (Bq) 209 (125 – 228) 472 (235-639) 477 (313-890) 1035 (833-1594)
[14C]AAP dose normalized 
(mg/kg)
(dose*5E6)/weight)
15.6 (16.3-17.3) 16.2 (16.07-17) 16.3 (10-16.7) 16.3 (16.1-16.7)
Microdose administration 
via (oral/gastric tube/
duodenal tube/
gastrostomy)
0/6/1/0 6/4/2/0 3/6/1/0 1/3/4/2
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figure 2. two individual plots: concentration-time curve AAP, AAP-glu en AAP-sul (bq/l)
table 2. [14c]AAP pharmacokinetics
[14c]AAP [14c]AAP-Glu [14c]AAP-sul
Plasma
AUC (0,t) (Bq/L*h) 152 (24-462) (n=39) 70 (9-339) (n=39) 69 (8-576) (n=39)
AUC (0,inf ) (Bq/L*h) 152 (25-489) (n=38*) 75 (11-367) (n=35*) 75 (9-597) (n=37*)
CL/F (L/h) 3.1 (0.4-26.6) (n=38) – –
CL/F (L/h/kg) 0.4 (0.1-2.6) (n=38) – –
Vss/F (L) 11.1 (3.0-82.2) (n=38) – –
Vss/F (L/kg) 1.7 (0.9-8.2) (n=38) – –
t1/2 (h) 2.8 (1.0-7.0) (n=38) – –
Cmax (Bq/L) 34.9 (3.8-89.6) (n=39) 8.6 (0.8-38.1) (n=39) 10.0 (1.1-41.0) (n=39)
Cmax (ng/L) 1.7 (0.2-4.6) (n=39) 0.9 (0.1-4.1) (n=39) 0.8 (0.1-3.2) (n=39)
Tmax (h) 1.0 (0.2-6.2) (n=39) 4.1 (0.8-12.6) (n=39) 3.0 (0.3-12.6) (n=39)
Oral (n=10) 2.0 (0.2-4.5) – –
Gastric tube (n=19) 1.1 (0.2-7) – –
Duodenal tube (n=8) 0.5 (0.3-2.4) – –
Gastrostomy (n=2) 1.5 (0.3-2.7) – –
AUC(0,inf ) ratio
AAP-glu/AAP
0.4 (0.1-1.6) (n=35) – –
AUC(0,inf ) ratio
AAP-sul/AAP
0.5 (0.2-1.4) (n=36) – –
AUC(0,inf ) ratio
AAP-glu/AAP-sul
1.1 (0.2-2.8) (n=34) – –
Urine
Urinary recovery as percentage of [14C]
AAP dose (%)
10 (4-17)%, 29 (4-46)%, 34 (12-74)%.
Total urinary recovery as percentage of 
[14C]AAP dose (%)
75% (28-99%)
Legend: Medians and ranges.
(*) Another 1, 4, and 2 patients were excluded from AUC0-inf analyses of respectively [14C]AAP, [14C]AAP-glu, 
and [14C]AAP-sul, as the part of the AUC0-inf that was extrapolated was larger than 20% of the AUC0-t.
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Effect of age on [14c]AAP disposition
No significant relationship was detected between postnatal age (which was log-
transformed) and paracetamol Cmax, Tmax, t1/2, AUC0-inf, weight-corrected Cl/F or weight-
corrected Vss/F.
Effect of age on plasma [14c]AAP metabolite ratios
The AAP-glu/AAP ratio increased with postnatal age (n=35, R2=0.224, P<0.01) (Figure 3a), 
whereas the AAP-sul/AAP ratio decreased with postnatal age (n=36, R2=0.255, P<0.01) 
(Figure 3b). Moreover, the AAP-glu/AAP-sul ratio increased with age from 0.32 at birth 
to 1.23 at the age of 6 years (n=34, R2=0.439, P<0.001) (Figure 3c). In these analyses, 
postnatal age and all plasma and urine ratio-outcomes were both log-transformed.
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figure 3A. increase of serum AAP-glu/AAP ratio with postnatal age.
For linear regression analysis: plasma ratio and age were both log-transformed
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figure 3b. Decrease of serum AAP-sul/AAP ratio with increasing age
For linear regression analysis: plasma ratio and age were both log-transformed
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urinary disposition and effect of age
Urine was collected reliably for at least 12 h (20.4 h [11.8-28.5]) in 24 patients. Total 
median (range) urinary recovery of [14C]AAP plus [14C]AAP-glu and [14C]AAP-sul as 
percentage of dose was 75% (28-99%). Percentage recovery of [14C]AAP, [14C]AAP-glu, 
and [14C]AAP-sul was respectively 10 (4-17)%, 29 (4-46)%, and 34 (12-74)%. Percentage 
recovery of [14C]AAP-glu increased with postnatal age (n=24, R2=0.306, P<0.01); [14C]
AAP-sul recovery decreased (n=24, R2=0.175, P<0.05); while [14C]AAP recovery remained 
stable. The percentage of total urinary [14C] recovery ([14C]AAP + [14C]AAP-glu + [14C]
AAP-sul) did not change with age.
The U-AAP-glu/AAP ratio significantly increased with postnatal age (n=24, R2=0.456, 
P<0.001) (Figure 4a), whereas the U-AAP-sul/AAP ratio showed a borderline non-signif-
icant decrease with age (n=24, R2=0.150, P=0.06) (Figure 4b). The U-AAP-glu/AAP-sul 
ratio increased linearly with postnatal age (n=24, R2=0.575, p<0.001) (Figure 4c).
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figure 3c. increase of serum AAP-glu/AAP-sul ratio with postnatal age
For linear regression analysis: plasma ratio and age were both log-transformed
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figure 4A. urinary recovery u-AAP-glu /AAP ratio vs. postnatal age
For linear regression analysis: urine ratio and age were both log-transformed
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A strong positive correlation was found between AAP-glu/AAP-sul and U-AAP-glu/
AAP-sul ratio (n=19, r=0.89, P< 0.001).
Discussion
Our study shows that [14C]-microdosing allows the study of age-related changes in drug 
metabolism in children, using both plasma and urine as matrix. Our data present new 
data covering the infant age range from 0 to 6 years. Both the plasma and the urine 
[14C]AAP glucuronide/sulfate ratio increased approximately four-fold with age, which 
reflects the maturation of combined intestinal and hepatic paracetamol glucuronida-
tion and sulfation.
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figure 4b. urinary recovery u-AAP-sul /AAP ratio vs. postnatal age
For linear regression analysis: urine ratio and age were both log-transformed
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figure 4c. urinary recovery u-AAP-glu/AAP-sul ratio vs. postnatal age
For linear regression analysis: urine ratio and age were both log-transformed
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Few pediatric studies have reported the paracetamol pharmacokinetics after oral 
administration [18, 21, 22, 28-30]. Our data, with average Cl/F 0.4 (0.1-2.6) L/h/kg and V/F 
1.7 (0.9-8.2 L/kg) are largely in line with these studies. In a population pharmacokinetic 
study combining data of these studies, concerning more than 250 patients receiving 
oral and/or rectal paracetamol, the mean CL/Foral was 0.2 l/h/kg [95%CI 0.16-0.23] (14.1 
L/h/70kg) and Vd/F was 1.12 l/kg [95%CI 1.02-1.21] (78.7 L/70kg) [21]. Cl/F was 0.07 L/h/
kg and V/F was 1.088 L/kg in a ‘post-hoc’ NONMEM analysis of a selection of 30 neo-
nates[22]. In contrast to this finding, we did not find an effect of age on weight-corrected 
Cl/F, but is very likely because the number of neonates in our cohort was relatively small.
In our study, both the plasma and the urine AAP-glu/AAP-sul ratio were related to 
age; they increased from 0.32 in neonates to 1.23 in 6-year-olds and a similar increase in 
urine. The AAP-glu/AAP-sul ration served as a surrogate marker for the relative contri-
bution of glucuronidation and sulfation to AAP metabolism as in previous studies [18, 
19, 21, 31]. Previous studies reported changes in the urinary metabolites ratio after oral 
paracetamol administration from 0.27 in 2-3-day-old neonates, to 0.69 in 12-month-olds, 
0.81 in 2-years-olds, 0.75 in 3- to 9-year-olds, 1.61 in 12-year-olds to 1.8 in adults [18, 
21, 28]. Limitations of existing studies were: only presenting neonatal data [28], or few 
patients less than 9 years of age [18] and a combined cohort of oral and rectal admin-
istration, with urinary data on AAP and metabolites (instead of plasma) of 15 patients 
with a small age range (11.8±2.5 months) [21]. To the latter study an additional cohort of 
>200 children receiving oral and/or rectal AAP was added in the AAP-clearance analysis 
(without metabolites concentrations). However, as rectal paracetamol completely 
bypasses the small intestine and partially bypasses the liver by draining in the lower 
haemorrhoidal circulation its metabolism not optimally represent combined intestinal 
and hepatic glucuronidation and sulfation activity.
Allegaert et al. showed in 23 preterm and term newborns a significant increase of the 
urinary glucuronide/total drug ratio with both increasing postnatal and postconception 
age after IV administration of the pro-drug propacetamol [32]. In 75 children (3 neo-
nates, 25 infants, 25 children, and 22 adolescents) who received repeated intravenous 
paracetamol, glucuronidation was the primary pathway of elimination in the older, 
but not the neonatal age group, where sulfation dominated [33]. The urinary AAP-glu/
AAP-sul ratio collected over 4 h after the last dose, was low in neonates and higher at 
older age; 0.6 in neonates, 1.0 in infants, 1.4 in children, and 1.2 in adolescents. First-pass 
drug metabolism after oral drug administration may occur at both the intestine and 
the liver. Here we see similar ratio AAP-glu/AAP-sul data after oral (our study) and IV 
administration (Zuppa et al., Allegaert et al.), suggesting that the intestinal contribution 
to paracetamol metabolism and its ontogeny either equals hepatic metabolism or is 
negligible.
227
11
Microdosing to study ontogeny of drug metabolism: the case of [14C]paracetamol
Exploring the possibility to model the maturation half-life of AAP-glu and AAP-sul 
activities as depicted in figure 3, we were able to model a sigmoidal Emax curve for the 
ratio of AAP-glu to AAP-sul (results not shown). Nevertheless, the confidence intervals 
of the estimated parameters were wide, suggesting a limited amount of evidence for 
a sigmoidal relationship. Visual inspection of the maturation curves suggests a quite 
sudden surge in glucuronidation after 200 days of age, but a more gradual decrease in 
AAP sulfation from birth to 6 years of age.
This study has several strengths. First, we show the feasibility to perform a drug me-
tabolism phenotyping study using [14C]AAP with only 0.2 millionth of the therapeutic 
dose. Although such a design has been used in healthy adults previously, we now show 
the feasibility to include a considerable number of pediatric patients in the intensive 
care unit with a rich blood sampling design and reliable urine collections. In addition, 
this study provides longitudinal data on both the plasma and the urinary [14C]AAP- me-
tabolism after exclusive oral administration in a continuous cohort from 3 days to 6 years 
of age. These data add to our understanding on the combined intestinal and hepatic 
glucuronidation and sulfation activities, which is of importance given that most drugs 
are given orally. Another strength is the combination of urine and plasma collection, 
showing the feasibility of [14C]microdosing to use either matrix for drug metabolism 
phenotyping. The very strong correlation between plasma and urinary AAP-glu/AAP-sul 
ratios, as well as the similar developmental changes in plasma (our study) and urine 
[28] suggest that both matrices can be used to study paracetamol disposition. Plasma 
calculations were more reliable (n=39 complete plasma collections, versus n=24 com-
plete urine collections) with less variation compared to the urinary recovery, but blood 
sampling are more invasive. Hence, dependent on the study population (with/without 
indwelling arterial/venous access), age range, or renal clearance-dependent drug, both 
plasma and urine could be considered.
A possible barrier for investigators to use a [14C]-microdosing study in children is the 
perceived risk of radiation [7]. To our own surprise, in this non-therapeutic study with 
radioactive labelled probe, fear of radiation was hardly a reason for parents to with-
hold consent. Similar to other drug studies on our intensive care unit, almost half of 
all approached parents agreed to participate. Refusal of consent was rather for reasons 
relating to the burden of blood sampling or additional procedures. The PAMPER group, 
also using [14C]AAP, experienced the same inclusion rate [14].
A limitation of our study was that study patients did not receive a single microdose 
exclusively and therefore one could argue that it is not a ‘true’ microdosing study but a 
microtracer study. We choose this design with the microdose in addition to the same 
therapeutic drug, as this was one of the first microdosing studies in children, and it was 
likely more acceptable to Ethics Board and parents. We are now convinced that this is 
not a major issue for parents, who understood the concept of microdosing clearly and 
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realized it was associated with minimal burden for the patient. Another limitation is the 
relatively low number of neonates meeting inclusion criteria.
In conclusion, we show the feasibility of using a [14C]drug microdose to phenotype 
the ontogeny of drug metabolism in children. The previously reported developmental 
change of paracetamol metabolism from mainly sulfation to glucuronidation was 
comparable, while plasma metabolite data were added on the combined intestinal 
and hepatic pathways in a large pediatric age range. The success of this study design is 
promising for future studies on the development of drug disposition.
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Pharmacotherapy is the key ingredient of many treatment approaches for diseases in 
children. Yet, the effects of pharmacotherapy change as children evolve during life; con-
sequently therapy strategies need to be adjusted to growth and development. Several 
information gaps remain on the impact of age on the processes involved in the dis-
position of drugs. More specifically, important factors governing oral bioavailability in 
children, including intestinal metabolism as well membrane transport, are understudied 
so far. The extent of oral drug use in critically ill children, the current state of knowledge 
on oral drug absorption in children, and the ontogeny of membrane transporters and 
phase II drug metabolism are the subjects presented in this thesis. The lack of pediatric 
data can partly be ascribed to difficulties in collecting pediatric tissue and performing 
pharmacokinetic studies. Using two innovative techniques primarily developed for 
adult studies, novel data were generated on drug metabolism and drug transport in 
young children.
To end with, future research perspectives, building on the data in this thesis, are 
presented that ultimately may have the potential to improve efficacy and safety of drug 
therapy in children.
orAl DruG usE
oral drug prescribing in the nicu and Picu
Oral drug absorption in critically ill children may be erratic and the use of the oral route 
for life-saving drugs is therefore discouraged. In the intensive care setting intravenous 
(IV) drugs are preferred and most patients will have an indwelling arterial or venous line. 
Nevertheless, for several reasons the oral route may still be preferable: i.e., appropri-
ate intravenous formulations may not be available (e.g., spironolactone, bosentan); IV 
administration may be associated with more severe adverse events (e.g., sildenafil and 
hypotension, infections associated with central lines); or the site of action is the gastro-
intestinal tract (e.g., antifungal prophylaxis). Moreover, polypharmacy with incompat-
ible drugs through the available intravenous access ports, inability to gain any venous 
access and higher costs of intravenous administration may all be reason to resort to the 
oral route.
Very few reports are available on the use of oral drugs in the neonatal and/or pedi-
atric intensive care units (ICUs). In one drug utilization study in an Indian NICU 92% of 
prescribed drugs over 6 months were given intravenously, of which the remainder were 
prescribed via other routes, including oral [1]. In contrast, we showed that up to 27% of 
drugs were prescribed orally to children in neonatal and pediatric intensive care units 
(NICU and PICU) [chapter 5]. The dissimilarity may be explained by differences in age 
ranges and setting (developing vs. western country).
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The potential erratic oral absorption may lead to unwanted variation in drug efficacy 
and safety. When looking at the 10 most frequently prescribed oral drugs, the target of 
probiotics, amphotericin B, and macrogol is the gut or gut flora; and therefore erratic 
oral intestinal absorption is less relevant. Nevertheless, when gut motility is severely 
impaired in critical illness, the drug may not even reach the relevant intestinal compart-
ment (e.g., colon for macrogol). In contrast, for other frequently prescribed oral drugs, 
erratic oral absorption may be more problematic: e.g., analgesics, diuretics, vitamin K, 
omeprazole, and lorazepam. Moreover, data from critically ill patients are often lacking. 
For example, the efficacy and safety of omeprazole for the prevention of ICU related 
gastric bleeding have not been shown in children. Moreover, no suitable oral formula-
tion is available to be given to young children or by gastric tube. And while oral diuretics 
for neonatal chronic lung disease seem effective, very limited data on their efficacy for 
treating heart failure or edema are available for older critically ill children [2]. Moreover, 
no licensed liquid drug formulations suitable for pediatric use are available for the oral 
diuretics hydrochlorothiazide and spironolactone. Also, for lorazepam no oral formula-
tion is available and instead the intravenous formulation or crushed tablets are given, 
very erratic drug levels and sedative effect could be expected.
Additionally, in a study on the risk of intervention on prescriptions by a clinical 
pharmacist the oral dosage form and oral route of administration had the highest risk 
for interventions. This was monitored in electronic dose prescribing for four years in a 
tertiary children’s hospital (excluding the ICUs) [3]. An intervention was defined as any 
action taken on a drug prescription to correct or complete the prescription. 81% of all 
interventions concerned a correction of a prescription that otherwise might have had 
adverse clinical consequences. This result emphasizes the importance of awareness on 
oral drug use in the NICU and PICU.
In summary, oral drug use is frequent in critically children and exposes them to poten-
tially ineffective and unsafe drug therapy.
Age-related changes in oral drug absorption processes
To better understand the impact of age on the gastrointestinal processes that govern 
the intestinal absorption of drugs, we reviewed the existing literature. Important age 
related variation was found for gastric pH. Apart from a brief peak postnatally, the gas-
tric pH is about 2-3 in children of all ages. It rises postprandially due to a buffering effect 
of milk-based feeding [4]. In frequently fed neonates (such as extreme low birth weight 
infants or in case of continuous nasogastric tube feeding) the pH may therefore peak 
longer than in older children who eat less frequently. This questions the general idea 
that pH is basic in the first days to weeks of life, reported more than seventy years ago 
by Miller et al. [5]. Other, more recent studies report that the gastric pH declines already 
within a few hours after birth [6, 7]. Many other studies subsequently showed that the 
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gastric pH remains low at a pH around 2 and 3 in children of all ages [4, 8-22]. Neverthe-
less, large information gaps still exist on the impact of age on almost all drug absorption 
processes: gastric pH, gastrointestinal motility, bile salts, pancreatic function, intestinal 
pH, intestinal drug metabolizing enzymes (DMEs) and transporter proteins. Hence, as 
even in critically ill children of all ages many drugs are prescribed orally, it is important 
to better understand the impact of age on these processes, as well as their interplay, so 
as to be able to individualize dosing.
The TNO Gastro-Intestinal Tract model (TIM) is an interesting in vitro model to study 
the passage of a drug across the intestinal tract. TIM is a computer-controlled dynamic 
system that mimics the physiological conditions in stomach and intestines [23, 24]. Gas-
trointestinal parameters can be adjusted and intraluminal processing of drug dosage 
forms can be simulated [25]. The effects of drug manipulations to enhance drug inges-
tion by children can be studied using TIM (e.g., dissolving tablets in apple juice, apple 
sauce, crushing). In a pilot study, the feasibility to study the influence of different dosage 
forms on pediatric oral drug disposition was shown using the pediatric TIM model [26].
Once a drug has reached the small intestine it needs to cross the intestinal wall and 
pass the liver to reach the systemic circulation. Important processes involved in this step 
of oral drug absorption are drug metabolism and membrane transporters, which will be 
discussed below.
conclusion
Oral drug absorption in critically ill children may be erratic, leading to inadequate phar-
macotherapy, nevertheless up to 27% of drugs are administered via oral route. To date, 
large information gaps exist regarding the effect of age on gastrointestinal processes 
involved in oral drug absorption.
MEMbrAnE trAnsPortErs
new insights on ontogeny of transporters
In vitro studies, adult pharmacogenetics and drug-drug interaction studies have shown 
that human membrane transporters play a clinically relevant role in drug disposition 
[27]. It seems not unreasonable to assume that they are also important in the develop-
ing child. Moreover, as these transporters are also implicated in physiological processes, 
age-related variation subsequent to their role in normal growth and development can 
be expected. A quite recent broader interest in pediatric membrane transporters activity 
has resulted in a white paper on this subject from the International Transporter Work-
ing Group [chapter 3]. Not surprisingly, data in fetuses and children about transporter 
expression and activity are very scarce.
240 Chapter 12
The research presented in this thesis has generated novel data on the ontogeny of he-
patic and intestinal transporters in fetuses and children. We studied a selection of efflux 
transporters from the ATP-binding cassette (ABC) family (ABCB1, ABCC2, ABCC3, ABCG2, 
ABCB11) and uptake transporters from the solute carrier organic anion (SLCO) family 
(OATP1B1, OATP1B3 and OATP2B1), and from the solute carrier (SLC) family (SLC2A1/
GLUT1, SLC15A1/PEPT1, SLC16A1/MCT1, SLC22A5/OCTN2) (figure 1).
At gene and protein expression level, we have shown that hepatic and intestinal mem-
brane transporters change with age in a transporter-specific and organ-dependent 
manner. At hepatic protein level, four different expression patterns emerged 1) ‘Stable’ 
through childhood; 2) ‘Low to high’; 3) ‘High to low’; 4) ‘Non-linear’ with highest expres-
sion in infants.
Interestingly, age-related changes in gene expression were not reflected in the same 
changes in protein expression for ABCB1 and OATP1B1, but were found for ABCC2. This 
discrepancy shows the relative weakness of relying solely on gene expression data to 
understand transporter maturation. Posttranscriptional changes – for example medi-
ated by microRNAs – could explain that mRNA does not correspond to protein expres-
sion [28]. Also in hepatic miRNA expression developmental changes have been shown, 
and for some, miRNA expression was correlated to mRNA expression of drug disposition 
genes [29]. Aside from the gene expression data, also the protein data should be in-
terpreted carefully. Transporter protein expression itself may not necessarily translate 
to transporter activity. Glycosylation, phosphorylation, and ubiquination might alter 
proteins into active or non-active forms [30, 31]. Hence, posttranslational regulation in 
light of ontogeny of transporters needs further elucidation.
The finding of age-dependent variation in transporter activity may also increase our 
understanding of the physiological transporter function during growth and develop-
ment. For example, transporters involved in energy supply in fetal life may be up regu-
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figure 1. transporters in enterocyte and hepatocyte
OATP2B1: immunohistochemistry shows basolateral coloring; literature suggests apical localization. MCT1: 
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lated in fetuses and newborns. Glucose transporter GLUT1 and L-carnitine (molecule 
that shuttles long-chain fatty acids to the mitochondria for oxidation) transporter 
OCTN2, are probably both essential for fetal energy supply, which seems to agree with 
our findings of high protein expression in fetuses and newborns [32-34]. On the other 
hand, transporters involved in the uptake and efflux of steroids and bilirubin (i.e., OATPs) 
may show less variability throughout life.
The research field on membrane transporters in pediatrics remains with numerous gaps 
and the following research efforts are recommended:
i) Expanding the pediatric age range. Even though most changes are to be expected 
in the first months of life, no conclusions can be made for the entire pediatric age 
range due to the lack of data. More specifically, data on hepatic protein expression 
between the ages of 3 months and 7 years is completely lacking. Given the func-
tional role of transporters to translocate hormones, of particular interest are children 
reaching puberty, in whom hormonal changes might influence transporter function 
and gender differences might appear [30].
ii) Given the role of transporters in translocating drug substrates over membranes and 
mediating pharmacokinetics, the ontogeny of transporters in other organs than liver 
and intestine should be explored. Human gene and protein expression studies sug-
gest ontogeny of transporters in the kidneys (influencing renal clearance of drugs); 
in the brain (crossing blood-brain barrier causing effect or side-effects) lower ABCB1 
protein expression was shown in fetuses or neonates [35-38]. Hence, these and other 
sites are of particular interest.
iii) Including clinical information in biobank tissue collections to supplement data cohorts. 
From drug-drug interaction studies we know that drugs may inhibit or induce trans-
porter activity. Also, disease state may affect the expression and activity of membrane 
transporters as has been shown in children with inflammatory bowel disease [39]. 
Including more patient details asks for more efforts in data collection and storage. 
While this may provide useful additional information to explain interindividual varia-
tion, its benefit should be balanced against the potential decrease in the number of 
samples collected because of more logistical, practical and ethical hurdles [40, 41].
iV) Expanding the selection of studied transporters. To date more than 400 transporters 
have been identified [42]. The disposition of drugs is most often associated with two 
superfamilies: the solute carrier (SLC) and ATP-binding cassette transporters (ABC) 
families. We have studied a selection of 11 hepatic transporters and 4 intestinal 
transporters. Even though this selection included the most relevant transporters for 
mediating drug pharmacokinetics based on adult pharmacogenetic studies or high 
abundance in liver or intestine, this selection is merely a start. For example, we did 
not study OCT1, which nevertheless seems important in the disposition of opioids 
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such as morphine and tramadol [43, 44]. Other transporters as well may appear to 
play an important role in pediatric drug disposition.
in vivo membrane transporter research
In vivo validation is the next step in transporter research. Gene and protein expression 
might change during childhood, but does this also results in differences in transporter 
activity? The in vivo activity of transporters remains a black box in view of the ambiguous 
nature of substrates to multiple transporters. In vitro activity tests in cell lines or tissue 
cultures do not account for age-related differences. To study transporter activity in vivo, 
preferably the disposition of a probe drug or endogenous substrate should be exclusively 
altered by changes in the activity of an individual transporter. For example, changes in 
clearance may serve as surrogate marker of transporter activity. Due to the broad mem-
brane specificity of most drugs, very few relevant probe drugs have been identified. In 
addition to drugs, endogenous substrates may serve as phenotyping probes, such as 
in the case of CYP3A4 and CYP2D6 [45, 46]. This approach avoids the ethical challenges 
associated with the administration of a non-therapeutic probe drug to children.
The clinical relevance of single transporters in children is mainly based on the oc-
currence of unexpected drug-drug interactions. An interesting example of altered 
transporter activity in children is the drug-drug interaction in a study with 8 children 
(age 2 weeks – 3.7 years) treated for dilated cardiomyopathy with digoxin and carvedilol 
[47]. Digoxin renal clearance relies on ABCB1; due to the interaction with carvedilol, less 
digoxin was excreted in the urine, and serum digoxin concentrations increased. This ef-
fect was also observed in adult patients although the digoxin clearance decreased less. 
This supports the hypothesis that renal ABCB1 is present from the age of 2 years and it 
suggests that renal digoxin clearance in young children might be more dependent on 
ABCB1-mediatred tubular secretion than in adults.
The use of pharmacogenetics is another way of studying transporter activity and 
resulting effect in pharmacokinetics. As an example, in childhood leukemia patients, 
multiple single nucleotide polymorphism (SNP) loss-of-function variants in the SCLO1B1 
gene (encoding for OATP1B1) are related to lower methotrexate clearance leading to 
toxicity [48]. This points to an important role of OATP1B1 activity in methotrexate phar-
macokinetics, as well as maturity of the transporter in the studied age group.
These transporter-specific, organ-dependent ontogeny profiles might already have 
consequences for a patient’s individual pharmacotherapy. Still it is too early to justify 
dose adjustments of substrates based on lesser transporter expression in the first month 
of life. Nevertheless we can argue that closer monitoring of drug levels by therapeutic 
drug monitoring (TDM) is justified for substrates of transporters with age-related 
changes in expression (ABCC2, ABCC3, ABCG2, GLUT1, MCT1, OCTN2, BSEP, OATP1B3), 
with a small therapeutic window and important safety problems.
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conclusion
Current data shows maturation profiles in human membrane transporters in an organ-
specific and transporter-dependent manner. These differential patterns are likely to 
affect the disposition of drugs and their metabolites in an age-dependent matter. 
Further research should cover the entire pediatric age range, and include clinical and 
genetic co-variates in expression and activity studies. Clinical studies should include 
observational drug-drug interactions, pharmacogenetic and potential probe-based 
phenotyping studies.
PhAsE ii DruG MEtAbolisM
new insights on the ontogeny of phase ii drug metabolizing enzymes
Drug metabolism is the biochemical modification of pharmaceutical substances by 
enzymes and is one of the main determinants of variation in drug disposition. Pheno-
typing studies can be used to elucidate age-related changes in in vivo drug metabolism 
pathways [49]. While phase I metabolism has been studied relatively well in children 
[50] by means of in vitro and phenotyping studies, phase II metabolism is understudied 
[51]. Moreover, most studies have focused on hepatic metabolism using intravenous 
substrates. Since drug metabolizing enzymes are also abundant in the intestine, the 
combined intestinal and hepatic metabolism forms a notably argument to investigate 
this aspect of pediatric drug metabolism.
To elucidate the combined intestinal and hepatic phase II metabolism, we chose to 
study the oral disposition of paracetamol [chapter 11]. Although multiple UGT and SULT 
enzymes metabolize paracetamol, its disposition has previously shown clear age-related 
changes [52-55]. However, exclusive oral paracetamol dosing has been sparsely used in 
these studies. Moreover, in larger pediatric population pharmacokinetic studies, mul-
tiple administration routes (oral, rectal and intravenous) have been analyzed together 
[53, 56]. This may have obscured age-related differences in oral paracetamol disposition, 
since paracetamol bypasses the gut after intravenous administration, or bypasses the 
gut and liver after rectal dosing. Furthermore, children with bodyweights 3-7 kg and 
25-50 kg) were not included in these population pharmacokinetics studies. Hence, 
the exact developmental pattern of paracetamol metabolism after oral administration 
has not been fully elucidated. To bridge these gaps we studied the oral disposition of 
paracetamol in children in the age range of 0 to 6 years.
To overcome the ethical objections of therapeutic drug dosing solely for research, 
we used a single [14C]paracetamol microdose in children already receiving intravenous 
paracetamol for clinical reasons. Since the oral bioavailability of paracetamol in adults 
is around 85-98% (Tylenol® product information), a major contribution of intestinal me-
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tabolism might not be expected. However, bioavailability paracetamol studies in young 
children are lacking and therefore the role of intestinal paracetamol metabolism is un-
clear. In a later stage, this study design will enable to specifically study the hepatic and 
intestinal contributions to paracetamol metabolism, as well as the ontogeny of both.
Our most important findings agree with literature data [52-55]; we showed the con-
verse developmental pattern of paracetamol with mainly sulfation in younger children 
to mainly glucuronidation in older children. Reported urinary metabolites ratio after oral 
paracetamol administration rise steady from 0.27 in 2-3 day-old-neonates, to around 1.8 
in adolescents and adults [53, 57, 58]. Population pharmacokinetic studies propose a 
non-linear increase of glucuronidation with increasing age, reaching maturity at 3 years. 
We have tested a non-linear model, however, in which the confidence intervals were 
wide, suggesting little evidence for a reliable estimation and therefore we preferred a 
linear model.
At the in vitro level, the ontogeny of DMEs involved in paracetamol metabolism 
has been described. Hepatic UGT1A1, UGT1A6, and UGT1A9 activities were almost 
negligible in neonates [59, 60]. Despite the assumed absence of UGT1A1, UGT1A6 and 
UGT1A9, urinary AAP-glu is present in neonates, and therefore UGT2B15 is supposed 
to have substantial activity at birth [57, 58]. The observed maturation of paracetamol 
glucuronidation may therefore reflect the combined maturation pattern of these three 
other UGTs, from the UGT1 family, with relatively minor contribution of UGT2B15 from 
birth onwards.
The relative contributions of different SULT enzymes are different in fetal and pediatric 
liver samples, with mainly SULT1A3/4 and SULT1E1 in fetal or SULT1A1 in pediatric liver 
samples contributing to variability in AAP metabolism [61]. The observed slower de-
crease in paracetamol sulfation may be a reflection of a gradual switch from SULT1A3/4 
and SULT1E1 to SULT1A1 activity. A similar switch is seen for fetal CYP3A7 to postnatal 
CYP3A4 metabolism, but this switch already occurs in the first days of life [62].
Based on urinary metabolite recoveries, it has been suggested that multiple dosing 
of paracetamol in neonates, infants, and adults up-regulates glucuronidation [63-65]. 
A recent population pharmacokinetic study, however, did not show up-regulation of 
glucuronidation after multiple paracetamol dosing, but only the time-related increase in 
bodyweight reflected the developmental changes in glucuronidation [66].
Paracetamol is a widely used analgesic agent in the ICU. Although critically ill patients 
may show altered drug pharmacokinetics, this is of minor relevance for paracetamol 
clearance. Paracetamol pharmacokinetic data in 38 adult patients, from medium care 
and intensive care units, showed comparable median and range paracetamol clearance 
[67]. Moreover, hepatic clearance in healthy adult persons and patients with medium 
liver-failure was comparable, suggesting no effect of critical illness on paracetamol 
metabolism [68]. Besides, plasma protein binding of paracetamol is low, so AAP me-
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tabolism will not be affected in critical ill patients who often have low albumin levels 
[68]. Lastly, our outcome measure (AAP-glu/AAP-sul ratio) was the same as reported for 
healthy neonates and critically ill neonates (0.33) [chapter 11][64, 69]. This suggests only 
a minor effect of critical illness on paracetamol glucuronidation. Nevertheless it cannot 
be excluded that it has an effect on individual DMEs, as has been suggested for CYP3A4 
[70].
A small portion of AAP is metabolized into other metabolites than glucuronide and 
sulfate metabolites: 3-hydroxy-paracetamol, 3-methoxy-paracetamol, 3-cysteinyl-
paracetamol, paracetamol-mercaptopurate, which in their turn might be conjugated 
with glucuronide or sulfate (Tylenol ® product information) [71]. Some metabolites have 
been measured in children receiving therapeutic IV paracetamol dose, though possible 
age-related differences in the formation of these metabolites are unknown[71]. The 
highly reactive intermediate NAPQI (N-acetyl-p-benzo-quinone imine) is formed from a 
small portion of AAP CYP2E1 metabolism. When NAPQI is not detoxified by glutathione it 
can cause hepatotoxicity. It has been speculated that young children are more resistant 
to AAP-induced toxicity than adults [72] due to higher glutathione stores, metabolism 
differences, or relatively larger liver size. These metabolites have not been analyzed in 
this study due to financial constraints.
conclusion
Paracetamol metabolism shows age-related changes with mainly sulfation in neonates 
to mainly glucuronidation in older children. Urinary and plasma AAP-glu/AAP-sul AUC 
ratio can serve as a surrogate marker for paracetamol metabolism. Remaining gap in the 
ontogeny of paracetamol is the knowledge on formation of the toxic metabolites.
innoVAtiVE MEthoDs to stuDy PEDiAtric PhArMAcoloGy
Children are a vulnerable population who are relatively incapable in understanding 
and expressing the protection of their own interest and therefore need to be protected 
against harm. The criteria for pediatric research trials are rather stringent, therefore, so 
that children are ’therapeutic orphans’, also in view of the fact that many trials in pedi-
atric populations fail. The widespread off-label or unlicensed use of drugs is a legitimate 
reason to generate new knowledge and improve care. The research question addressed 
in this thesis – to elucidate the ontogeny of membrane transporter and drug me-
tabolism – cannot be studied outside the pediatric population however. Animal studies 
might reveal certain ontogeny, nevertheless the results cannot be simply extrapolated 
to humans.
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Thus we need to explore new ways of performing drug studies within the boundaries 
of the law and the medical ethical reviews. This thesis describes two innovative meth-
ods, LC-MS/MS and microdosing to elucidate developmental changes in membrane 
transporters and metabolism pathways. Below, we discuss the background as well as 
the pros and cons of these techniques.
Microdosing
Microdosing is an interesting tool to study pharmacokinetics in children for the fol-
lowing reasons: i) it has minimal burden and carries minimal risk; ii) it requires a small 
blood volume since plasma (or urine) samples can be as little as 30 µL due to the highly 
sensitive Accelerator Mass Spectrometry (AMS) technique; iii) an oral labeled microdose 
enables bioavailability studies when a therapeutic IV dose is administered simultane-
ously, which reduces the amount of blood samples.
To date, three actual pediatric microdosing studies in both Europe and the US have 
been performed. Including position papers and reviews, seven reports were published 
on microdosing in children (table 1) [chapter 11][73-78]. Our experience using micro-
dosing is predominantly positive, and rational designed microdosing studies can be of 
benefit to pediatric drug research.
A few critical notes are in order here. First, to predict pharmacokinetics, dose-linearity 
is essential. Some compounds show non-linearity in adults and are therefore unsuit-
able to study pharmacokinetics in children, e.g., erythromycin and warfarin [79]. It is 
recommended to test dose-linearity in an adult population first if possible. From an 
organizational perspective, pediatric microdosing studies are challenging. Radiophar-
maceutical preparation requires extra licenses for pharmaceutical and radiochemical 
handling, which implies that involvement of a common pharmacy alone is insufficient. 
Extra permissions from institutional radiation offices may be needed [76]. As for the 
analysis stage, AMS facilities are scarce. Though prices are probe-specific, both radio-
pharmaceutical preparation and AMS analysis drive prices and in our study resulted in 
the main costs expenditures (Euro 500.000,-).
Regulatory issues were differently addressed in the published studies. In our case, a 
single microtracer was considered ‘a drug in a pharmacokinetics study’ therefore the 
study was considered as a clinical trial of an investigational medicinal product (CT-
IMP). This was not the case in the UK and Estonia [75, 76], where it was considered ‘a 
well-characterized probe in a physiological experiment’ (a study involving a less well-
characterized probe would be a CTIMP in the UK). In the Netherlands, the hospital’s Ra-
diation Safety Officer considered the formulation radioactive and requested Radiation 
Safety training by the junior researcher, as well as a study-specific radiation handling 
protocol. In the UK and Estonia it was not considered radioactive. Body fluids and blood/
urine samples were considered radioactive only in the Netherlands. The radiation dose, 
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however, was so low that in none of these three countries special handling was required 
in all. Vuong and Gordi et al. did not describe the regulatory issues concerning handling 
of [14C]-materials within their hospitals [73, 74].
Regarding the use of microdosing studies in pediatrics, the U.S. Food and Drug 
Administration (FDA) requires they address a question which is a ‘scientific necessity’ 
and put minimal burden on the child [77]. Correspondingly, the Dutch legislation on 
non-therapeutic trials allows them only when there is minimal risk and minimal burden.
The major barrier to a [14C]microdosing study in children has been the perceived risk 
of radiation [80, 81]. Still, doses in the published microdosing studies are low, ranging 
from 37 Bq (Gordi et al.) to a maximum of 1594 Bq (60 Bq/kg) (our study), and a dose of 
115 Bq/kg in 0-2-year-olds (Garner et al.). This leads to very low radiation exposure of 
1 µSv in neonates and less than 10 µSv in older children, which is far below the yearly 
background exposure of 2.5 mSv/year in the Netherlands. And the exposure from the 
microdose is low compared to the exposure during a European continental flight (>4 
µSv), from a chest X-ray (100 µSv) or CT-scans (10 mSv). During informed consent con-
versations, most parents appeared to understand the minimal risk involved. Also, fear of 
harmful radiation exposure was not the main reason to deny informed consent. Consent 
was usually refused for other reasons: e.g., the burden of additional procedures such as 
blood sampling [chapters 9 and 10].
Alternatively, microdosing studies without a radioactive label are an option. Very 
sensitive LC-tandem mass spectrometry techniques measure very low concentrations 
[82]. Nevertheless, this method has not reached the very low limits of detection of AMS, 
and a larger unlabeled compound would be necessary. Also the use of an unlabeled 
microdose excludes the option to administer the dose simultaneously with an (unla-
beled) therapeutic dose. Thus, the use of an unlabeled microdose might be suitable 
to study single dose pharmacokinetics in children or the effect of pharmacogenetics 
on pharmacokinetics. Blake et al. used a subtherapeutic dose of dextromethorphan to 
study the CYP2D6 genotype’s correlation with pharmacokinetics [83].
Aside from using microdosing for phenotyping studies, other objectives can be con-
sidered. i) An early phase I study to predict the pharmacokinetics of a new drug specifi-
cally for the pediatric population, especially when metabolism is likely to be complex. 
ii) A study in which it is important to distinguish between an exogenous and an endog-
enous compound, e.g., as in the ursodiol study [73]. And iii) to study pharmacokinetics 
in special populations such premature neonates or critically ill children, where the PK 
may be different than the reference population (e.g. older, healthier children).
tissue sampling and lc-Ms/Ms
Transporter protein abundance in our study was quantified with LC-MS/MS. Few studies 
so far have used LC-MS/MS to quantify transporter protein levels and to related results 
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to age (table 2) [chapter 8] [84-86]. Moreover, taken our study aside, only a few children 
from the age of 7 years onwards have been studied to date. This section reviews the use 
of LC-MS/MS to study transporters during childhood.
LC-MS/MS is an attractive new method to optimize the use of sparse samples with 
limited sizes pediatric tissue. Other quantitative protein determinations have used 
antibody-based immunoassays, including Western blotting of membrane preparations, 
fluorescence activated cell sorting (FACS) methods, and enzyme-linked immunosorbent 
assay (ELISA). A general drawback of these methods is the requirement to prepare 
specific antibodies. Although a large variety of antibodies are commercially available, 
the issue of cross-reactivity between protein isoforms or species remains of concern 
[87]. Other than these antibody-dependent methods, the LC-MS/MS technique relies 
on proteotypic peptides to detect and quantify the protein of interest. Cross-reaction 
might still occur, but this can be accounted for in the design of the peptide or by choos-
ing two different peptides for the protein of interest, so that cross-reactivity remains 
only with unknown proteins. No more than 10 mg of human tissue is needed for LC-MS/
MS [88]. In contrast to for example a single protein identification with a Western blotting 
experiment, multiple proteins can be quantified on a single LC-MS/MS run.
Functional membrane transporters are the ones present on the plasma cell mem-
brane. Therefore determination of the total transporter protein amount per cell will not 
table 2. overview of lc-Ms/Ms transporter studies with pediatric samples
Prasad et al.
[84]
Prasad et al.
[85]
Deo et a.
[86]
Mooij et al.
[chapter 8]
Year 2014 2013 2012 this thesis
Transporters ABCB1, OATP1B1, 
OATP1B3
ABCG2 ABCC2 ABCB1, ABCC2, ABCC3, ABCG, BSEP, 
OATP1B1, OATP2B1, OCTN2, GLUT1, 
MCT1
Organ Liver Liver Liver Liver
Sample size n=64 n=50 n=51 n=25
Age range 7-70 years 7-70 years 7-63 years 10 fetuses, 12 infants 0-11 weeks, 3 
adult
Method Total membrane 
fraction
Total membrane 
fraction
Total membrane 
fraction
Crude membrane fraction
Results Protein 
expression of 
transporters 
were not 
associated with 
age
ABCG2 protein 
expression was 
nog associated 
with age
ABCC2 protein 
expression was 
not associated 
with age
With postnatal age four patterns 
emerged from fetal to adult age: 
1) ABCB1, OATP1B1, and OATP2B1 
expression levels were stable 2) ABCC2, 
ABCC3, and BSEP were low to high 
expressed 3) ABCG2, GLUT1, OCTN2 
protein levels were high to low 4) 
MCT1 was highest in infants
These patterns were also found for 
postmenstrual age within the fetal/
infant groups.
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suffice to relate to possible activity. Therefore, the abundance of transporter proteins 
in tissues is quantified after subcellular fractionation resulting in enriched membrane 
fractions. The preparation of the most relevant matrix (e.g., plasma cell membrane) is 
not uniform across laboratories. This may result in inter-study variability. To incorporate 
absolute protein abundance information into PBPK models, losses of target proteins, 
need to be estimated in a standardized manner [89].
An important limitation of this method is the need for a specialized lab and equip-
ment, while Western blot is a standard laboratory technique, which most labs can use 
easily. This likely also results in a difference in costs between the methods.
future challenges
Incorporating ontogeny data for pediatric drug dosing
Many processes involved in drug disposition mature and change with age, and the 
ontogeny of a single process is hardly meaningful without the context of other body 
processes and their maturation. Modeling and simulation can be used in different ways 
to design dosing regimens. Examples of evidence-based complex models based on 
physiologically processes or population pharmacokinetic data, are respectively, physi-
ologically based pharmacokinetics (PBPK) or population pharmacokinetics (popPK) 
models.
These models are valuable tools in designing clinical trials. Simulations from PBPK 
models, which incorporate available drug property and physiological information, can 
predict pediatric dosing [90]. Importantly, high-quality ex vivo data must be incorporated 
and continuous updating of physiological ontogeny data is crucial. PBPK modeling can 
also be used to simulate the impact of maturation of specific transporters or enzymes, 
preferably with actual ex vivo data on expression/activity [91]. Ultimately, these models 
also must be validated with real-life pharmacokinetic data, which still asks for confirma-
tory pharmacokinetic sampling in clinical trials including the concept of opportunistic 
sampling, using doses derived from these simulations [92].
PopPK models of substrate drugs for specific drug disposition pathways have been 
used to describe the developmental patterns of these pathways, e.g., CYP3A4 and 
glomerular filtration rate (GFR) clearance [93, 94]. Validation of these models with the 
use of other substrate drugs has been quite challenging, as drugs may share one main 
disposition pathway, e.g. GFR clearance, but the contribution of membrane transport-
ers may differ, thus affecting the age-related variation in pharmacokinetic parameters. 
Nevertheless, for individual drugs these models have proven useful to generate dosing 
guidelines. The final step of evidence-based pharmacotherapy is prospective validation 
of the popPK models. This approach has been successfully applied in case of morphine 
in postoperative neonates [95].
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Nowadays PBPK and popPK models are used in fields such as in clinical drug develop-
ment and investigator-initiated research. It would be worthwhile, though, to make these 
models more accessible and user-friendly for clinicians, for example as a bed-side tool 
in the form of an App- or other program. After entering details of the drug in question, 
age, kidney and liver function, and possible co-medication a pediatrician would receive 
a dosing suggestion based on substrate properties and in vitro ontogeny data of, among 
other things, transporter or metabolism. Considering that these models are currently far 
from ideal, this might still be the best option for a present patient who needs a drug for 
which no age-appropriate dosing guidelines are available.
The question remains at what point ontogeny data, PBPK or popPK models can be 
used to design dosing guidelines. Although validated evidence-based dosing guidelines 
are preferred, often no data is available on essential drugs even though these drugs are 
already given to children.
conclusions
Although the ontogeny of membrane transporters and drug metabolism pathways 
remains to be further elucidated and clinically demonstrated, the current maturational 
profiles can be used in multifactorial dose-prediction models.
For the purpose of ontogeny studies, and taking its limitations into account, LC-MS/
MS is suitable to quantify transporter abundance while optimally using sparse pediatric 
tissue samples; and [14C]-labeled microdosing studies in children are a feasible tool 
to phenotype the ontogeny of drug metabolism, as has been shown for paracetamol 
metabolism.
The ultimate goal is to provide optimal age-appropriate drug dosing in children.
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suMMAry
Appropriate pediatric dosing needs to account for developmental changes in drug 
absorption, distribution, metabolism and excretion. There is a lack of knowledge on 
the age-related changes in drug transporters and metabolism pathways. This thesis 
addresses the ontogeny of intestinal and hepatic membrane transporters, as well as 
of glucuronidation and sulfation, which comprise important building blocks of drug 
disposition pathways in children. As pediatric drug studies are hampered with practical 
and ethical challenges, this thesis addresses the use of innovative clinical methods.
Part i introduction
While oral drug absorption in critically ill children may be erratic and the use of this route 
therefore is discouraged for drugs. We show in chapter 2 that up to 27% of drugs are 
prescribed orally to children in neonatal and pediatric intensive care. This stresses the 
importance to study the processes involved in oral drug absorption in this population 
and the impact of age-related changes on these processes. The current state of knowl-
edge is reviewed in chapter 3. Large information gaps exist on the impact of growth and 
development of almost all drug absorption processes (gastric pH, gastrointestinal motil-
ity, bile salts, pancreatic function, intestinal pH, intestinal drug metabolizing enzymes, 
and transporter proteins). More in depth on the membrane transporters; chapters 4 
and 5 present our current knowledge on developmental changes in clinically relevant 
transporters in intestine, liver, and kidney. In chapter 4, based on in vitro studies, dif-
ferent developmental patterns for individual transporters emerge. Following on from 
this work, in chapter 5 drug disposition and pharmacogenetics studies in children are 
reviewed to add to our understanding of age-related changes in individual transporters. 
Overall, a striking information gap remains on the role of membrane transporters in 
pediatric drug therapy.
Part ii Membrane transporters
The age-related changes in gene and protein expression of intestinal and hepatic drug 
transporters are presented in chapters 6, 7, and 8. A selection of efflux transporters from 
ATP-binding cassette (ABC) family (ABCB1, ABCC2, ABCC3, ABCG2, ABCB11/BSEP) and 
uptake transporters from solute carrier organic anion (SLCO) family (OATP1B1, OATP1B3 
and OATP2B1), and from the solute carrier (SLC) family (SLC2A1/GLUT1, SLC15A1/PEPT1, 
SLC16A1/MCT1, SLC22A5/OCTN2), are studied in one or more chapters.
chapter 6 shows that hepatic ABCB1, ABCC2, OATP1B1 and OATP1B3 gene expres-
sions in fetuses, neonates and infants are significantly lower than in adults. Neonatal 
intestinal expressions of ABCB1 and ABCC2 are comparable to those in adults. Intesti-
nal OATP2B1 expression in neonates is significantly higher than in adults. chapter 7 
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presents slightly lower, but clinically insignificant, intestinal PEPT1 gene expression in 
neonates and young infants than in adolescents. Furthermore, we found comparable 
localization of PEPT1, ABCB1, ABCC2 and OATP2B1 proteins in the neonates and the 
young infants compared to adolescents. They are visualized in the apical part of the 
brush border (PEPT1, ABCB1, ABCC2) and intraepithelial at the basolateral enterocyte 
border (OATP2B1). chapter 8 focuses on hepatic transporter protein expression, using 
innovative liquid chromatography tandem mass spectrometry (LC-MS/MS). Four pat-
terns emerge with postnatal and postmenstrual age: ABCB1, OATP1B1, and OATP2B1 
expression levels are stable from fetal to adult age. ABCC2, ABCC3, and BSEP are low 
in fetuses and infants and higher in adults, while ABCG2, GLUT1, OCTN2 protein levels 
are higher early in life to low in adults. MCT1 expression levels are highest in infants 
compared to fetuses and adults. Interestingly, age-related changes in gene expression 
are not reflected in the same changes in protein expression for ABCB1 and OATP1B1. 
In conclusion, these studies show transporter-specific maturation, with a discrepancy 
between gene and protein expression for selected transporters.
Part iii Phase ii Drug metabolism
Drug metabolism is one of the main determinants of variation in drug disposition. Phe-
notyping studies can be used to elucidate in vivo drug metabolism pathways in the pe-
diatric population, but they are hampered by practical, ethical and scientific challenges. 
To overcome these challenges, an innovative approach of an open-label microdose 
study was performed using oral [14C]paracetamol(AAP). The results of this project are 
presented in chapters 9, 10, and 11. chapter 9 presents pilot data, showing that micro-
dosing is a feasible and promising tool to study AAP pharmacokinetics. In collaboration 
with the European PAMPER consortium, chapter 10, evaluates the experiences from 
two microtracer and -dosing studies, and concludes that if challenges in dose-linearity 
and costs are overcome this technique is of added value for pediatric drug develop-
ment. chapter 11 presents the final results of this phenotyping microdosing study to 
investigate the age-related changes in glucuronidation and sulfation. Metabolite ratio 
of paracetamol-glucuronide (AAP-glu) and paracetamol-sulfate (AAP-sul) was used as 
a surrogate marker for paracetamol metabolism. In 50 children [median age 6 months 
(range 3 days - 6.9 years)] both plasma and urinary AAP-glu/AAP-sul ratios significantly 
increased by 4-fold. These data confirm literature data on the developmental pattern 
of paracetamol sulfation and glucuronidation, and add data on combined intestinal 
and hepatic pathways in a large pediatric age range. [14C]labeled microdosing appears 
feasible to phenotype age-related differences in drug metabolism in children.
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Part iV General discussion
chapter 12 discusses the results of our research in light of the current literature and 
makes recommendations for future studies on ontogeny of transporters and drug me-
tabolism. We conclude that
A) major gaps remain on the ontogeny of oral drug disposition processes, in particular 
of membrane transporters;
b) intestinal and hepatic transporter expressions change in transporters-specific pat-
terns in an age-dependent manner;
c) AAP glucuronidation and sulfation are age-related, from mainly sulfation in neo-
nates, changing to mainly glucuronidation in older children;
D) [14C]labeled microdosing is a feasible and promising approach for phenotyping stud-
ies in children to elucidate age-related changes in drug disposition;
E) innovative methods in drug development i.e., microdosing and LC-MS/MS protein 
abundances offer excellent opportunities to overcome ethical and practical limita-
tions in pediatric drug research.
This thesis shows new insights of the ontogeny of transporters, presenting one of the 
first transporter expressions (gene and protein) data in children. Due to the ambiguous 
nature of substrates for transporters no solid marker can yet be defined to study activity 
in vivo. Hence, at this moment we rely on expression studies. LC-MS/MS serves as an 
elected tool as it quantifies a palette of multiple transporters in a minimal amount of 
pediatric tissue. First, transporters in other organs, regulation factors (i.e., epigenetics, 
transcription factors) and influencing factors (i.e., disease, nutrients, substrate exposure) 
need to be identified. In vivo studies should aim to study amongst others; pharmacoge-
netics of transporters and drug-drug interactions of transporter substrates.
Our data adds, in a meaningful way, to the information about combined intestinal 
and hepatic metabolism of paracetamol using an oral probe, and about the important 
age gap (1-2 years). Furthermore, this was reached using an inventive minimal risk and 
minimal burden microdosing study, which serves as a stepping stone on the path to 
increasing pediatric drug study options. The use of this promising technique should be 
expanded into other substrates for phenotyping drug metabolism (if dose linearity is 
present), especially in vulnerable populations (i.e., prematures, the critically ill), but also 
in the early evaluation of new drugs when metabolism is likely to be complex and suited 
for a specific pediatric population.
Data from in vitro membrane transporter studies and in vivo pharmacokinetic pheno-
typing studies serve as input for complex multifactorial models (physiologically-based 
or population pharmacokinetic models), which predict pediatric drug dosing. The 
ultimate goal is to provide better age-appropriate drug dosing for children, taking into 
account the evolution of drug disposition pathways.
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sAMEnVAttinG
Bij kinderen wordt de juiste dosering van een geneesmiddel bepaald door de mate van 
absorptie, distributie, metabolisme, en excretie van dat geneesmiddel op een bepaalde 
leeftijd. Over de leeftijdsafhankelijke veranderingen in de transport en omzetting van 
geneesmiddelen is nog weinig bekend. Dit proefschrift beschrijft de ontwikkeling van 
membraantransporters en geneesmiddel metaboliserende enzymen in de darmen en in 
de lever, als belangrijke processen voor de dispositie van geneesmiddelen bij kinderen. 
Geneesmiddelenstudies bij kinderen kennen praktische en ethische beperkingen. In-
novatieve onderzoeksmethoden zijn toegepast om de onderzoeksvraag te kunnen 
beantwoorden met minimale belasting en risico voor het individuele kind.
Deel i introductie
Bij kritiek zieke kinderen kan de absorptie van orale geneesmiddelen sterk wisselen, 
en daarom wordt de orale toediening vaak ontmoedigd. In hoofdstuk 2 laten wij zien 
dat tot 27% van alle geneesmiddelen in onze neonatale en pediatrische intensive care 
units oraal wordt gegeven. Dit benadrukt het belang van meer kennis over de absorptie 
van orale geneesmiddelen bij deze kritisch zieke kinderen. De huidige stand van kennis 
over de invloed van leeftijd op orale absorptie wordt beschreven in hoofdstuk 3. Er zijn 
hiaten in de kennis over het effect van groei en ontwikkeling op bijna alle processen 
die betrokken zijn bij de absorptie van orale geneesmiddelen (zuurgraad van de maag 
en de darm, snelheid van maag en darm ontlediging, galzouten, alvleesklierfunctie, 
omzetting en transport van geneesmiddelen in de darmwand). hoofdstukken 4 en 5 
beschrijven specifiek het effect van leeftijd op membraan-transporteiwitten in de dar-
men, lever en nieren. hoofdstuk 4 beschrijft resultaten van in vitro studies, hieruit blijkt 
dat er verschillende ontwikkelingspatronen zijn voor verschillende transportereiwitten. 
Vervolgens is in hoofdstuk 5 gekeken naar studies over geneesmiddeldispositie en 
farmacogenetica bij kinderen met de vraag of deze iets toevoegen aan ons inzicht in 
veranderingen bij individuele transporters. Over het geheel genomen blijft de rol van 
membraantransporters bij de farmacotherapie voor kinderen een grotendeels onont-
gonnen terrein. De beperkte beschikbare data wijzen er wel op dat er een effect van 
leeftijd is op de activiteit van transporters, maar dat dit effect per transporter verschilt. 
Dit suggereert dat het effect en de veiligheid van geneesmiddelen, die substraat zijn 
voor transporters hierdoor kan variëren bij kinderen van verschillende leeftijden.
Deel ii Membraantransporters
Nieuwe data die leeftijdsafhankelijke veranderingen in de gen- en eiwitexpressie van 
transporters in de darmen en de lever beschrijven worden gepresenteerd in de hoofd-
stukken 6, 7 en 8. Het betreft hier uitstroomtransporters van de ATP-binding cassette 
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(ABC) familie (ABCB1, ABCC2, ABCC3, ABCG2, ABCB11/BSEP), en opnametransporters 
van de solute carrier organic anion (SLCO) familie (OATP1B1, OATP1B3 en OATP2B1) 
en van de solute carrier (SLC) familie (SLC2A1/GLUT1, SLC15A1/PEPT1, SLC16A1/MCT1, 
SLC22A5/OCTN2).
De genexpressie van de transporters ABCB1, ABCC2, OATP1B1 en OATP1B3 in de 
lever bij foetussen, pasgeborenen en kinderen blijkt lager te zijn dan bij volwassenen 
(hoofdstuk 6). De genexpressie van ABCB1 en ABCC2 in de darm bij pasgeborenen is 
vergelijkbaar met die bij volwassenen. De genexpressie van OATP2B1 in de darm bij 
pasgeborenen is significant hoger dan bij volwassenen. De genexpressie van PEPT1 in 
de darm van pasgeborenen en jonge kinderen is iets lager dan bij adolescenten, maar 
dit lijkt klinisch niet relevant (hoofdstuk 7). Bovendien was de lokalisatie van PEPT1, 
ABCB1, ABCC2, en OATP2B1 eiwitten in darmcoupes van pasgeborenen, jonge kinde-
ren en adolescenten vergelijkbaar. PEPT1, ABCB1, ABCC2 eiwitten kleurden aan in het 
apicale gedeelte van de borstelzoom en OATP2B1 kleurde intra-epitheliaal aan aan de 
basolaterale zijde van de enterocyt. hoofdstuk 8 beschrijft het effect van leeftijd op de 
eiwitexpressie in een selectie lever transporters met behulp van ‘liquid chromatography 
tandem mass spectrometry’ (LC-MS/MS). Vier patronen konden worden onderscheiden: 
De expressie van ABCB1, OATP1B1 en OATP2B1 is stabiel van de foetale naar de vol-
wassen leeftijd. De expressie van ABCC2, ABCC3 en BSEP is laag op de foetale en jonge 
kinderleeftijd en hoog op de volwassen leeftijd, terwijl voor ABCG2, GLUT1 en OCTN2 
het omgekeerde geldt. Ten slotte, de expressie van MCT1 was het hoogst bij jonge 
kinderen vergeleken met foetussen en volwassenen. Een belangrijke bevinding was 
dat de leeftijdsafhankelijke verschillen in genexpressie van ABCB1 en OATP1B1 niet in 
overeenstemming zijn met de verschillen in de eiwitexpressie. We mogen concluderen 
dat er sprake is van een transporter-specifieke rijping, en dat een discrepantie bestaat 
tussen de gen- en eiwitexpressie van geselecteerde transporters.
Deel iii fase ii geneesmiddelen metabolisme
Het metabolisme is een van de belangrijke determinanten van de variatie in de 
geneesmiddeldispositie. Zogenaamde fenotyperingstudies zijn nuttig om de meta-
bolismeroutes bij kinderen in vivo te ontrafelen, maar kennen praktische, ethische en 
wetenschappelijke bezwaren. Een alternatief is het innovatieve concept van ‘microdo-
sing’ met een [14C] gelabelde microdosis. Hierbij wordt een zeer lage dosering, zeer zwak 
radioactief gelabelde dosis van een geneesmiddel gegeven, waarna de farmacokinetiek 
bepaald kan worden. Dit kan doordat we met de zeer gevoelige analysemethode ‘ac-
celerated mass spectrometry’, de zeer lage concentraties kunnen meten in plasma en 
urine. Door de zeer lage dosis kan er geen effect van het geneesmiddel zelf optreden. 
Deze methode om farmacokinetiek te bestuderen is hierdoor minimaal belastend voor 
de proefpersoon en gaat gepaard met minimaal risico. De resultaten van ons micro-
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dosing onderzoek worden gepresenteerd in de hoofdstukken 9, 10 en 11. In een pilot 
studie bleek microdosing met [14C]paracetamol goed uitvoerbaar te zijn bij kinderen 
en veelbelovend ten aanzien van onderzoek naar de farmacokinetiek van paracetamol 
(hoofdstuk 9). In samenwerking met het Europese PAMPER consortium hebben we de 
ervaringen bij twee microtracer en microdosing studies geëvalueerd. We concluderen 
dat deze methode nuttig kan zijn voor geneesmiddelenstudies op de kinderleeftijd, mits 
er sprake is van een ‘dosis-lineair’ effect en de kosten beperkt kunnen worden (hoofd-
stuk 10). De uiteindelijke resultaten van de fenotyperingstudie waarbij de leeftijdsaf-
hankelijke veranderingen in de glucuronidering en sulfatering van paracetamol zijn 
onderzocht worden beschreven in hoofdstuk 11. De plasma en urine metaboliet-ratio’s 
van paracetamol-glucuronide (AAP-glu) en paracetamol-sulfaat (AAP-sul) dienden als 
surrogaatmarkers voor het metabolisme van paracetamol. Het betrof 50 kinderen met 
een mediane leeftijd van 6 maanden (spreiding 3 dagen – 6.9 jaar)] en zowel in plasma 
als in urine steeg de AAP-glu/AAP-sul ratio met de leeftijd viervoudig. Dit bevestigt het 
al bekende ontwikkelingspatroon van paracetamol sulfatering en glucuronidering. Het 
concept van [14C]gelabeld microdosing blijkt geschikt om het fenotype van geneesmid-
del metabolisme te bepalen bij kinderen en daarmee naar het effect van leeftijd te 
kijken.
Deel iV Algemene discussie
In hoofdstuk 12 wordt het volgende geconcludeerd:
A) er zijn grote hiaten in de kennis over dispositieprocessen van orale geneesmiddelen, 
vooral op het gebied van membraantransporters;
b) de expressie van transporters in de darmen en in de lever verandert met een toene-
mende leeftijd volgens een transporter-specifiek patroon;
c) de glucuronidering en sulfatering van paracetamol zijn leeftijdsafhankelijk, dat wil 
zeggen dat er bij pasgeboren vooral sprake is van sulfatering en bij oudere kinderen 
vooral van glucuronidering;
D) [14C]gelabeld microdosing is uitvoerbaar en veelbelovend voor fenotyperings stu-
dies bij kinderen om leeftijdsafhankelijke veranderingen in geneesmiddeldispositie 
te ontrafelen, het bevestigt eerder onderzoek naar het effect van leeftijd op parace-
tamolmetabolisme;
E) innovatieve methoden zoals microdosing en LC-MS/MS eiwitbepaling bieden uitste-
kende mogelijkheden om de ethische en praktische beperkingen van geneesmid-
delenonderzoek bij kinderen te verminderen.
Als gevolg van het wisselende affiniteit van substraten voor vaak meerdere transpor-
ters en de noodzaak een therapeutische middel te geven, zijn er tot op heden weinig 
goede markers om de activiteit in vivo te onderzoeken bij kinderen. Zodoende zijn 
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we momenteel in belangrijke mate afhankelijk van laboratorium studies. LC-MS/MS is 
een geschikte methode omdat deze verschillende transporters kan kwantificeren in 
een minimale hoeveelheid weefsel. Dit is van belang bij kinderen, omdat het vaak een 
uitdaging is om voldoende weefsel voor onderzoek te kunnen verzamelen. De volgende 
aspecten dienen in de toekomst onderzocht te worden: transporters in andere organen 
dan de darmen en lever, regulerende factoren (zoals epigenetica, transcriptiefactoren) 
en beïnvloedende factoren (zoals ziekte, voedingsstoffen, blootstelling aan substraten). 
In vivo studies die ons begrip over membraantransporters kunnen vergroten, zijn farma-
cogenetica en geneesmiddeleninteractie-studies van betrokken transportersubstraten.
De gebruikte innovatieve microdosing methode kent een minimaal veiligheidsrisico 
en is weinig belastend, en is daarom veelbelovend is voor geneesmiddelenstudies bij 
kinderen. Deze methode kan ook worden gebruikt voor andere geneesmiddelen (mits 
de farmacokinetiek van het middel dosis-lineair is), met name bij kwetsbare prematuren 
en kritiek zieke kinderen, maar ook in de eerste fasen van de ontwikkeling van genees-
middelen voor kinderen waarbij een complex metabolisme wordt verwacht.
Data van in vitro studies naar membraantransporters en in vivo studies naar de 
fenotypering van farmacokinetiek kunnen dienen als de bron voor complexe multifac-
toriële modellen (op fysiologie of populatie gebaseerd) om doseringen voor kinderen 
te voorspellen. Het uiteindelijke doel is om te komen tot betere, op leeftijd gebaseerde 
geneesmiddeldoseringen met inachtneming van de maturatie van de betrokken farma-
cokinetische processen.
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list of AbbrEViAtions
14C Carbon 14
AAP Paracetamol or acetominophen
AAP-glu Paracetamol-glucuronide
AAP-sul Paracetamol-sulfate
ABC ATP-Binding Cassette
ALL Acute Lymphatic Leukemia
AMS Accelerator Mass Spectrometry
AUC Area Under the Curve
AUC0-inf Area Under the Curve from time zero to infinity
AUC0-t Area Under the Curve from time zero to last observed timepoint
BCRP (ABCG2) Breast Cancer Resistance Protein
BCS Biopharmaceutics Classification System
bDNA assay branched DNA assy
Bq Bequerel
BSEP (ABCB11) Bile Salt Export Pump
CAR Constitutive Androstane Receptor
Cav Average concentration
CES2 Carboxylesterase 2
CL/F Oral clearance
Clast Last observed concentration
C max Maximum concentration
CO2 Carbon dioxide
CT Computer Tomography
CTIMP Clinical Trial of Investigational Medicinal Product
CYP Cytochrome P450
DDI Drug-Drug Interaction
DME Drug Metabolizing Enzyme
E-1 Elastase 1
EA Elemental Analyzer
EMA European Medicines Association
EMIT Enzyme Multiplied Immunoassay Technique
FDA US Food and Drug Administration
GA Gestational Age
GERD Gastroesophageal Reflux Disease
GFR Glomerular Filtration Rate
GI Gastrointestinal
GLUT1 Glucose transporter 1
GMP Good Medicinal Practice
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GWAS Genome-Wide Association Study
HCC Hepatocellular carcinoma
HIV Human Immunedeficiency Virus
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A
ICRP International Committee on Radioactivity Protection
IHC Immunohistochemistry
IRB Independent Review Boards
IV Intravenous
LC Liquid Chromatography
LLOQ Lower Limit Of Quantification
MATE (SLC47A) Multidrug And Toxin Extrusion protein
MCT1 Monocarboxylate transporter 1
MDR1 (P-gp; ABCB1) Multi-Drug Resistance 1; P-glycoprotein
miRNA microRNA
MPA Mycophenolic acid
mRNA Messenger RNA
MRP (ABCC) Multidrug Resistance-associated Protein
MRSA Methicillin-Resistant Staphylococcus Aureus
MTX Methotrexate
NAPQI N-acetyl-p-benzoquinone imine
NOAEL No Observed Adverse Effect Level
NTCP (SLC10A1) Na+-Taurocholate Cotransporting Polypeptide
OAT (SLC22A) Organic Anion Transporter
OATP (SLCO) Organic Anion Transporting Polypeptide
OCT (SLC22A) Organic Cation Transporter
OCTN (SLC22A) Organic cation/ergothioneine transporter
OCTT Orocecal Transit Time
OSTα/β Organic Solute Transporter
PAH P-aminohippurate
PAMPER Paediatric Accelerator Mass Spectrometry Evaluation Research study
PBPK Physiologically-based pharmacokinetic
PD Pharmacodynamic
PDA Photodiode array
PEDMIC PEDiatric MICrodosing
PEPT (SLC15A) Peptide transporter
PGx Pharmacogenetics; pharmacogenomics
PK Pharmacokinetics
PMA Postmenstrual age
PNA Postnatal age
popPk Population pharmacokinetic
PXR Pregnane X Receptor
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QC Quality Control
qRT-PCR Quantitative Reverse Transcription Polymerase Chain Reaction
RIN RNA integrity number
RNAse Ribonuclease
RT-PCR Reverse Transcription Polymerase Chain Reaction
SD Standard Deviation
SLC Solute carrier
SLCO Solute carrier organic anion
SNP Single-Nucleotide Polymorphism
SULT Sulfotransferase
Sv Sievert
t1/2 Elimination half-life
λz Terminal elimination slope
TIM TNO gastro-Intestinal tract Model
Tlag Time delay of absorption
tmax Time at maximum concentration
UGT Uridine 5’-diphospho-glucuronosyltransferase
UK United Kingdom; Great Britain
UPLC Ultra-Performance Liquid Chromatography
UPLC-MS/MS Ultra-Performance Liquid Chromatography tandem Mass Spectrometry
URAT1 (SCL22A12) Urate transporter 1
US United States of America
VSOP Dutch collaborative patients’ organization for rare and genetic diseases; Vereniging 
van Samenwerkende Ouder- en Patientorganisaties voor zeldzame en genetische 
aandoeningen
VSS/F Apparent volume of distribution
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Dit proefschrift is tot stand gekomen dankzij de steun, mede- en samenwerking van 
velen, die ik graag wil bedanken. Ten eerste, de ouders en patiënten; in mijn ogen zijn 
jullie de echte helden, omdat in tijden van onzekerheid en ziekte jullie toch de kracht 
vinden om belangeloos mee te doen aan wetenschappelijk onderzoek. De ICK verpleeg-
kundigen, altijd betrokken bij de patiënt en bereidwillig om bloed en urine af te nemen 
of te bellen wanneer ouders er zijn. De ICK stafleden, fellows en arts-assistenten, geïnte-
resseerd en behulpzaam om een patiënt te overleggen, onderzoekers op de hoogte te 
brengen of een keer geduldig langs ouders te lopen wanneer zij behoefte hadden aan 
extra informatie.
Prof. dr. Tibboel, beste Dick, vier jaar geleden kwam ik als een onervaren onderzoeker 
op uw geoliede onderzoeksafdeling met uiteenlopende onderzoeken en onderzoekers. 
Ik bewonder uw veelzijdigheid en gedrevenheid voor de wetenschap. Telkens hield u 
de grote lijnen in de gaten en stelde u kritische vragen wanneer ik te gedetailleerd met 
een ‘transportertje’ bezig was en met onmogelijke afkortingen gooide. Dank voor uw 
waardevolle begeleiding.
Dr. de Wildt, beste Saskia, de afgelopen vier jaren heb jij mij met twee dingen besmet: 
passie voor kinderfarmacologie en wielrennen waarvoor ik je tot op de dag van vandaag 
dankbaar ben. Ik heb bewondering voor jouw grote toewijding en inzet in de klinische 
farmacologie zowel binnen het Sophia als internationaal. Ik heb ontzettend genoten 
van onze discussies. Of het nu ging over radioactiviteit op de afdeling, een klinisch 
farmacologisch consult of wat er in de bidon moest. Terwijl we vele kilometers aflegden 
op de wielrenfiets waren we ook op wetenschappelijk gebied een goed team. Dank voor 
de afgelopen jaren!
De leden van de kleine promotiecommissie, Prof. dr. van Gelder, Prof. dr. Allegaert, en 
Prof. dr. Leeder, wil ik hartelijk danken voor het beoordelen van mijn proefschrift. Prof. 
van Gelder, beste Teun, dank voor de leerzame klinische farmacologie en farmacogene-
tica bijeenkomsten. Prof. Allegaert, beste Karel, dank voor uw kritische commentaren. 
Prof. Leeder, dear Steve, thank you for an inspiring and productive brainstorm session 
in Rotterdam and for your willingness to oppose me in my PhD defense. Prof. dr. de 
Hoog, dr. Samsom en dr. Vaes wil ik hartelijk danken voor het plaats nemen in de grote 
commissie.
Alle co-auteurs wil ik bedanken voor de prettige samenwerking de afgelopen jaren. In 
het bijzonder onze samenwerkingspartners van TNO; dr. Wouter Vaes, dr. Esther van 
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Duijn, dr. Evita van de Steeg en dr. Heleen Wortelboer. Ik wil jullie danken voor de suc-
cesvolle samenwerking met laagdrempelig overleg. Het was keer op keer stimulerend 
om met jullie over transporters of microdosing te praten. En ik hoop van harte dat de 
samenwerking een lang vervolg krijgt.
Dr. Richard Kim, dr. Ute Schwarz, dr. Marianne DeGorter, dr. Mathilde Leon-Ponte, thank 
you for your hospitality during my stay at your department in London (Ontario) and for 
learning me the ins and outs of RT-PCRs. Dear Sara and Al Gallien, thank you so much for 
taken me into your house when I was ripped off by my landlady. Staying with you and 
your cats made my Canadian experience unforgettable.
Beste Ko Hagoort, je bereidheid om een manuscript snel van scherp commentaar te 
voorzien vanuit Rotterdam of Lombok is fantastisch. Dr. Joost van Rosmalen, bedankt 
voor je statistische hulp. Dr. Monique van Dijk, dank voor de klinische promovendi bij-
eenkomsten en met name de kerstontbijten. Annemarie Illsley, dank voor je hulp en de 
gezellig kletspraatjes. Chantal, Judith, Marie-Louise en Marja, bedankt voor jullie hulp. 
Dr. Barbara de Koning, dank voor je enthousiasme over transporters.
Joke Dunk, je steun was onmisbaar. Databases controleren, samples afdraaien of een 
kopje thee, je staat altijd voor elke onderzoeker klaar. Je betrokkenheid bij de patiënt, 
het onderzoek, en de onderzoeker is bewonderenswaardig. Hiervoor ben ik jou heel erg 
dankbaar. Marianne Maliepaard, dank voor je inzet in de GUTS-studie. Studenten: Mark 
dank voor je hulp; Jonathan, held, dank voor je enorme inzet!
Mede klinische farmacologie fellows, dank voor jullie samenwerking en farma-enthousi-
asme. Dr. Lidwien Hanff, altijd geïnteresseerd en enthousiast.
De club Sophia-onderzoekers is een grote familie, met onvergetelijke borrels, diners en 
ski-trips. Sp-1324, deze kleine ruimte liep over van gezelligheid, Nespresso en briljante 
research. Nienke, je hebt mij betrokken bij de DSI-studie en mij vanaf moment één ont-
zettend enthousiast gemaakt voor IC-onderzoek. De vele koffies en goede gesprekken 
over van alles en nog wat waren heerlijk. Binnenkort een dagje Blijdorp! Brabantse MC, 
altijd lachen en vastberaden. Bram, een gedisciplineerd en gepassioneerd anesthesist. 
Erik, jouw filosofische gedachten waren hilarisch en we hebben veel gelachen.
Sp-2430, Dorian, Kitty, Lisette, Marlous, Manuel, Raisa en Willem. Dorian, je staat altijd 
voor iemand klaar, een mooie eigenschap die niemand mag overzien. Kitty, je wordt een 
slimme anesthesist. Marlous, je ziet altijd het positieve in de mens. Willem, blij met de 
nieuwste technische snufjes, ik ben benieuwd naar jouw boekje! Lisette, Manuel, Navin 
en Raisa dank voor de gezelligheid. Andere (oud)-onderzoekers van Prof. Tibboel of de 
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kinderchirurgie, dank voor jullie hulp en gezelligheid. Gerbrich, de vrolijke noot, dank 
voor je gezelligheid. Niina, thanks for your honesty, humour, and most of all your peptalk 
over a cheese fondue. All the best for you and your girls in Montreal.
Suzanne, lotgenoot in de laatste weken met blauwe vingers van het typen. Je positivi-
teit inspireert me, jullie grote zee-avontuur gaat bijna beginnen! Michiel, bedankt voor 
het nodige uitblazen en afstampen op de pedalen. En daarnaast beide bedankt voor de 
Mont Ventoux avonturen, evenals de andere dappere fietsers.
Lieve Alexandra, Alex, mijn promotietijd had er heel anders uitgezien zonder jou! Het 
was één groot avontuur: succesvol een meer overroeien in Canada, vakkundig ons 
eten in een (te dun) boompje hangen voor de beren; wielrennen naar Zwolle of langs 
11-steden in Friesland, Jut en Jul op de spinningfiets, menig skipiste onveilig maken als 
een Roze Konijn en Banaan. Een blik, mailtje of foto zegt dikwijls genoeg. Dank voor je 
adviezen over van alles, je luisterend oor, en je steun. Je discipline, je energie en devotie 
zijn allen onuitputtelijk. Op naar een volgend avontuur!
Lieve Joke en Alexandra, vriendinnetjes sinds een hele lange tijd, samen in Zwolle en 
Maastricht. Onvergetelijke momenten hebben wij meegemaakt en jullie zijn mij onge-
looflijk dierbaar. Lieve Rob, het begon allemaal met de mosselpan, en sindsdien maatjes 
voor het leven, dank dat je erbij bent. Timon, Franse marktjes afstruinen als de beste! 
Inge, dank voor het prachtige omslag. Je mag er trots op zijn! Ellen, Char en Laura, SFG-
maatjes. Fleur, ik kom bij jou helemaal tot rust in het mooie Mestreech. Iris, zo trots op 
mijn ‘kleine zusje’, we blijven onafscheidelijk.
SSA, lief en leed samen delen, de heerlijke weekendjes waar geen moment stiltes val-
len, en de uitgebreide diners zijn onbetaalbaar. Lieve Jolien, je vrolijkheid zal ik nooit 
vergeten. Verbandje voor altijd!
Lieve Kapjes en Keizers, Bertha en Bennie, dank voor jullie steun en interesse in alles. 
Lieve Anne-Greet, wat is het fijn om jou in de buurt te hebben. Arjan, nooit gedacht dat 
toen ik jouw promotie bijwoonde, ik er zelf een keer zou staan.. Gelukkig is het niet zo’n 
moeilijk onderwerp als de Japanse economie. Arnold, Riny, Kathelijne en Charlotte, dank 
voor de dierbare momenten wanneer het gaat ‘sneeuwen’.
Mijn paranimfen, Sanne en Irene, wat ben ik blij dat jullie vandaag naast mij staan. Sanne, 
India was onvergetelijk en het begin van een hechte, dierbare vriendschap. Ik bewonder 
je moed en open kijk in de wereld. Irene, op de eerste dag van de geneeskunde studie 
heb ik je ontmoet; goudeerlijk, vrolijk en behulpzaam. St Petersburg en All I want for 
Christmas zeggen genoeg!
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Lieve Hanneke, ik ben harstikke trots op jou als mijn zus. De dierenarts die stoer in de 
Ierse heuvels loopt. Je bent er altijd voor me. Lieve pap, ik kan je onmogelijk bedanken 
voor je onvoorwaardelijke steun en liefde. Je hebt mij nooit tegengehouden in mijn 
keuzes en je hebt altijd alles voor Hanneke en mij over. Mama en jij hebben ons geleerd 
altijd trouw te blijven aan onszelf.
James, everything is fine are the magic words, I am so happy with you in my life!


